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Abstract
Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia, a 
commercially expensive respiratory disease of swine. Currently there are no easily 
administered, cost effective vaccines against this pathogen. The development of 
efficacious recombinant subunit vaccines would aid greatly in ameliorating economic 
losses incurred in the pig meat industry as a consequence of enzootic pneumonia. As 
part of a program aimed at identifying protective antigens of Mycoplasma 
hyopneumoniae, a random pEX library was constructed and screened with antisera 
from hyperimmunised pigs. One clone (pSD9), identified by Dr S.P. Djordjevic, 
contained a 0.8 kb M. hyopneumoniae DNA fragment which encodes an 
immunoreactive antigen of that pathogen. This antigen was expressed as an 11 kDa M. 
hyopneumoniae component fused to the carboxy-terminus of the 117 kDa p- 
galactosidase protein to produce a 128 kDa fusion protein. Antibodies generated in 
rabbits against the 128 kDa fusion protein reacted in immunoblots against a 42 kDa 
protein of M hyopneumoniae. The vaccine potential of purified fusion protein was 
assessed in pig vaccine trials by delivery of the antigen emulsified in different 
adjuvant formulations. Following experimental challenge with virulent M. 
hyopneumoniae, the mean Goodwin lung score of all vaccinated animals, irrespective 
of the adjuvant treatment, was significantly reduced compared to control unvaccinated 
pigs (P < 0.05) (performed by staff at the Elizabeth Macarthur Agricultural Institute).
In order to thoroughly evaluate the impact of the 11 kDa M. hyopneumoniae antigen 
the p-galactosidase component was removed. The 0.8 kb M. hyopneumoniae DNA 
fragment was cloned from pSD9 into pHSG398 to produce the plasmid pKFl. This 
plasmid expressed the 11 kDa M hyopneumoniae antigen as a component of a much 
smaller 15 kDa recombinant protein in Escherichia coli. For simple one-step large 
scale purification of the 11 kDa M hyopneumoniae antigen, the 0.8 kb DNA insert 
was cloned into pQE9 to produce plasmid pETEl. This plasmid expressed the 11 kDa
XX
antigen with an N-terminal 6x histidine tag which allowed for simple affinity 
purification of the protein.
Southern hybridisation and polymerase chain reaction analyses demonstrated that the 
cloned 0.8 kb M hyopneumoniae DNA fragment did not cross-react with Mycoplasma 
hyorhinis chromosomal DNA but did so with Mycoplasma flocculare DNA The 
plasmid pKFl was used as a template to sequence the 0.8 kb M hyopneumoniae DNA 
fragment. Sequence analysis revealed the presence of three open reading frames, two 
of which had amino acid sequence homology to the prokaryotic class I nrdF 
ribonucleotide reductase and an associated gene. In both the 128 kDa fusion protein 
and the 15 kDa protein, the recombinant M hyopneumoniae antigen consisted of the 
carboxy terminal 11 kDa of a 42 kDa M hyopneumoniae protein thought to be the 
NrdF ribonucleotide reductase R2 subunit protein.
Antibodies raised in rabbits against the 11 kDa portion of the recombinant proteins 
reacted against the wild type protein in all M hyopneumoniae strains isolated from a 
number of regions throughout the world. These antibodies were able to react against 
the wild type protein in whole cell ELISA, demonstrating the surface accessibility of 
the 42 kDa protein. Furthermore, in-vitro growth inhibition studies using antibodies 
specific for the 15 kDa NrdF antigen demonstrated the vulnerability of viable M. 
hyopneumoniae to neutralising antibodies.
Salmonella typhimurium aroA SL3261 was used as a live carrier of the plasmids 
pSD9 and pKFl, which expressed the respective 128 kDa and 15 kDa recombinant 
proteins. When used as live oral vaccines, S. typhimurium SL3261(pSD9) and S. 
typhimurium SL3261(pKFl) induced a significant secretory IgA immune response in 
the lungs of orally immunised mice against the M. hyopneumoniae antigen. The S. 
typhimurium SL3261 (pSD9) also elicited significant NrdF serum IgG, a response 
which was not seen in mice immunised with S. typhimurium SL3261(pKFl).
XXI
The efficacy of the S. typhimurium aroA SL3261 (pKFl) vaccine strain was evaluated 
in a pig trial. Pigs were split into 4 immunisation groups; NrdF intraperitoneal, PBS 
negative control, oral salmonella vector and oral salmonella vaccine and immunised 
twice prior to experimental challenge. Pigs parenterally immunised with the 15 kDa 
NrdF antigen had a significantly higher (P < 0.05) serum IgG response after the 
second vaccination and before challenge compared with all other groups. Oral 
immunisation with the Salmonella vaccine strain did not elicit any antibody response 
against the recombinant NrdF antigen after vaccination but prior to challenge. 
However, after challenge the oral salmonella vaccine elicited a significant (P < 0.05) 
secretory IgA response in the lungs of pigs against the 15 kDa NrdF antigen compared 
to all other immunisation groups. Immunised swine in the NrdF intraperitoneal and 
oral salmonella vaccine groups, which received the recombinant NrdF antigen, 
showed higher average daily weight gains and reduced lung pathology compared to 
the control groups.
Utilisation of live oral vaccines expressing potentially protective M. hyopneumoniae 
proteins, such as the NrdF antigen, which can stimulate a lung mucosal response 
against surface accessible proteins may provide a cost affective alternative to the 
present control strategies used for porcine enzootic pneumonia.
XXII
Chapter 1
Review of the literature
C hapter 1
Review of literature
1.1 Biology of the mycoplasmas
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia 
(PEP), a chronic non-fatal respiratory disease of pigs (Simecka et al, 1992) which 
incurs severe economic losses on pig meat producers throughout the world due to 
reduced growth rate, ongoing management costs and antibiotic supplements (Leman et 
al, 1982). Worldwide estimated losses due to the disease are approaching $1 billion 
per year, with approximately $ (Aust) 20 million per annum being lost in Australia 
(Eamens, 1992). M. hyopneumoniae colonises porcine ciliated epithelial cells of the 
trachea, bronchi and bronchioles (Blanchard et al, 1992), subsequently damaging and 
eventually causing the loss of cilia (DeBey et al, 1994). Ciliostasis compromises 
mucosal clearance and, coupled with characteristic PEP lung lesions, predisposes 
infected pigs to potentially fatal secondary invaders such as Pasteurella multocida 
(Ciprian et al, 1988) and Actinobacillus pleuropneumoniae (Yagihashi et al, 1984). 
Presently, in Australia, there are no cost effective vaccines available for the control of 
PEP. This thesis describes work involved in vaccine development using a live 
Salmonella typhimurium aroA mutant as a carrier of recombinant M. hyopneumoniae 
antigens. Previous studies by other groups using attenuated mutants of S. typhimurium 
aroA (Hoiseth and Stocker, 1981) have demonstrated the strains to be invasive yet 
non-virulent and capable of eliciting immune responses (Cardenas and Clements, 
1992; Lumsden and Wilkie, 1992; Mukkur, 1992). Furthermore, other studies have 
determined the usefulness of using attenuated S. typhimurium aroA strains expressing 
heterologous mucosal pathogen antigens as live oral vaccine vectors that are capable
1
of stimulating a secretory immune response ( Fairweather et al, 1990; Guzman et al, 
1991, Cardenas and Clements, 1992). It is the aim of this study to target the mucosal 
immune system of swine using attenuated S. typhimurium aroA strains expressing an 
immunogenic and protective M. hyopneumoniae antigen.
1-1-1 The mollicutes
The Mollicutes are a genetically diverse group characterised by their lack of cell wall, 
morphologically small size, very low G.C content and small genome size. Analysis of 
5S rRNA sequences and a number of evolutionary conserved proteins indicate that the 
Mollicutes evolved by a degenerative evolutionary process from larger ancestral 
eubacteria closely related to the Genera of Bacillus and Lactobacillus (Ferrell et al, 
1989; Razin, 1992a). The largest of the Mollicutes, the Acholeoplasma, have a 
genome of approximately 1700 kb. Divergence from this branch led to the sterol- 
requiring Spiroplasma and further genomic reduction led to the 620-1140 kb 
Mycoplasma and Ureaplasma lineages (Weisburg et al, 1989).
M. hyopneumoniae belongs to the Genus Mycoplasma within the Mollicute Class. The 
Mollicutes are classified according to cell morphology, genome size and nutritional 
requirements. Genera within this Class are Mycoplasma, Acholeoplasma, 
Anaeroplasma, Asteroleplasma, Spiroplasma and Ureaplasma (Weisburg et al, 1989). 
Recently, the two Genera Entomoplasma and Mesoplasma, also referred to as 
mycoplasma-like organisms (for review see Lee and Davis, 1992) were also included 
into the Class Mollicutes within the order Entomoplasmatales (Tully et al, 1993). 
Organisms within the Mollicutes can also be phylogenically grouped as determined by 
parsimony analysis of the full 16S rRNA gene sequence (Gundersen et al, 1994). This 
type of grouping identifies a number of closely related groups. Under this scheme M. 
hyopneumoniae is grouped into the M. hominis clade that contains only the genus 
Mycoplasma. Other groupings include the Mycoplasma pneumoniae clade containing 
organisms from both the genera Mycoplasma and Ureaplasma. The Spiroplasma clade
2
contains Aiycoplasynas and Spiroplaswias\ the Anaeroplastna clade contains the 
mycoplasma-like organisms, Acholeplasmas and Anaeroplasmas, and the final 
grouping the Asteroleplasma (Gundersen et al, 1994). In the future, these 
phylogenetic groupings will be combined with the present phenotypic groupings to 
form a new integrated Mollicute classification scheme (Gundersen et al, 1994).
1-1-2 The Mycoplasmas
Mycoplasmas, like all Mollicutes, lack a cell wall and many biosynthetic pathways in 
response to adopting a symbiotic/parasitic mode of existence (Razin, 1992a; Razin 
1992b; Razin, 1978). These organisms rely on the host for a maintained environment 
providing saccharides, amino acids, lipids, nucleic acid precursors, vitamins and 
certain co-enzymes (Miles, 1992). Although the nutritional requirements of only a 
limited number of mycoplasmas have been determined, it is apparent that 
mycoplasmas lack major energy producing pathways such as the tricarboxylic acid 
cycle (Manolukas et al, 1988). The mode of ATP synthesis is varied between 
mycoplasma species, and is through a number of different aerobic and anaerobic 
processes utilising transported primary energy sources. The predominant pathways are 
glycolysis, oxidation of pyruvate and the hydrolysis of arginine (Miles, 1992; Razin, 
1992b).
There are a number of essential “housekeeping” genes that mycoplasmas, being a 
minimal cell, must conserve. These genes include those encoding ATPase, DNA 
gyrase, DNA polymerase, RNA polymerase, rRNA, tRNA, adhesin and attachment 
proteins and a number of other proteins associated with nucleotide salvage and the 
synthesis of ribonucleotides (Razin, 1992b). In all mycoplasma species characterised 
there is always a single DNA polymerase (Labarere, 1992) compared to three in 
Escherichia coli. Similarly, mycoplasmas contain one or two ribosomal gene copies 
compared to between seven and ten copies in eubacteria (Razin, 1992b). Furthermore,
3
in Mycoplasma capricolum there are 30 tRNA genes for 29 tRNA species compared 
to 78 tRNA genes for 45 tRNA species in E. coli (Razin, 1992b).
Perhaps the most significant of losses due to reductive evolution is the loss of uracil- 
DNA glycosylase. This enzyme is responsible for the excision of uracil from genomic 
DNA. Cytosine in DNA may become deaminated to form uracil and consequently a 
C.G pair will be converted to a U.G pair. After a subsequent round of replication an 
A.T pair is yielded. Thus the absence of the uracil-DNA glycosylase will result in A.T 
bias transition mutations, leading to an A.T accumulation and the characteristic low 
G.C composition of mycoplasmal genomic DNA (Labarere, 1992). Only a single 
mycoplasma, Mycoplasma lactucae, is the exception. This organism is reported to 
contain a uracil-DNA glycosylase. However, this enzyme is extremely inefficient and 
its action is not sufficient to prevent an accumulation of A.T and subsequently the G.C 
content of its genome falls within the characteristic mycoplasma range of 24-33% 
(Williams and Pollack, 1990).
The structural organisation of mycoplasma genomes is essentially similar to that 
found in eubacteria such as E. coli and Bacillus subtilis (Muto et al, 1992), with 
exceptions being due to the effect of the differing G.C content rather than structural 
differences (Taschke et al, 1987). Conserved -10 and -35 consensus sequences that 
can also function in E. coli have been reported for M capricolum rRNA and tRNA 
genes (Gafny et al, 1988). Similarly Shine-Dalgamo sequences from Mycoplasma 
genitalium that function in E. coli have also been reported (Loechel et al, 1991). 
However, in M. hyopneumoniae the reported transcription initiation sites and 
promotor-like consensus sequences do not function within other bacterial systems 
(Taschke et al, 1987). This difference is assigned to significant sequence divergence 
in M hyopneumoniae, however, the underlying basis for gene expression is thought to 
be similar (Taschke et al, 1987). Regulation and termination of transcription in the 
my coplasmas has been extensively researched for M capricolum and Mycoplasma
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hyorhinis, however the large genetic diversity between mycoplasma species precludes 
any speculation on these processes in M. hyopneumoniae.
Another effect of A.T accumulation in the mycoplasma genome is the usage of the 
UGA codon to encode tryptophan rather than the bacterial stop. Transition mutation 
bias towards A.T accumulation would have led the UGA stop codon to become UAA, 
leaving UGA unassigned, and allowing mutation from the tryptophan UGG codon to 
the UGA tryptophan codon found in M hyopneumoniae (Futo et al, 1995) and other 
mycoplasma species (Jukes, 1985; Yamoa et al, 1985; Inamine et al, 1988).
1.1.3 Mycoplasma pathogenesis
Evidence indicates that most mycoplasmas are genetically predetermined to be 
commensals (Simecka et al, 1992), with some species being considered low level 
parasites. Mechanisms of mycoplasma pathogenicity have not been elucidated and it 
is considered that pathogenicity is largely due to a bystander effect where the hosts 
immune response plays a major role in the development of the disease (Simecka et al,
1992). In all cases the mycoplasma colonises a specific mucosal surface of the host. 
The mycoplasmas Mycoplasma penetrans, M. pneumoniae and M. genitalium have 
been shown to actively invade the hosts epithelial surface (Razin, 1992b; Baseman et 
al, 1995); all other species studied remain associated with the external mucosal 
surface. Toxins have been identified and linked to the pathogenicity of some 
mycoplasmal diseases. Viable Mycoplasma mycoides produces a diffusable toxin 
which can induce tissue necrosis in rabbits and cattle (Simecka et al, 1992), 
Mycoplasma arthriditis produces a 15 kDa protein that induces a damaging localised 
inflammatory response (Fleischer, 1994). Mycoplasma gallisepticum produces a 
neurotoxin which is capable of producing encephalitis in turkeys (Simecka et al, 
1992). Presently, a single non-diffusable 54 kDa protein purified from M. 
hyopneumoniae has been identified as a potential toxin. This factor is a membrane 
associated cytosolic protein which after purification can induce cellular rounding,
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lysis and detachment of cultured human lung fibroblast cells in vitro (Geary and 
Walczak, 1985). However, the actual role of the native protein in pathogenesis of PEP 
is not understood. Studies on the effects of this cytopathic protein, purified from high 
passage number M hyopneumoniae indicate that its toxicity does not diminish after 
high passage. This observation is contrary to results obtained from ciliostasis studies 
which indicate that cellular damage and loss of cilia, by unknown factors, is 
diminished in high passage number M. hyopneumoniae strains (DeBey and Ross,
1994). This discrepancy between passage number and toxin activity indicates that the 
54 kDa cytotoxic factor may not be directly involved in initial cellular damage of 
ciliated epithelial cells of swine caused during colonisation. Rather, it is feasible that 
the 54 kDa protein is a cytosolic metabolic enzyme, possibly a nuclease or protease, 
with the observed toxicity being due to the tracheal culture cells being exposed to the 
active purified enzyme.
1.2 Pathogenesis of Mycoplasma hyopneumoniae
Historically PEP has always been recognised as an economically important swine 
disease. During the 1920s and 1930s an all encompassing description of “hog flu” was 
used to describe bacterial, viral and mycoplasmal respiratory diseases (Betts, 1953). 
Research in the mid 1930s identified that Haemophilus influenzae suis and 
Pasteurella multocida were frequently cultured from pneumonic lungs, yet at times 
the lung lesions were found to be bacteriologically sterile (Betts, 1953). Researchers 
at the time agreed that pneumonia of swine was due to viral infection, distinct from 
swine influenza, and frequently complicated by secondary bacterial infections. The 
mycoplasmal etiological agent of PEP was isolated and characterised in both America 
(Mare and Switzer, 1966) and England (Goodwin et al, 1967) at approximately the 
same time. Recent studies (Morrison et al, 1986; Wilson et al, 1986; Straw, 1991) 
have demonstrated that producers with herds infected with M. hyopneumoniae will 
only lose money if compounding factors such as secondary invaders, environmental
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conditions, strain variation and poor animal husbandry practices are not addressed. 
However, it is also feasible that by addressing the compounding factors and 
introducing an efficacious vaccination program M. hyopneumoniae could be 
eradicated from herds.
1.2.1 Mycoplasma colonisation
Most mycoplasmas utilise more than one mechanism to bind host cells. The most 
characterised adherence mechanism studied is that of M pneumoniae. This pathogen 
has two characterised adhesins, PI and P30 (Dallo et al, 1989), as well as mycoplasma 
A, B, C, HMW1-HMW5, P65, P41 and P24 proteins. These proteins interact to form 
an attachment organelle which allows for host specific cytadherence (Krause, 1996). 
Other mycoplasmas, such as Mycoplasma iowae utilize a “fuzzy” layer of interlocking 
fimbrils which interact with host cell microvilli, allowing attachment but not intimate 
association with the epithelial surface (Kahane and Harowitz, 1993).
In M. hyopneumoniae, adherence can be abrogated by trypsin and periodate treatment 
of the pathogen, indicating attachment is facilitated by proteins and polysaccharides 
(Zeilinski et al, 1990 and 1993). The presence of a “fuzzy” layer on M. 
hyopneumoniae cells has been reported and interaction between this layer and porcine 
cilia has been demonstrated (Tajima and Yagihashi, 1982).
A single M. hyopneumoniae adhesin, designated P97 has been identified and is 
associated with the external fuzzy layer. This protein has an uncharacterised porcine 
epithelial target (Zhang et al, 1995). However, DNA sequence analysis of the gene has 
revealed predicted proline rich repeat sequences (Wilton et al, 1997). The presence of 
these repeats in other organisms has been associated with receptor-ligand binding 
(Williamson, 1994).
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The P97 adhesin displays size variation between M. hyopneumoniae strains (Wilton et 
al, 1997; Hsu et al, 1997). Similar antigenic variation has been demonstrated in M 
hyorhinis (Rosengarten and Wise, 1990; Yogev et al, 1991; Rosengarten et al, 1993), 
M pulmonis, Ureaplasma urealyticum and M. hominis virulence antigens (Kahane 
and Horowitz, 1993). In M hyopneumoniae, the mechanism responsible for antigenic 
variability has yet to be experimentally proven. However, the presence of copy 
number variations of the proline rich P97 repeat sequences, AKPE(V)A and 
GA(E,S)PN(S)QGKKAE implicates genetic rearrangements by homologous 
recombination as one possible mechanism (Wilton, 1996).
N-terminal amino acid sequence comparisons have revealed no P97 protein homology 
to any other characterised mycoplasma adhesins, indicating this adhesin may be a 
novel antigen specific for M hyopneumoniae (Zhang et al, 1995). Monoclonal 
antibody blockage of the P97 adhesin, or preincubation of M. hyopneumoniae with 
high concentrations of hyperimmune sera, does not completely inhibit attachment to 
porcine ciliated cells (Zielinski and Ross, 1993; Zhang et al, 1995), indicating that 
there are other adhesins or nonspecific mechanisms of attachment present. 
Furthermore, reduction of IgM or removal of tetrameric IgM molecules from the 
hyperimmune sera restores M. hyopneumoniae adherence, indicating inhibition is 
attributable to the agglutinating activity of various anti-M hyopneumoniae epitopes 
rather than specific adhesin blockage (Zielinski and Ross, 1993).
Three porcine glycolipids found on ciliated tracheal epithelial cells, designated La, Lb 
and Lc, have been identified as major binding targets for M hyopneumoniae (Zhang et 
al, 1994). Colonisation of ciliated tracheal cells can be inhibited by the addition of 
laminin, a basement membrane component which competes for these porcine 
glycoproteins. However, the M. hyopneumoniae receptors responsible for recognising 
and binding to the porcine glycolipids have yet to be identified (Zhang et al, 1994). 
Nonspecific hydrophobic interaction also plays a role in M. hyopneumoniae
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attachment and colonisation. Adherence to glass surfaces is a characteristic of the 
normally extremely fastidious M. hyopneumoniae and has been demonstrated to be 
due to hydrophobic interactions (Zielinski and Ross, 1993). Colonisation of inert glass 
surfaces by mycoplasmas is energy dependent and any inhibition of energy 
metabolism significantly reduces attachment (Bredt et al, 1982). However, the exact 
role and mechanism of this phenomenon is unknown. In summary, the adherence of 
M hyopneumoniae in vivo to porcine tracheal cells is essential for PEP pathogenesis 
and involves a complex relationship between specific and nonspecific mechanisms.
1.2.2 Lesion development
Characteristic lung lesions symptomatic of PEP in swine occur in the ventral regions 
of the apical and cardiac lobes (Ross, 1986). The severity of the disease can be 
determined at slaughter by identifiable areas of plum coloured discolouration (Fig 
1.1). The progression of characteristic PEP induced lung lesions corresponds to 
morphological sequential changes which are due to nonspecific host immune 
inflammatory responses. The onset of PEP after exposure to M. hyopneumoniae will 
usually occur within six months of exposure (Ross, 1986). Disease progression is 
dependent upon a number of factors related to the conditions under which livestock 
are housed. Initially the disease was thought to have an incubation period after 
exposure to the pathogen of two to seven days with disease onset being sudden and 
occurring “simultaneously amongst all the pigs in the herd” (Betts, 1953). This onset 
is now understood to be due to a number of compounding factors (discussed in 
Section 1.3). Evidence of lesion development can be seen in slaughtered pigs lungs in 
as few as three days after PEP infection (Baskerville, 1972). Initial host response to 
infection consists of accumulation of polymorphonuclear cells (Ross, 1986) and 
isolated
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Fig 1.1. Pig lungs removed at slaughter. Characteristic plum coloured 
lesions are indicated by arrow. Ear tag disc can be seen in the intermediate 
lobe region.

mononuclear cells (Baskerville, 1972) in the lumina of the bronchioli and small 
bronchi. This response is compounded approximately five days post infection by the 
accumulation of lymphocytes in the peribronchial space and lamina propria of the 
alveoli. Significant lymphoid hyperplasia is visible around the affected airways by day 
7-10; this lymphoid tissue accumulation continues causing stenosis of the bronchioli 
and peribronchiolar alveoli. Hypersecretion of mucus is also detectable during this 
period, and predominantly there is an increased level of sulfation of mucosubstance 
(DeBey et al, 1992). By day 15 post infection there is extensive alveolar oedema, 
regional alveolar collapse and irregularities in the bronchioli epithelium (Baskerville, 
1972; Ross, 1986). Mucopurulent exudate is predominant in the small airways at this 
time. Build up of exudate is due to hypersecretion compounded by ciliostasis (DeBey 
et al, 1992) brought about by extensive damage due to lesion progression.
1-2.3 Cell mediated immune responses to M. hyopneumoniae
infection
In both natural and experimental M. hyopneumoniae infection, bronchial lymphocytes 
are sensitised to M. hyopneumoniae antigens as early as one week post exposure 
(Kristensen et al, 1981). Other studies observed that sensitised lymphocytes appear to 
marginate in the lymph nodes, particularly in the bronchial region. However, there are 
no reports of sensitised lymphocytes in the systemic population until late in infection 
and during the period corresponding to recovery 15 to 44 weeks post infection (Suter 
et al, 1985; Messier and Ross, 1991). The lack of responsiveness of systemic blood 
lymphocytes corresponds to the lack of a M. hyopneumoniae specific DTH response 
and has been used as evidence to demonstrate immunosuppression of CMI by the 
pathogen (Adegboye 1978a and 1978b). However, this may also be due to 
compartmentalisation of the immune system, particularly within the bronchial 
associated lymphoid tissue (BALT), and margination of sensitised immune cells in 
regions associated with this lymphatic tissue such as the bronchial lymph nodes. 
There are conflicting studies examining the regulation of nonspecific responses to
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mitogens such as phytohemagglutinin by M. hyopneumoniae infection (Adegboye, 
1978a and 1978b; Messier et al, 1990; Messier and Ross, 1991). Clarification of these 
studies would be useful to determine what regulation there is on the lymphocyte 
populations.
Nonspecific mitogenic effects by mycoplasmal antigens on a range of naive 
lymphocytes have been reported in a number of studies (Cole et al, 1982; Daynes et 
al, 1982). The most studied mycoplasmal mitogen is a 15 kDa factor secreted by 
Mycoplasma arthritidis which is shown to greatly exacerbate damage caused by 
localised hyperplasie inflammation (Fleischer, 1994). The extent of the nonspecific 
mitogenic effects caused by M. hyopneumoniae antigens is not well characterised. A 
number of experimental trials have demonstrated a moderate mitogenic effect on 
porcine blood lymphocytes (Adegboye, 1978; Kishima et al, 1985; Messier and Ross, 
1990; Messier and Ross, 1991), however, the weak response is extremely variable and 
the degree and extent of the effect varies with the pigs genetic lineage, age of the 
swine at infection and the M. hyopneumoniae strain used.
1.2.4 Nonspecific activation of alveolar macrophages
As early as 2 weeks post-infection, M. hyopneumoniae stimulates increases in 
phagocytosis of non-opsonised particles by nonspecific activation of alveolar 
macrophages (Caruso and Ross, 1990). This is a possible route of colonisation by a 
low level invasion of secondary pathogens such as A. pleuropneumoniae (Nicolet, 
1992). These bacteria secrete a cytocidal toxin that kills the phagocyte allowing the 
internalised viable bacteria to evade host defences and colonise the host (Caruso and 
Ross, 1990). Conversely, experimental challenge doses of secondary mucosal 
invaders have been demonstrated to significantly decrease macrophage function that 
could also increase the incidence of secondary infections (Caruso and Ross, 1990).
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1*2.5 Humoral immune responses
Colostrum derived neutralising antibodies against M. hyopneumoniae are responsible 
for protection against PEP in suckling pigs. Antibodies can persist in the serum of 
piglets for up to 51 days (Durisic et al, 1975), with the average half life of serum anti­
M. hyopneumoniae IgG being 8-15 days (Morris et al, 1994). Swine are likely to 
develop serum antibodies (seroconvert) after 3 months of age (Kobisch et al, 1993), 
which corresponds to the period when pigs show clinical signs of disease and when 
weaners are usually transferred into the growing population. Unvaccinated PEP 
negative pigs will seroconvert within 3-4 weeks after experimental inoculation and 6­
9 weeks after natural exposure to virulent M. hyopneumoniae (Djordjevic et al, 1994). 
Serum antibody responses following seroconversion are of a low magnitude (Nicolet, 
1987) and are predominantly IgG (Sheldrake et al, 1993). M. hyopneumoniae specific 
antibodies detected in lung washes are predominantly IgA during the early stages with 
IgG becoming predominant later in the infection (Messier et al, 1990). No correlation 
in weaned pigs has been determined between the presence of serum or mucosal 
antibodies and protection from PEP (Kishima et al, 1985; Djordjevic et al, 1997). 
However, passive transfer of hyperimmune serum has been shown to protect swine 
against the development of disease (Messier et al, 1990). Furthermore, acute infection 
(Sheldrake et al, 1992) and resolution of disease has been correlated to marked 
increases in serum immunoglobulin levels (Messier et al, 1990).
1.2.6 Resolution
Resolution of PEP in swine is dependent upon many factors, similar to those factors 
involved in the onset and severity of disease. Resolution of disease can be affected by 
secondary invaders, environmental conditions, strain variation and poor animal 
husbandry practices. Recent studies which strictly control these factors demonstrated 
that swine with PEP infection take more than 4 weeks but less than 13 weeks post 
challenge to resolve lesions and clear viable M. hyopneumoniae from the lungs
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(Amass et al, 1994). More severe outbreaks which last in excess of 16 weeks post 
inoculation without any recovery signs being detected have been reported (Underdahl 
et al, 1980). However, it is possible that uncontrolled confounding factors in this 
study may have combined to alter disease pathogenicity and epidemiology.
1.2.7 Growth performance changes due to PEP and complications
Uncomplicated PEP has an uncertain effect on average daily gains (ADG) and the 
feed: gain ratio (F/G) of infected swine. Large variations of growth performance exist 
between studies examining the association between these indicators and PEP; these 
have been summarised in the comprehensive study by Morrison and colleagues 
(1986). Of 23 studies examined in this review, 10 studies reported no significant 
variations in growth performance, the remaining studies reported decreased ADG 
between 5% and 25% and F/G increases between 4.6% to 25%. A study by Noyes et 
al (1990) found no correlation between the incidence of lesions at slaughter and 
weight gain, however, using radiological techniques they were able to show 
correlation between lifetime complicated PEP burden and weight gain. In the herd 
studied, for every 1% increase in lifetime burden there was a 1.46 kg decrease in body 
weight at slaughter (180 days old). This radiological technique is cost prohibitive and 
labour intensive yet this study is useful as an indicator to demonstrate that PEP results 
in large economic losses. Large variations between growth rate and the extent of PEP 
have been reported from many other researchers using various other diagnostic 
methods (Pointon et al, 1985; Christensen and Mousing, 1992; Amass et al, 1994). 
For all these studies the reported differences are due to a number of recognised 
factors, and in particular environmental factors, secondary pathogens and animal 
husbandry practices. However, assigning formula to describe the extent of causality 




Any PEP lesion damage to swine lungs in an intensive piggery situation can leave 
affected pigs susceptible to opportunistic secondary invaders. The most common 
economically important pathogens involved in the complication of PEP are P. 
multocida (Ciprian et al, 1988; Ross, 1992), M. hyorhinis, M. flocculare (Christensen 
and Mousing 1992), Bordetella bronchiseptica (Christensen and Mousing, 1992; 
Bernardo et al, 1990; Wilson et al, 1986; De Jong, 1992) and A. pleuropneumoniae 
(Wilson et al, 1986; Straw, 1991). M. hyorhinis, M. flocculare, E. coli, non hemolytic 
streptococci and staphylococci are routinely isolated from the respiratory tract of 
healthy swine. Although some of these organisms are potentially pathogenic, the 
presence of these organisms may not indicate any deviation from normal flora. B. 
bronchiseptica, non-toxigenic P. multocida and less pathogenic strains of A. 
pleuropneumoniae are also occasionally detected in healthy lung flora (Christensen 
and Mousing, 1992). The pathogenic strains of A. pleuropneumoniae, like M. 
hyopneumoniae, are never found in the respiratory tract of healthy swine, their 
presence is always associated with disease at either a subclinical or acute level 
(Christensen and Mousing, 1992).
1.2.8.1 Pasteurella multocida
P. multocida does not colonise pig lungs unless the lung epithelial surface is 
compromised (Amass et al, 1994). This pathogen is the causative agent of progressive 
atrophic rhinitis and is associated with pleuritis (Pijoan and Fuentes, 1987; Gardner et 
al, 1994) Strains vary in toxigenicity and as a consequence the extent of complication 
caused by P. multocida varies widely. The bacteria were detected in 7% of swine 
herds in Australia in 1991 and 1992 (Christensen and Mousing, 1992). However, in 
other nations it is the most frequently isolated secondary invader in PEP and is 
considered to play a significant role in determining the severity of this disease 
(Morrison et al, 1986). The bacteria complicate PEP and in severe cases the F/G ratio
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has been decreased up to 37.5% (Ciprian et al, 1988). Clearance of P. multocida from 
non-compromised lungs is rapid and the best strategy for eradication of the pathogen 
from a herd is to treat primary invaders such as B. bronchiseptica and M. 
hyopneumoniae and allow the host respiratory defences to clear the other secondary 
pathogens (Amass et al, 1994).
1.2.8.2 Bordetella bronchiseptica
B. bronchiseptica is a pathogenic bacterium which is a chronic infectious agent in 
many mammals. In pigs, acute B. bronchiseptica infection causes catarrhal 
inflammation of the nasal mucosa (Christensen and Mousing, 1992). The presence of 
disease facilitates the colonisation of secondary invaders, particularly toxigenic P. 
multocida strains. The pathogen may also be linked to the predisposition of pigs to the 
development of acute PEP (Switzer et al, 1981).
1.2.8.3 Actinobacillus pleuropneumoniae
A. pleuropneumoniae causes pleuropneumonia with the resulting lesions occurring in 
the cardiac, apical and diaphragmatic lobes, and is associated with the development of 
fibrous pleuritis (Nicolet, 1992). Swine with PEP and other porcine respiratory 
pathogens have a demonstrable reduction in resistance to A. pleuropneumoniae 
resulting in more rapid onset and exacerbation of the severity of pleuropneumonia. 
The acute condition is often fatal and results in large economic losses due to the cost 
of treatment and mortality caused by acute outbreaks (Nicolet, 1992).
1.2.8.4 Mycoplasma flocculare and Mycoplasma hyorhinis
M. flocculare is considered non-pathogenic in swine (Hovind-Hougen and Friis, 
1991). However, it is extremely widespread and is commonly isolated from the lungs 
and nasal cavities of pigs, including specific pathogen free (SPF) pigs. Although this 
mycoplasma is not considered pathogenic it can cause problems in the early detection 
and identification of M. hyopneumoniae. Polyclonal antisera raised against M.
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hyopneumoniae antigens will cross react with M. flocculare (Bolske et al, 1990; 
Scarman et al, 1997) resulting in “false positives”. M. hyorhinis is another 
mycoplasmal agent commonly isolated from porcine respiratory tracts (Baskerville, 
1972). This pathogen has been implicated as an agent of polyserositis and arthritis 
(Friis and Feenstra, 1994). M. hyorhinis has also been suggested to play a role in the 
development of PEP (Simecka et al, 1992). This organism is a common tissue culture 
contaminant which rapidly outgrows M. hyopneumoniae, making species-specific 
identification by culture difficult (Ross 1986).
1.2.9 Transfer of pathogen
A lack of sensitive M. hyopneumoniae specific early detection diagnostic assays 
coupled with low virulence and a long incubation period of the pathogen makes it 
difficult to control chronic infections within a swine herd (Jericho, 1986). Because 
routine detection within herds relies heavily upon necropsy to determine the extent of 
the infection, the actual mode of transmission is not well understood. Sow-to-piglet 
transfer prior to weaning has been implicated as a mode of transmission. Although 
PEP is rarely seen in pigs younger than 3 months of age (Morris et al, 1995) early 
reports indicated possible infections in pigs as young as 2 weeks (Holmgren, 1974) 
where the only carrier could be the farrowing sow. However, this early study may 
have detected passively acquired resistance to the pathogen via colostral antibodies 
which were misinterpreted as a serological host response against the pathogen (Clark 
et al, 1991; Morris et al, 1994). Most studies downplay the role of sow-to-piglet 
transfer of M hyopneumoniae because animal husbandry practices may be utilised 
which prevent mixing of weaned pigs with older acutely infected animals thereby 
significantly reducing the extent of PEP within these pigs (Clark et al, 1991). The 
predominant form of transmission of M. hyopneumoniae is direct contact between 
acutely infected and uninfected swine (Ross, 1992; Morris et al, 1995). Repeated low 
dose exposure in rapidly growing weaned pigs is optimal for the transmission and 
colonisation of this fastidious pathogen (Jericho, 1986) and direct contact between
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cohorts allows for this type of exposure. Aerosol exposure is another mode of transfer 
which significantly affects transmission and is blamed for the less frequent 
transmission between non-contiguous pens. Once infected, a single swine can then 
transfer the pathogen to penmates and swine in adjacent stalls by direct contact. 
Airborne transmission between M. hyopneumoniae free piggeries and infected 
piggeries nearby is implicated in new outbreaks (Ross, 1992). This form of 
transmission is particularly prevalent when piggeries are less than 3.2 kilometres apart 
and the infected farm has more than 500 swine (Ross, 1992).
1.2.10 Diagnosis of PEP
The control of M. hyopneumoniae has been difficult due to a lack of a commercially 
available, rapid, cost effective and simple diagnostic assay which can detect this 
pathogen in low numbers in the respiratory tract of swine. Pig meat producers rely 
heavily upon lung examination at slaughter to determine the extent and severity of 
PEP in their herds. This method of detection is not optimal because it will only give 
an indication of PEP severity at the point of slaughter due to lung lesions being 
transitory and resolving over time. Furthermore, lung examination at necropsy gives 
no indication of the chronic levels of infection in pigs where all visual respiratory 
damage has been resolved.
1.2.10.1 Incidence of coughing
A dry unproductive cough in swine older than three months of age is an early 
indicator of an established outbreak of PEP within a herd. Coughing can be correlated 
to the presence of pneumonic lesions if the coughing is observed between 1 and 30 
days prior to slaughter; if the period is longer no comparison can be made due to the 
resolution of lesions (Morris et al, 1995). Coughing is a disease symptom but is not a 
good indication of the severity of disease. Coughing is exacerbated by moderate 
exercise, however, the area restrictions imposed by modem intensive piggeries often
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preclude exercise and subsequently coughing may not be observed in swine with 
severe PEP (Eamens pers com).
1.2.10.2 Visual appraisal of porcine lungs at slaughter
The lungs of swine are divided into seven lobes. On both sides, left and right, there are 
apical, cardiac and diaphragmatic lobes. A single intermediate lobe is also found 
between the diaphragmatic lobes. Lobes found on the left side are smaller compared 
to those on the right to accommodate the heart. PEP is detected at slaughter by 
characteristic rose-coloured areas in the apical, cardiac and intermediate lobes (Fig 
1.1). Uncomplicated PEP is seen in the upper areas of these lobes which represent 
approximately 25-30% of the lung area. When PEP is complicated by secondary 
invaders a further area of approximately of 15-20% may be affected (Fig 1.2). The 
diaphragmatic regions of the lungs are not affected by PEP, with lesions detected in 
these areas considered to be due to pleuropneumonia (Christensen and Mousing, 
1992).
There is no universally applied standard for the visual appraisal of the severity of PEP 
in the lungs of slaughtered swine. Most researchers who use gross lung morphology as 
a diagnostic will observe the percentage of each lobe affected then calculate the 
overall percentage by applying a weighted average determined for each of the lobes. 
There is not a widespread consensus on the overall percentage value weighting that 
each of the lung lobes should be given (Table 1.1), leading to a standardisation 
problem between studies. Further problems may also arise due to variation being 
introduced by different inspectors, however, a widespread education of scorers would 
standardise this problem (Humik et al, 1993).
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Fig. 1.2: Schematic representation of swine lungs showing the region affected by 
uncomplicated enzootic pneumonia (light grey), complicated pneumonia (dark grey) 
and pleuropneumonia (stippled) (modified Christensen and Mousing 1992).
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Table 1.1: Table showing the differences between the percentage value area assigned 
by various researchers to the relevant lobes.
Lung lobe Reference
Morrison et al, 
1985




Straw et al, 
1983
Right apical 11.9% 10% 11% 10%
Right cardiac 7.5% 10% 10% 10%
Right
diaphragmatic
30% Leading edge 
5%
34% 25%
Intermediate 4.6% Leading edge 
5%
5% 10%
Left apical 7.1% 10 5% 10%
Left cardiac 6.9% 10 6% 10%
Left
diaphragmatic
31.6% Leading edge 
5%
29% 25%
Total score: 100% Max score 55 100% 100%
For the purposes of diagnosis of PEP within a herd, visual appraisal of the lungs at 
slaughter is sufficiently accurate to give a good indication of the severity of disease 
when large numbers of animals are scored and the average age of the animals is 
approximately 6 months (Morrison et al, 1986). A more accurate method of diagnosis 
for researchers would be to remove and weigh affected lung tissue and calculate the 
percentage value of the total lung weight. To overcome variation due to the resolution 
of disease sample, sizes must be large. This method is time consuming, labour 
intensive and impractical for large scale screening of herds. However, for use in
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studies examining the correlation between ADG and feed conversion efficiency in 
relation to PEP severity, this method overcomes standardisation problems.
Both visual appraisal and weighing affected lung tissue at necropsy also give 
inspectors and researchers an indication of the severity of disease within a herd 
(Goodwin, 1971) (Table 1.2).
Table 1.2: Table correlating the percentage of pigs within a herd to the severity of the 
outbreak (Goodwin, 1971).
Percentage of herd detected with lesions Severity of outbreak
0 Not affected
< 30% Slightly affected
30 - 50% Common prevalence
50 - 70% Moderate
70 - 85% Severe
> 85% Very severe
1.2.10.3 Serological detection ofM, hyopneumoniae
M. hyopneumoniae is a nutritionally fastidious organism which is rapidly overgrown 
in culture by less fastidious serologically cross-reactive mycoplasmas such as M. 
flocculare and M. hyorhinis (Simecka et al, 1992). These organisms are commonly 
isolated from porcine respiratory tracts and make culturing of M. hyopneumoniae 
extremely difficult. Although M. hyopneumoniae can easily be distinguished from 
other mycoplasmas either morphologically (Hovind-Hougen and Friis, 1991) or by 
immunofluorescence, the less fastidious organisms can overgrow cultures and prevent 
the subsequent detection of M. hyopneumoniae. The labour intensive nature of
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culturing M. hyopneumoniae often produces false negatives and requires long 
incubation periods; as a consequence it is considered a poor screening technique. 
Growth inhibition assays rely on the inhibition of M. hyopneumoniae growth by 
porcine sera to indicate the presence of neutralising antibodies (Stanbridge and 
Hayflick, 1967). This technique requires 3 to 7 days incubation of the assay plates 
during which time contamination may overgrow the plate. Other techniques requiring 
the culturing of M. hyopneumoniae include the indirect hemagglutination assay, 
complement fixation and immunoflourescence. These assays do not have the problem 
of co-isolation of other mycoplasmas leading to overgrowth, however, the cross­
reactivity of contaminating mycoplasmas (Friis, 1971; Freeman et al, 1984; Scarman 
et al, 1997), expense of culture and the long incubation periods prevent these 
techniques being used as routine diagnostics. The indirect hemagglutination assay 
gives a relative measure of the antibody binding capacity by serially diluting porcine 
sera against M. hyopneumoniae until no further visible agglutination is detected 
(Hudson and Hay, 1980). The test has a poor (41%) accuracy rate in the detection of 
PEP when compared against necropsy lung scores (Freeman et al, 1984). Complement 
fixation utilises cascade reactions thereby amplifying a small antibody-antigen 
interaction to result in a large detectable assay response (Hudson and Hay, 1980). This 
test is sensitive in the initial 38 days post exposure, however doubts have been raised 
about the accuracy of the test after this early stage (Freeman et al, 1984).
1.2.10.4 Enzyme linked immunosorbant assay (ELISA) detection
A number of ELISA techniques have been developed to specifically detect M. 
hyopneumoniae (Nicolet et al, 1980; Mori et al, 1987; Feld et al, 1992; Sheldrake and 
Romalis, 1992; Djordjevic et al, 1994). ELISA detects antibody in seroconverted pig 
samples, however, it is not useful in detecting subclinical infections of M. 
hyopneumoniae. Results from ELISA are recorded as a ratio calculated by dividing 
the obtained sample absorbance by a control negative sera. Ratios greater than 3 are 
designated PEP positive, less than 2 are PEP negative and those sera between 2 and 3
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are inconclusive. This screening is 98.8% specific; no M. jlocculare or M. hyorhinis 
infected pigs had ELISA readings outside the negative upper limit of 2 (Sheldrake and 
Romalis, 1992). False negatives occurred in the Sheldrake study at a rate of only 1% 
and was successful in detecting 95.6% of PEP positives when compared to gross lung 
examination at necropsy. ELISA has been useful in a number of seroepidemiological 
studies (Sheldrake et al, 1990; Morris et al, 1995); the method is rapid, relatively 
inexpensive and can handle large numbers of samples. The problem that prevents the 
commercialisation of the Sheldrake ELISA is that the antigen cannot be quality 
controlled between batches. Furthermore, this method requires the animals to have 
seroconverted which may take up to 10 weeks post natural exposure (Djordjevic et al, 
1994) during which time the pathogen can spread further within the herd. Djordjevic 
et al (1994) have developed a 43 kDa antigen M. hyopneumoniae specific ELISA 
which overcomes the problems encountered by the Sheldrake method. The 43 kDa 
ELISA is based upon a single preparative SDS-PAGE purified antigen which can be 
quality controlled. This antigen is specific for M. hyopneumoniae and is present in all 
strains tested (Scarman et al, 1997). This ELISA is more sensitive and can detect 
seroconverted pigs 2-3 weeks earlier than the Sheldrake method (Djordjevic et al, 
1994). As a research diagnostic assay this ELISA is specific, accurate and 
reproducible.
1.2.10.5 Molecular biology techniques
Using the molecular techniques of PCR and DNA hybridisation allows investigators 
to determine the presence of M. hyopneumoniae before the onset of clinical 
symptoms. Both techniques utilise species specific DNA sequences, in which the 
sequences of interest may not be a single gene; rather the sequences may span regions 
covering a number of uniquely arranged open reading frames, which may have no 
single function when expressed. Mycoplasmas have been shown to use gene 
rearrangements to evade host defences by producing structurally variant forms of 
surface components (Rosengarten and Wise, 1990; Yogev et al, 1991; Yogev et al,
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1993; Rosengarten et al, 1993). Consequently, a foreseeable problem with the 
molecular techniques is that if the mycoplasmal DNA undergoes frequent 
rearrangement, the unique random DNA fragments may only be present in a certain 
strain at a specific point in time. This problem is further compounded by the presence 
of repeated genetic elements resembling prokaryotic insertion sequences (Ferrell et al, 
1989). These genetic elements are 1550 bp in length, show variation in their 
chromosomal location and are present in various copy numbers in a majority of M. 
hyopneumoniae strains studied (Ferrell et al, 1989). The size and random nature of 
these elements can lead to false negatives if they have rearranged into a target DNA 
sequence.
DNA probes are able to detect the organism by hybridising to M. hyopneumoniae 
specific DNA sequences. A number of sequences unique to this pathogen have been 
detected (Table 1.3). Only the DNA probe described in the Johansson study 
(Johansson et al, 1992) uses a demonstrated essential gene, the 16S rRNA gene. These 
genes are the most conserved genetic elements in all organisms due to their essential 
role in protein synthesis (Olson et al, 1986; Woese, 1987). However, there is 
sufficient variation in the DNA sequences between organisms to make these genes 
species-specific and consequently useful target regions.
Molecular probes are a useful tool in research where only small numbers of samples 
are being tested. Under these conditions the associated Southern blot or dot blot 
hybridisation techniques may be routinely used. However, the polymerase chain 
reaction (PCR) has superseded DNA hybridisation techniques, offering a safer, more 
rapid and more sensitive M. hyopneumoniae detection system (Artiushin et al, 1993). 
PCR is an expensive technique to establish in a laboratory due to the cost of 
equipment and reagents. The training of research staff is vital to prevent 
contamination due to the extreme sensitivity of the technique which will often result 
in false positives (Razin, 1994). Once the technique is established in a laboratory, the
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PCR detection of M. hyopneumoniae is a simple and reproducible early detection 
method (Narita, 1993).
Table 1.3: M. hyopneumoniae specific DNA probes
Probe Detection method Sensitivity Reference
16S rRNA 
(rDNA probe)
32p Not determined Johansson et al, 
1992
1.3 kb DNA (f5) 35S 100 pg in culture Aherns & Friis, 
1991
2 kb £coRI DNA 
fragment
32p 10 pg in culture Stemke, 1989
1.65 kb DNA 
fragment (1141)
32p 400 pg in lung 
sample
Abiven et al, 1992
Studies by Artiushin and colleagues (Artiushin et al, 1993; Artiushin and Minion, 
1996) have demonstrated that genetic variation within M. hyopneumoniae field 
isolates can lead to false negatives and differing PCR banding patterns when arbitrary 
DNA primers are used. However, as described previously, the amplification of 16S 
rRNA genes overcomes this problem of genetic heterogeneity. Blanchard (Blanchard 
et al, 1994) described the development of a 16S M. hyopneumoniae specific PCR 
diagnostic sensitive enough to detect 1000 mycoplasmas seeded into porcine 
tracheobronchial secretions. The sensitivity of amplification of DNA from such 
biological samples is difficult due to the presence of PCR inhibitors which may also 
lead to false negative results (Razin, 1994). Furthermore, collection of 
tracheobronchial washings is not viable for widespread herd screening due to the 
labour costs and time involved. Immunomagnetic capture of the pathogen is a
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technique which removes inhibitors and subsequently increases sensitivity (Djordjevic 
et al, 1995) to reproducibly detect fewer than 10 mycoplasmas per assay (Zalanardo,
1995), a level that would allow for routine screening of nasal secretions.
1.3 Prevention and treatment of PEP
Introduction of M. hyopneumoniae and subsequent outbreaks of PEP can be 
minimised by both treatment and prevention. Effective control of the disease depends 
predominantly on the provision of a stable healthy environment, sound hygiene 
practices, low levels of bioaerosols, adequate ventilation, climatic control and 
adequate floor space for animals (summarised in Table 1.4). Correct animal husbandry 
practices must be adhered to because the buildings used for intensive pig production 
may represent health risks not only to the swine being housed but also to pig meat 
industry workers (Donham, 1995).
1.3.1 Selection of Swine
Sourcing of pigs from SPF herds for most producers is not a commercially viable 
option. There are methods, however, which minimise the introduction and spread of 
M. hyopneumoniae within a commercial piggery. Furthermore with correct animal 
husbandry practices, PEP free herds may be obtained. Research has demonstrated that 
pigs sired by Yorkshire boars have more extensive lung lesions and significantly 
reduced market weights than pigs of other breeds (Morris et al, 1995); subsequently, 
selection of less predisposed breeds such as Landrace pigs will reduce the impact of a 
pneumonia outbreak (Done, 1991). The sex of swine does not have any predisposing 
influence on the extent or severity of PEP (Done, 1991).
1.3.2 Antibiotic treatment
Antibiotics are used both for the treatment of outbreaks and for the prevention of 
colonisation by the pathogen. Due to the problems of screening a swine herd for M. 
hyopneumoniae, the symptoms of a dry unproductive cough and general poor
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condition will alert producers to a disease problem. Only when the cost of 
pharmaceutical treatment is justified, such as in breeding stock, will antibiotics be 
used to treat animals at an individual level. The most potent antimycoplasmal agent is 
tiamulin (Dynamutalin), which is often used in conjunction with a tetracycline class 
antibiotic such as oxytetracycline (tetramycin) or chlortetracycline (aureomycin, 
aurofac) which act synergistically not only against M. hyopneumoniae but are also 
very potent against the common secondary invaders P. multocida and B. 
bronchiseptica (Eamens, 1992; Miller, 1995). The routine use of antibiotics in 
piggeries is directed against the enzootic pathogen rather than against the subsequent 
disease. Medicated early weaning involves treating the sow with antibiotics in the late 
period of gestation. The sows offspring are subsequently weaned at a maximum of 14 
days into an isolated nursery piggery (Tubbs, 1995). The 14 day limit is the period 
after which the colostrum derived passive immunity against M. hyopneumoniae 
begins to decline, leaving the piglets at risk of being infected by the pathogen from the 
sow. Medicated early weaning when used in conjunction with the All-In All-Out (AI- 
AO, see 1.3.3) batch production system has been shown in studies to minimise PEP 
from experimental herds (Miller, 1995). Nurseries should be routinely disinfected 
between batches and weaners should be isolated from other pigs. During the period 
after weaning the piglets feed is supplemented with 100 parts per million (ppm) 
tiamulin and 300 ppm chlorotetracycline for one week then subsequently 25 ppm 
tiamulin for the next two weeks. Research has demonstrated that provided the cohort 
of pigs are moved into disinfected finishing sheds as an isolated batch the problem of 
PEP within the study groups was eradicated (Miller, 1995).
There are a number of problems associated with the use of antibiotics both as a 
prophylactic and a treatment measure. Antibiotic usage has more recently become 
socially unacceptable and all nations now have strict regulations concerning the use of 
antibiotics and the minimum residual levels that are permissible in food for human 
usage. The impetus behind this social unacceptance is that consumption of low levels
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of antibiotics selects for antibiotic resistant strains of microorganisms. There are three 
mechanisms which can lead to antibiotic resistance: gene mutation, acquisition of new 
antibiotic resistance genes and an innate resistance already present in the strain or 
species. All three mechanisms have been shown to operate in the mycoplasmas 
(Roberts, 1992). Different field isolate strains of M. hyopneumoniae have different 
sensitivities to a range of antimicrobials (Miller, 1995) including those antibiotics 
used to treat PEP. Therefore it is feasible that the continued large scale usage of 
antibiotics may lead to antibiotic resistant strains.
1.3.3 Optimal system of swine production
The conditions in which swine are housed and good animal husbandry practices can 
make significant differences to losses incurred by PEP (DiFranco et al, 1989; Straw, 
1991). There are a number of animal management systems each of which have 
benefits for the particular sector of the pig meat industry they serve. Pig housing 
facilities for all systems should be a minimum of three kilometres from other pig 
housing facilities to prevent the airborne transmission of M. hyopneumoniae 
(Goodwin, 1985). Continuous pig production is the predominant animal production 
system used in very large scale intensive piggeries. In this system weaners through to 
finishing swine are housed in the same production unit (Curtis and Backstrom, 1992). 
Upon a single farm there may be a number of continuous facilities isolated by distance 
and strict worker practices in use to prevent contamination between sheds. Under this 
system, meeting the animals needs as well as monitoring and controlling disease is 
critical. Once M. hyopneumoniae or any other pathogen is enzootic it is extremely 
difficult to eradicate due to the older chronically infected animals introducing the 
pathogen to the younger healthy pigs. The AI-AO production system is where all 
animals at each step are treated as a batch unit and kept isolated from all other animals 
on the farm. Within the AI-AO production system of housing swine, pathogens are 
easier to control because all batches are isolated. Under these conditions there is no
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chronic source of disease and it is difficult to introduce new pathogens (Scheidt et al, 
1990; Clark et al, 1991a; Clark et al, 1991b).
1.3.4 Environmental factors which optimise prevention of PEP
1.3.4.1 Temperature
There is no global relationship between season and the incidence of PEP. Regionally 
there are patterns of PEP outbreaks corresponding to times when temperatures are the 
most extreme and daily variations are greatest (Done, 1991). An optimum temperature 
within a piggery is important to prevent energy from feed being expended upon the 
maintenance of body temperature (Curtis and Backstrom, 1992). However, more 
importantly, the temperature must be maintained constant and the animals must be 
kept out of draughts. Furthermore, pigs must be well insulated from the conductive 
chilling caused by floors and average variations in temperature must not be greater 
than 12°C within 24 hours if the incidence of PEP is to be reduced (Done, 1991).
1.3.4.2 Humidity
Humidity can play a role in the incidence of PEP when high humidity causes damp 
conditions which favour the survival of secondary respiratory pathogens which can 
reduce an animals resistance to disease (Done, 1991; Curtis and Backstrom, 1992). 
Because pigs within modern environmentally controlled piggeries do not rely on 
evaporative heat loss to maintain temperature, humidity as a factor is not significantly 
correlated to the incidence of PEP.
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1.3.4.3 Ventilation
Adequate ventilation is vital in intensive piggeries. High stocking densities lead to 
high levels of airborne pollutants all of which influence respiratory tract infections. 
Animals housed in extreme winter climates have a higher prevalence of pneumonia 
due to the ventilation in winter being reduced to maintain temperature. This in turn 
effectively increases humidity, bioaerosol concentrations and air pollution, all of 
which contribute to increasing the extent and severity of PEP (Done, 1991). 
Concentrations of airborne bacteria have been shown to increase due to restrictions in 
ventilation. In one study, bacterial numbers increased from 15,000 cfu/m3 in summer 
to 350,000 cfu/m3 in winter (Curtis and Backstrom, 1992). Poor ventilation can also 
lead to an accumulation of ammonia. Studies have demonstrated that extended 
exposure to levels exceeding 100 ppm leads to the depression of pathogen clearance in 
swine lungs (Curtis and Backstrom, 1992). Further studies have also indicated that 
high levels of ammonia will increase the severity of PEP and correspondingly reduce 
ADG in the affected swine (Diekman et al, 1993; Andreasen et al, 1994).
1.3.4.4 Floor space and pig numbers
Pig numbers confined within a single airspace should be kept between the ideal 
number of 150 swine and the economically feasible upper limit of 500 swine. More 
than 500 pigs in the same airspace results in a significant increase in the incidence of 
PEP (Done, 1991). Weaned pigs in nurseries should be kept with between 12 - 20  
penmates depending upon the weather conditions. In colder conditions pen densities 
should be increased to allow for greater shared warmth (Curtis and Backstrom 1992). 
If weaners are to be raised to approximately 30 kg before moving into a finishing shed 
the floor space required per pig should be 0.75 - 1.0 m2 (Tubbs 1995). Finishing pigs 
require 35 cm of trough space and similar floor space allowances as large weaners 
(0.75 - 1.0 m2) (Curtis and Backstrom, 1992).
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Table 1.4: Summary list of physical parameters which must be maintained to ensure a 




Temperature > 12°C range per day significantly increases PEP.
Herd size >500 pigs housed per shed increases PEP prevalence even if all 
other parameters are controlled.
Pen population No correlation if floor space is maintained.
Floor space Pig weight to floor space > 120 kg/m2 increases PEP.
Air space Minimum of 3 m2/pig (if air quality is maintained).
Air quality Ammonia, bacteria, hydrogen sulphide and dust must be
minimised.
Feeding < 0.35 m feed trough per pig increases PEP.
1.3.4.5 Experimental vaccines
Early work using parenterally delivered whole cell M. hyopneumoniae antigens 
demonstrated that without adjuvant there is no protection offered (Goodwin and 
Whittlestone, 1973). Protection against the development of PEP can be elicited using 
whole cell M. hyopneumoniae antigens parenterally delivered with Freund’s complete 
adjuvant or a mixture of Bayol/Arlacel adjuvants (Goodwin and Whittlestone, 1973). 
Due to severe adverse reactions against these adjuvants their use is unacceptable. 
However, modem adjuvant mixtures such as the Auspharm adjuvant (Auspharm Int. 
Ltd. Australia) do not produce such side-effects (Sheldrake et al, 1991). Studies have 
shown significant protection against virulent challenge using formalin-killed M. 
hyopneumoniae mixed with Auspharm adjuvant delivered parenterally (Sheldrake et
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al, 1991). Similarly, Djordjevic et al (1997) used a range of adjuvant formulations and 
demonstrated significant reductions in lung damage caused by experimentally induced 
PEP. These studies differ from earlier reports because the trials were carried out using 
purified M. hyopneumoniae subunit antigens (in the 70-85 kDa range) that were size 
fractionated using preparative SDS-PAGE column electrophoresis. This approach 
facilitates the identification of antigens which are not only immunogenic in swine, but 
which also confer a degree of protection against experimental challenge.
High passage number attenuated M. hyopneumoniae vaccines have been developed 
(Li et al, 1992; Ding et al, 1992). These lapinized strains elicit significant protection 
against experimental challenge using the parental strain. Obviously, any attenuated M. 
hyopneumoniae vaccine strain must be protective against geographically diverse 
strains, be cheap to produce and easy to administer. Details as to whether these 
attenuated M. hyopneumoniae strains are strain specific are not published. 
Furthermore, there has been no literature post-1992 which describes further 
development and assessment of these vaccines.
Research into PEP vaccines has produced encouraging results. It has been 
demonstrated that it is possible to provide immunological protection against virulent 
M. hyopneumoniae challenge. However, commercialisation of these vaccines is slow. 
Both protection from disease and economic benefits to producers must be 
demonstrated before any product can be considered for marketing.
1.3.4.6 Commercial vaccines
Presently there are only two commercially available M. hyopneumoniae vaccines 
available; Suvaxyn™ (Europe) also called Respifend™ (outside Europe) produced by 
Solvay Animal Health and Stellamune™ (Europe) also called Respisure™ (outside 
Europe) produced by SmithKline Beecham Animal Health. Both of these vaccine
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preparations consist of inactivated M. hyopneumoniae whole cells mixed with 
adjuvant. The mode of delivery is intramuscular and relies on the adjuvant to 
stimulate the vaccinated animals immune system to give a protective response. 
Murphy and colleagues (Murphy et al, 1993) demonstrated that the systemic immune 
system did not direct an immediate response against intramuscularly delivered 
Respifend™ vaccine antigens, as determined by measuring serum antibody levels. 
However, after challenge, serum antibody levels were significantly higher than levels 
detected in control pigs and this subsequent antibody response resulted in a significant 
decrease in both the incidence and severity of PEP. This study indicates that the 
vaccine primed the antibody producing cells for a response. The role of these 
antibodies in protection from PEP was not examined, but a correlation between serum 
antibody levels and protection was observed. Field trials which examined the efficacy 
of both the Respifend™ and Respisure™ vaccines in conventional piggeries have 
been carried out in numerous countries under widely varying conditions (Miller et al, 
1992; Bilic et al, 1992; Charlier et al, 1993; Christensen and Vraa-Anderson, 1993; 
Charlier et al, 1994; Doohoo and Montgomery, 1996). Studies show the vaccine 
Respifend™ is able to reduce the frequency of PEP affected pigs by greater than 50% 
and significantly decrease the extent of pneumonic lesions in a majority of herds 
tested (Christensen and Vraa-Anderson, 1993). Similarly, Respisure™ has also been 
demonstrated to produce highly significant reductions in frequency and severity of 
pneumonia (Bilic et al, 1992; Charlier et al, 1993). Because PEP outbreaks are 
influenced both in severity and frequency by so many compounding factors, results 
for all studies vary widely, and in no cases is there a 100% eradication of both the 
disease and causal agent. Furthermore, in many studies even though the frequency and 
severity of damage was significantly decreased by vaccination there was no 
significant differences in average daily gains between vaccinated and control swine 







Identification and characterisation of the recombinant M. 
hyopneumoniae antigen recognised by porcine immune sera
Preliminary research described within this introduction was carried out by a team 
coordinated by Dr Steven P. Djordjevic at the Elizabeth Macarthur Agricultural 
Institute (NSW Agriculture, EMAI, PMB 8, Camden New South Wales. 2570). The 
aim of this research was to identify immunogenic antigens from M. hyopneumoniae 
and to assess the protective efficacy of these proteins for use in subunit vaccines for 
the protection of swine against PEP.
2.1 Preliminary research
A recombinant gene library was constructed by ligating Sau3Al digested M. 
hyopneumoniae (strain J) chromosomal DNA into the BamHl site of the expression 
plasmids pEXl-3 (Takeshita et al, 1987). Ligation into this site fuses the inserted 
fragment to the 3' end of the lacZ gene, resulting in an open reading frame which, if in 
frame, expresses a hybrid B-galactosidase fusion protein. After transformation into E. 
coli MCI061 (pCI857), colonies were screened for recombinant protein expression 
using porcine hyperimmune M. hyopneumoniae antiserum. A positive clone, 
designated pSD9 (Fig 2.1), was identified containing DNA which encoded 11 kDa of 
a M. hyopneumoniae antigen fused to B-galactosidase resulting in a 128 kDa fusion 
protein. The fusion protein was purified and subsequently used to raise rabbit 128 kDa 
fusion protein antisera.
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Fig 2.1: Schematic representation of the construction of the expression plasmid
pSD9. Plasmid pEXl is an expression vector containing an ampicillin resistance gene 
(Ap, open box), origin of replication (oriR, open box), lambda Pr promoter (P r , filled 
arrow) directing the expression of the (3-galactosidase transcriptional unit (cro'-lacf- 
lacZ, open box) and stop codons in all three reading frames followed by a phage fd 
terminator (stop/term, filled box). Plasmid pSD9 contains a M. hyopneumoniae 
Sau3Al 0.8 kb DNA fragment (mycoplasma gene fragment, filled box) ligated into the 
BamHl site of pEXl.
This 128 kDa fusion protein was subsequently used in a vaccination trial to determine 
the effect on severity of PEP after immunisation. Pigs were immunised according to 
the protocol described by Djordjevic et al (1997) with the following changes. Pigs 
(n=12) were inoculated intramuscularly with 128 kDa fusion protein (1 mg/pig) 
complexed with one of 4 different adjuvants (3 pigs/adjuvant): alhydrogel (Cyanamid 
Websters), algammulin (Cooper and Steele, 1991), DEAE-Dextran/mineral oil 
(Hoskinson et al, 1990) and DEAE-Dextran/Auspharm vegetable oil (Auspharm 
International). After challenge with the virulent Beaufort strain (Etheridge et al, 1979) 
of M. hyopneumoniae, visual appraisal of the lungs at slaughter demonstrated that pigs 
vaccinated with the 128 kDa fusion protein had a significantly lower (P<0.05) mean 
logistic-transformed lung score (mean lung score = 8.0) than the unvaccinated controls
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(n -  6) (mean lung score = 15.3) (Fig. 2.2) but there were no significant differences 









Fig 2.2: Graph showing average lung lesion scores at slaughter in 128 kDa fusion 
protein vaccinated and unvaccinated pig groups after challenge with virulent M. 
hyopneumoniae. The 128 kDa vaccine group represents the pooled mean of all 
adjuvant groups. Standard error of the mean is indicated by vertical bars.
The significant reduction in the lung scores of vaccinated pigs led to the antigen 
encoded by the plasmid pSD9 being considered as a candidate antigen for use in the 
development of a live oral recombinant vaccine against M. hyopneumoniae.
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2 .2 Materials and methods
2.2.1 Construction and identification of clones expressing a M
hyopneumoniae antigen
2.2.1. l Bacterial strains, plasmids and media
Bacterial strains and plasmids used in the work described in this chapter are listed in 
Table 2.1. All bacteria were grown in Luria Bertani broth (LB) (Sambrook et al, 1989) 
or on Z agar medium (Walker et al, 1988). Antibiotics were used at the following 
concentrations: chloramphenicol 50 pg/ml; ampicillin 100 pg/ml; kanamycin 50 
pg/ml. For transformation experiments bacteria were grown overnight on Z agar with 
appropriate antibiotic selection then subsequently seeded into 500 ml of selective LB 
broth cultures, with selection, and grown at 37°C to mid log phase (ODgso = 0.5 - 0.6) 
prior to harvesting by centrifugation (2000 x g for 15 min). Transformation of bacteria 
was performed as described by Sambrook et al (1989).
2.2.1.2 Plasmid extraction
Plasmids were isolated by either the commercial QIAGEN 100 pg (Midi) plasmid 
preparation kit or by phenol/chloroform small scale plasmid extraction. QIAGEN 
extractions were carried out according to the manufacturer's instructions using the 
supplied buffers. Phenol/chloroform extractions were carried out by growing a 10 ml 
culture of bacteria containing plasmid overnight at 37°C in LB with selection. Cells 
were pelleted at low speed in a 15 ml Falcon tube using a bench top centrifuge. 
Pelleted bacteria were resuspended in 1 ml of 10 mM Tris (pH 8.5) containing 1 mM 
EDTA (TE) buffer. These were then transferred to a 1.5 ml Eppendorf tube and 
pelleted for 1 min at 12000 x g using an Eppendorf 5415C microfuge; all subsequent 
spin steps were performed at 12000 x g using this microfuge model. The supernatant 
was discarded and bacteria was resuspended in 0.4ml TE containing 15% sucrose
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Table 2.1: Plasmids and bacterial strains described within this chapter.
Bacterial Strains Source and
Reference (where applicable)
M. hyopneumoniae strain J A. Pointon. Adelaide, Australia.
M. hyopneumoniae strain C l735/2 Queensland Australia. 
Scarman et al, 1997
M. hyopneumoniae strain YZ M. Kobish. France. 
Scarman et al, 1997
M. hyopneumoniae strain 232 T. Young. U.S.A. 
Scarman et al, 1997
M hyopneumoniae Beaufort strain Australian Mycoplasmal 
Reference Collection.
M. hyopneumoniae strain Sue If
M. hyopneumoniae strain OMZ407 I t
M. hyorhinis strain GDL f t
M. hyorhinis strain BTS7 I t
M. hyorhinis field strain 1 f l
M. hyorhinis field strain 2 M
M. flocculare strain Ms42 I t
E. coli JM109 Yanisch-Perron et al, 1985
E. coli MCI061 (pCI857) Messier et al, 1987
Plasmids
pHSG398 Takeshita et al, 1987
pKFl * This study
pEXl-3 Stanley and Luzio, 1984
pSD9 Dr Steven Djordjevic EMAI, 
Camden. N.S.W. Australia.
pQE-9-11 Janknecht et al, 1987
pETEl This study
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(TES) and 1 mg/ml lysozyme (Sigma) then left at RT for 30 min. After incubation 0.3 
ml of TE containing 0.1% Triton X-100 was added and tubes were inverted twice 
prior to incubation at 65°C for 15 min. Cell debris were pelleted for 30 min at 12000 x 
g. The supernatant was transferred into a new 1.5 ml tube and 0.5 ml of phenol 
saturated TE was added and mixed. After centrifugation for 1 min the upper aqueous 
layer was transferred to a clean Eppendorf tube and the phenol/TE step was repeated. 
To the transferred aqueous layer, 1 ml of diethyl ether was added. Tubes were mixed 
and centrifuged briefly prior to the transfer of the lower layer. A drop of 3 M sodium 
acetate was subsequently added and the tubes vortexed prior to the addition of 2.5 
volumes of chilled ethanol. The mixture was left for 5-10 min at -20°C then 
centrifuged for 5 min. The ethanol was poured off and the pelleted plasmid DNA was 
air dried before being resuspended in 50 pi of dH20 containing 20 pg/ml ribonuclease 
A (Sigma) and incubated at 37°C for 30 min prior to use or storage at -20°C.
2.2.1.3 Bacterial chromosomal DNA isolation
Chromosomal DNA isolation from E. coli and S. typhimurium strains was performed 
by phenol extraction, mycoplasma chromosomal DNA was kindly donated by A. 
Scarman from EMAI. Bacteria was streaked for single colonies onto Z agar with 
selection and grown at 37°C overnight, or to confluence, after which the growth was 
transferred into 25 ml of 1 M NaCl in a sterile 50 ml centrifuge tube and shaken on ice 
for one hour. After incubation on ice, cells were centrifuged at 12000 x g for 10 min 
(Sorvall RC-5B superspeed centrifuge; SS-34 rotor). The pellet was resuspended in 25 
ml of chilled TES buffer and the centrifugation step repeated. The supernatant was 
poured off and the cells resuspended in 5 ml of chilled TE buffer containing lysozyme 
(0.2 mg/ml) (Sigma) to degrade peptidoglycan and incubated for 15 min at 37°C. 
After incubation, 0.6 ml of TE solution containing 10% sodium dodecyl sulphate 
(SDS) and protease (5 mg/ml; Sigma) was added and the solution was incubated for 1 
h at 37°C. Subsequently 5 ml of TE saturated phenol was added and the tube was 
briefly shaken and centrifuged at 12000 x g for 10 min. The upper aqueous layer was
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transferred to a sterile 1.5 ml Eppendorf tube and a further phenol extraction step was 
performed before 1 ml of diethyl ether was added to remove remaining phenol. The 
tube was briefly vortexed and centrifuged at 16000 x g for 1 min in an Eppendorf 
5415C microfuge after which the lower phase was transferred to a sterile 1.5 ml 
Eppendorf tube and the diethyl ether step was repeated. To the transferred lower 
phase, 50 pi of 3M sodium acetate was added and mixed well. The nucleic acids were 
then precipitated by the addition of 2.5 volumes of ice cold ethanol followed by 
centrifugation at 16000 x g in a microfuge for 5 min after which the supernatant was 
poured off. The remaining pellet was air-dried then resuspended in 50 pi dH20
containing 20 pg/ml ribonuclease A.
2.2.1.4 Agarose gel electrophoresis
Agarose gel electrophoresis was used to detect and resolve DNA fragments using a 
BioRad MiniSub DNA cell. A 5 pi aliquot of agarose gel loading buffer was mixed 
with approximately 1 pg (5-10 pi) of DNA sample and loaded into the wells of a cast 
agarose gel. The percentage of agarose was determined by the size of the fragment to 
be resolved (0.7-1.5%). Electrophoresis was carried out at 50 V (constant voltage) for 
an appropriate period of time. After running, the DNA was stained using 1 pg/ml 
solution of ethidium bromide and visualised under ultraviolet light (UV 
Transilluminator, UVP).
2.2.1.5 Electroelution of DNA from agarose gel
Prior to electroelution the restricted DNA was separated by agarose gel 
electrophoresis and visualised. Agarose containing the fragment was excised and 
placed in an Eppendorf tube with a small hole cut in the base. Parafilm was wrapped 
around the sides of the tube, which was then secured firmly to the top of a Centricon 
100 microconcentrator tube (Amicon). Both Eppendorf and Centricon tube were filled 
with TAE buffer. The lower end of the Centricon was secured into a TAE buffer 
reservoir containing a positive electrode, a circuit was completed by placing a
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platinum negative electrode wire into the open top of the tube. A current of 100 V was 
passed through the apparatus for 30-120 min, depending on the fragment size, thereby 
eluting the DNA fragment into the underlying Centricon tube. The Centricon tube was 
then used according to the manufacturer’s instructions to purify and concentrate the 
DNA down to a total volume of 50-100 pi in aqueous solution.
2.2.1.6 Southern hybridisation
DNA was analysed by Southern hybridisation (Southern, 1975). Restricted DNA was 
resolved by agarose gel electrophoresis, visualised and photographed. The gel was 
subsequently washed (2x10 min duration) in 0.25M HC1, to induce the breakdown of 
large DNA fragments to assist in transfer, then rinsed briefly in water. The gel was 
then washed (2 x 10 min) in 1.5M NaCl; 0.5M NaOH to denature DNA and 
neutralised by washing (4x10 min) in IM Tris HCl; 1.5M NaCl. DNA was then wet- 
transferred onto positively charged nylon membrane (Boehringer Mannheim) by 
capillary transfer (Sambrook et al, 1989). Transferred DNA was bound to the 
membrane by cross-linking for 3 min at 254 nm (UV Stratalinker 1800; Stratagene). 
Probe DNA was a-32P dATP (Bresatec) labelled by nick translation using a nick 
translation kit (Gibco BRL) following the manufacturer's instructions. The nylon 
membrane was prehybridised for 6 h in prehybribisation solution at 65°C using a 
mini-hybridisation oven (MK II, Hybaid). The denatured labelled DNA probe was 
then added and hybridisation was carried for 6-12 h. This was followed by 2 washes 
with 2x SSC containing 0.1% SDS at RT for 15 min, then 2 washes in O.lx SSC 
containing 0.1% SDS at 65°C for 15 min. Membranes were subsequently exposed to 
X-ray film (Kodak) at -80°C for 2-24 h prior to development.
2.2.1.8 DNA sequence analysis
The dideoxy chain termination method (Sanger et al, 1977) was performed on plasmid 
pKFl using the T7 Sequenase kit (Pharmacia) following the instructions of the 
manufacturer. The universal M l3 forward primer and M l3 reverse primer (Table 2.2)
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were used initially to sequence the 0.8 kb M. hyopneumoniae DNA fragment. Further 
internal primers were synthesised (Table 2.2) after analysis of sequence data to allow 
both strands of the M. hyopneumoniae DNA fragment to be completely sequenced. 
Protein sequence comparisons were carried out using a Blast2 network service 
provided by the National Center for Biotechnology Information (NCBI) accessed 
through the Australian National Genomic Information Service (ANGIS, Australia). 
Databases searched were the GenBank, SwissProt, PDB, EMBL and DDBJ databases.
2.2.1.9 PCR amplification
The PCR primers 5 '-TTTGCCGAACCTTTTTACA-3' (primer 1469) (MUCAB, 
Australia) and 5'-AATCAGCAATAAAATTTAGC-3' (primer 1470) (MUCAB, 
Australia) were synthesised based upon data obtained from the cloned M. 
hyopneumoniae DNA sequence spanning an internal 750 bp region. Purified plasmid 
DNA, M. hyopneumoniae, M. flocculare or M. hyorhinis chromosomal DNA were 
used as templates for the PCR. Amplifications were carried out in a final volume of 
100 pi and contained 100 ng of template DNA; 200 pmol of primers 1469 and 1470; 6 
mM MgCl2; 10 mM KC1; 20 mM Tris-HCl (pH 8.2); 0.1% Triton X-100, 6 mM 
(NH4)2SC>4; dATP, dGTP, dCTP and dTTP (Boehringer Mannheim) at 2 mM each; 
and 5 units of Pfu DNA polymerase (Stratagene). Parameters for amplification 
consisted of 1 cycle at 96°C for 3 min (denaturation), 55°C for 1 min (primer 
annealing) and 72°C for 1 min (extension) followed by 29 cycles of 96°C for 20 sec; 
55°C for 20 sec; and 72°C for 30 sec with a final extension cycle at 72°C for 2 min. 
Amplifications were conducted in a PCR thermal reactor (Hybaid). A 10 pi aliquot of 
the reaction mixture was analysed on a 1% agarose gel and the PCR products were 
stained with ethidium bromide and visualised under UV light.
43
Table 2.2: DNA primers used in the sequencing of the 0.8 kb M. hyopneumoniae 
DNA fragment.
Primer Sequence Supplier
Forward M l3 5'-GTAAAACGACGGCCAGT-3' Pharmacia
Universal
Reverse M l3 5'-TTCACACAGGAAACAGCTATGACC-3' Biotech
Universal International,




Internal forward 2 5 ’ -CIGCAGGATOCAAACDCACITnTTCAT-3 ’ t f
(Pstl)
Internal forward 3 5 ’ -TCGTCG ATTTT GT A A AGCT G-3 ’ I t
Internal reverse 4 5 ’ -TTC AAAAGAGGAAACCGAA-3 ’ I t
Internal reverse 5 5 ’ -T G ACT AA A A ATTT C AGGTT C-3 ’ f t
Internal reverse 6 5 ’ -TGTTCCTAAT AATTC AAAAC-3 ’ f t
2.2.1.10 Construction of pKFl
The plasmid pKF 1 was constructed by subcloning the M. hyopneumoniae fragment of 
pSD9 into the parental plasmid pHSG398 (Fig.2.3). The plasmids pHSG398 and 
pSD9 were separately digested with the restriction enzymes Smal and Pstl, which cut 
pHSG398 and released the M. hyopneumoniae DNA fragment from pSD9. After 
ligation, the mixture was used to transform E. coli JM109 and subsequent 
transformants were selected on Z agar containing chloramphenicol. A clone, 
designated pKFl, expressed a recombinant 15 kDa protein, comprising the 11 kDa M. 





Fig 2.3: Schematic representation of the steps involved in the construction of the 
plasmid pKFl. The 0.8 kb M. hyopneumoniae DNA fragment was excised from the 
plasmid pSD9 using the restriction enzymes Smal and Pstl and ligated into pHSG398 
digested with Smal and Pstl. Plasmid pHSG398 is a high copy number vector 
containing an origin of replication (oriR, filled box), chloramphenicol resistance gene 
(Cm, open box), polylinker cloning site within the lacZa gene (LacZa, open box). 
Plasmid pKFl contains the 0.8 kb M. hyopneumoniae DNA fragment (filled box) 
ligated into the Smal and Pstl sites of the polylinker cloning site of pHSG398.
2.2.1.11 Construction of pETEl
To facilitate the rapid one-step purification of the recombinant antigen the M. 
hyopneumoniae insert was cloned into the pQE expression vector system (Qiagen Inc, 
Chatsworth, CA, USA) which allows for high level expression of histidine affinity-
45
tagged recombinant proteins in E. coli. Using pKFl as a template the 0.8 kb M. 
hyopneumoniae insert was PCR amplified as described previously using the Internal 
reverse 1 {Bam HI) and Internal forward 2 {Pst I) primers (Table 2.2) to amplify the 
0.8 kb fragment. After amplification the fragment was analysed on a 1% agarose gel 
and the PCR product was stained with ethidium bromide and visualised under UV 
light. The fragment was electroeluted from the gel and ligated into the plasmid pCRII 
using a TA cloning™ kit (Invitrogen) following the manufacturer’s instructions. One 
plasmid construct containing the 0.8 kb fragment was designated pKFlO (Fig 2.4). 
This TA cloning™ system was used as an intermediate step because it has been 
developed to allow for the rapid and efficient cloning of PCR products into a plasmid 
with lacZ colour selection. The constructed plasmid pKFlO was used to transform E. 
coli JM109 which was grown either in LB or on Z agar plates with selection 
(ampicillin 100 pg/ml and kanamycin 50 pg/ml) to recover large amounts of pKFlO. 
No investigation was carried out to determine whether the recombinant antigen 
encoded by the 0.8 kb M. hyopneumoniae insert was expressed in the E. coli JM109 
(pKFlO) strain. The 0.8 kb fragment was released from isolated pKFlO DNA by a 
single Bam HI restriction and ligated into the same enzyme site within the polycloning 
site of the plasmid pQE9 (Qiagen Inc, Chatsworth, CA, USA). Constructed clones 
were screened using colony hybridisation analysis to determine the presence of the 0.8 
kb M. hyopneumoniae insert.
2.2.1.12 Colony hybridisation
Colony hybridisation was used to detect pQE9 clones containing the 0.8 kb M. 
hyopneumoniae DNA fragment. Transformed colonies were replica plated onto Z agar 
containing ampicillin, Z agar containing ampicillin and kanamycin and also onto 
nylon membrane discs (Hybond-N+ transfer membrane discs. Amersham) laid on Z 
agar containing ampicillin (100 pg/ml). Replica plates were grown overnight at 37°C. 
After incubation the Z agar plates with selection were stored for future use at 4°C and 
the nylon membranes were processed. The membrane was placed colony side upwards
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onto 2 sheets of filter paper saturated with 10% SDS for 3 min after which the 
membrane was transferred onto filter paper saturated with denaturing solution (0.5 N 
NaOH with 1.5 M NaCl) for 5 min and subsequently transferred onto filter paper 
saturated with neutralising solution (0.5 M Tris (pH 7.4) with 1.5 M NaCl) for 5 min. 
The nylon membrane was then placed onto filter paper saturated with dH20  for 5 min
after which the membrane was placed onto filter paper saturated with 2x SSC for 20 
min, air-dried on a clean bench for at least 30 min then the membrane was baked for 
10 min at 80°C. After baking, the membrane was treated as described in the Southern 
hybridisation protocol, using the 0.8 kb M. hyopneumoniae fragment which was a-32P 
dATP (Bresatec) labelled by nick translation using a nick translation kit (Gibco BRL) 
following the manufacturer's instructions. Hybridised membranes were exposed to X- 
ray film (Kodak) overnight and developed. Positive colonies were identified and 
compared with the stored Z agar plates; if a positive was kanamycin resistant it was 
ignored as a parental pKFlO plasmid. Once positive pQE derived clones (Fig 2.4) 
were detected, the corresponding colonies were examined using Western 
immunoblotting to detect expression of the 11 kDa recombinant protein.
2.2.1.13 Pre-absorption of 128 kDa fusion protein antiserum
To reduce the presence of antibodies against p-galactosidase, the rabbit 128 kDa 
polyclonal antiserum (described in 2.1) was extensively preabsorbed against 
commercially available p-galactosidase (Boehringer Mannheim). Three nitrocellulose 
membranes (10 x 10 cm Transblot, BioRad) were impregnated with p-galactosidase 
(100 mg/membrane) and air-dried. Rabbit 128 kDa fusion protein antiserum was 
diluted 1:200 in phosphate buffered solution (PBS: pH 7.4) and exposed to the first 
membrane for 1 h at room temperature (RT) followed by exposure to a second 
membrane for 1 h at RT. The antiserum was then exposed to the third impregnated 
membrane overnight at 4 C. The antiserum was subsequently collected and stored at -
o „  .20 C prior to use.
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Fig 2.4. Schematic representation of the steps involved in the construction of 
the subclone pETEl, which encodes a recombinant histidine tagged 11 kDa protein. 
The plasmid pCRII (Invitrogen) contains the lac promotor (P lac, filled arrow) which 
directs expression of the lacZa gene (open arrow). This gene contains a polycloning 
site in its 5’ region; the lacZa gene allows for blue/white screening of recombinant 
constructs by a-complementation of (3-galactosidase. The plasmid also contains the 
ampicillin resistance gene (shaded box), kanamycin resistance gene (open box) and an 
origin of replication (ColEl ori, open box). The M. hyopneumoniae 0.8 kb DNA insert 
(filled box) from the plasmid pKFl was PCR amplified and ligated into pCRII to 
produce an intermediate plasmid pKFlO. This plasmid was recovered from E. coli 
JM109 and the 0.8 kb fragment was excised with a single BamHl restriction. The 
fragment was inserted into the same enzyme site of pQE9 (Qiagen) and a positive 
construct was identified and designated pETEl. The parental plasmid pQE9 contains 
the T5 phage promotor (Promotor, open box) and two lac operator sequences which 
control expression of DNA fragments ligated into the polycloning site (open box). A 6 
histidine coding sequence (6xHistidine tag, filled box) is immediately 5’ of the 
polycloning site. Immediately 3’ of the poly cloning region there are translational stop 
codons in all reading frames as well as a X-phage transcriptional terminator. Also 
present are the amplicillin resistance gene (shaded box) and an origin of replication 
(Origin, open box). The plasmid pETE contains the M. hyopneumoniae 0.8 kb DNA 






























2.3 Purification of expressed recombinant antigens
2.3.1 Preparative PAGE purification of recombinant 15 kDa antigen
Purified 15 kDa antigen was used for the preparation of rabbit antiserum. Antigen was 
purified using SDS-polyacrylamide preparative column electrophoresis according to 
the method described by Djordjevic et al (1994) Briefly, a 6 cm 15% polyacrylamide 
matrix was used for the resolving phase which was overlaid with a 1 cm 4% stacking 
gel. Bacterial culture containing the recombinant antigen was harvested, reduced with 
boiling for 10 min in splitting solution (60 mM Tris-HCl, 1% SDS, 1% P- 
mercaptoethanol, 10% glycerol and 0.01% bromophenol blue) and fractionated using 
a 491 PrepCell column (37 mm internal diameter) (BioRad). Fractions (10 ml) were 
routinely monitored for the elution of the recombinant protein by Western blotting 
using rabbit anti-128 kDa fusion protein serum (supplied by Dr. S.P. Djordjevic). 
Samples containing the 15 kDa recombinant antigen were pooled and concentrated by 
ultracentrifugation using an ultrafiltration cell according to the manufacturers 
instructions (model 8050, Amicon).
2.3.2 Raising of rabbit antiserum specific for 15 kDa antigen
Rabbit antiserum was raised against the 15 kDa recombinant protein expressed by 
pKFl for use in Western immunoblot and ELISA techniques. Purified 15 kDa antigen 
was emulsified with Freund's complete adjuvant and subcutaneously administered at 4 
sites (0.25 ml/site) into a single New Zealand white rabbit (25 pg/rabbit) after pre­
immunisation bleeds indicated that no cross-reactive antibodies to the antigen were 
present. A booster injection containing 15 kDaNrdF antigen (25 pg/rabbit) emulsified 
with Freund's incomplete adjuvant was administered 2 weeks after the primary 
vaccination and the rabbit was sacrificed two weeks post booster and serum collected.
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2.3.3 Desalting and concentration of recombinant protein
Purified recombinant proteins were concentrated and resuspended in PBS using a 
Centriprep 10 concentrator tube (Amicon, USA) in accordance with the 
manufacturer's instructions. Tubes containing 15 ml of sample were spun at 2000 x g 
for 10 min after which the supernatant was poured off and the concentration step 
repeated. Samples were reduced to a volume of less than 1 ml then made up to 15 ml 
with sterile PBS. This process was repeated 2-4 times to remove detergents and salts. 
Centriprep 10 concentrators have a molecular weight exclusion limit of 10 kDa 
allowing for concentration of the 15 kDa and 11 kDa recombinant proteins expressed 
by pKFl and pETEl respectively.
2.3.4 SDS-PAGE and Western blot analysis
Recombinant proteins were analysed by reducing SDS-PAGE (Laemmli, 1970) using 
the BioRad Protean II mini gel system in accordance with the manufacturer’s 
instructions. The percentage polyacrylamide in the gel varied according to the proteins 
being resolved (10-20%). All gels were run at a constant 70 V until the dye front was 
eluted (2-4 h). Western blotting was carried out essentially as described by Burnette 
(1981). Proteins were transferred onto nitrocellulose membranes with a semi-dry 
TransBlot SD transfer cell (BioRad). The gel and nitrocellulose were equilibrated for 
15 min in transfer buffer. Transfer buffer was used to saturate 5 Whatman (No.l) filter 
papers ( 1 0 x 7  cm) which were laid carefully to avoid air bubbles onto the negative 
electrode of the transfer cell. Nitrocellulose membranes (TransBlot, BioRad) were 
then placed on top of the filter papers, followed by the gel which was then covered by 
another 5 Whatmann filter papers saturated in transfer buffer. The positive electrode 
was installed and the transfer conducted at 15 V for 20 min. Transferred immunoblots 
were blocked for 1 h at RT using PBS containing 10% powdered low fat skim milk 
(Carnation) and 0.1% Tween 20. Blots were subsequently reacted for 1 h at RT with 
rabbit 128 kDa fusion protein antiserum diluted 1:200 in PBS which was pre-absorbed
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against p-galactosidase as described previously. The blots were washed (3 x PBS) 
prior to the addition of 1.200 diluted goat anti-rabbit horse-radish peroxidase 
conjugated second antibody (BioRad) which was incubated for 1 h at RT. Blots were 
then washed and developed using 4-chloro-l-napthol (BioRad).
2.3.5 Subunit ELISA profiling of M. hyopneumoniae antigens
A subunit ELISA profiling technique (Scarman et al, 1997) was used to determine the 
molecular weight of the M. hyopneumoniae wild type protein from which 11 kDa 
recombinant protein component was derived. Whole M. hyopneumoniae strain J cells 
were centrifuged (10 000 x g for 15 min) and 10 mg of cell pellet was reduced with 
boiling for 10 min in SDS-PAGE splitting buffer. To aid loading of the sample and 
determine the sample collection point, bromophenol blue (0.001%) was added to the 
lysate. The sample was loaded onto a 9% preparative (37 mm internal diameter) SDS- 
PAGE resolving column (491 PrepCell, BioRad) containing a 4% stacking gel, and 
electrophoresed at 40 mA constant current (150-250 V). Fractions (8.5 ml) were 
collected after the bromophenol blue dye front was eluted (Djordjevic et al, 1994).
M. hyopneumoniae protein fractions were diluted 1:10 in ELISA coating carbonate 
buffer. Aliquots of 100 pi were then added in duplicate to 96 well microtitre plates 
(Nunc) and incubated for 1 h at 37°C. Plates were subsequently washed 5 times with 
0.05% Tween 20 (Sigma) in PBS. A 100 pi sample of rabbit 128 kDa fusion protein 
antiserum (pre-absorbed against B-galactosidase) diluted 1:200 in PBS containing 
10% normal goat serum and 0.05% Tween 20 was added and plates were incubated 
for 2 h at 37°C. After washing the plates five times with 0.05% Tween 20, 100 pi of 
horse-radish peroxidase conjugated goat anti-rabbit antibodies (Bio Rad) diluted 
1:2000 in PBS containing 10% goat serum and 0.05% Tween 20 was added to each 
well. Plates were incubated at 37°C for 1 h then washed 5 times with 0.05% Tween 20 
in PBS. ELISA plates were developed using 100 pi of 1 mM 2,2-azino-diethyl- 
benzthiazolin-sulfonate (Sigma) diluted in carbonate buffer (0.15% sodium
51
bicarbonate and 0.29% sodium carbonate pH 4.2) and absorbance was read at 405 nm 
using a BioRad plate reader (model 3550, BioRad).
2.3.6 M. hyopneumoniae whole cell ELISA
The accessibility of the native antigen on the surface of intact M. hyopneumoniae 
cells was examined using whole cell ELISA. Unless otherwise stated these assays 
were carried out as described in the previous section (2.3.5) with the following 
modifications. The primary antigen was 100 pi M. hyopneumoniae whole cell 
suspension (0.03 A650 units) in 0.20 mM Tris-HCl (pH 7.2) containing 10%
methanol. Cells were coupled to 96 well microtitre plates (Linbro) by centrifugation 
(2000 x g for 30 min). After coupling the supernatant was removed and wells were 
blocked using 200 pi of 2% skim milk in PBS for 1 h at RT.
2.3.7 M. hyopneumoniae growth inhibition assay
Growth inhibition assays were carried out using a procedure modified from that 
described by Stanbridge and Hayflick (1967). Viable M. hyopneumoniae strain J cells 
were spread onto modified Friis medium containing 1.5% Noble agar (Friis, 1971) 
and air-dried briefly under sterile conditions. Sterile paper discs (25 mm) were 
impregnated with 40 pi of undiluted antiserum and placed onto the surface of the 
seeded agar. Plates were incubated for 4 days at 37°C, with an additional 20 pi of 
undiluted antiserum being added to each disc daily. After incubation the plates were 
examined microscopically for zones of clearance, and subsequently stained with R250 
Coomassie brilliant blue (0.1% in 40% methanol and 10% acetic acid). The period of 
staining was sufficiently brief to prevent staining of the underlying agar. Excess stain 
was removed by washing with destaining solution (40% methanol and 10% acetic 
acid).
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2.3.8 Purification of 6xHis-tagged 11 kDa recombinant antigen
Affinity chromotography was performed using TALON™ metal affinity resin 
(Clontech laboratories, CA, USA). E. coli JM109 transformed with pETEl was grown 
overnight in a 500 ml LB culture with ampicillin (100 pg/ml) at 37°C. A smaller 200 
ml LB culture with antibiotic selection was subsequently seeded from the overnight 
culture and grown to mid logarithmic phase (OD 0.6) before cells were induced with 
10 mM IPTG. Cells were grown until the end of logarithmic phase (approximately 
OD 1) then cells were harvested and lysed by gentle vortexing in 45 ml of 0.01M 
Tris/HCl (pH 8) containing 8M urea and 0.1 M NaH2P04 for 10 min. Cell debris was 
pelleted at 4000 x g for 10 min and the supernatant containing the His-tagged protein 
was decanted into a sterile 50 ml Falcon tube. Into this supernatant, 4 ml of a 50% 
Talon Ni-NTA resin slurry was added and incubated for 30 min at room temperature. 
After incubation the affinity resin with bound proteins was pelleted at 4000 x g for 10 
min, then resuspended in 45-50 ml of wash buffer (Tris/HCl pH 6.3 containing 8M 
urea and 0.1M NaH2P04) and subsequently pelleted (4000 x g for 10 min). This
washing step was repeated three times. After washing, the pellet was incubated in 20 
ml of wash buffer containing 0.5 M imidazole for 3 min at room temperature which 
released bound proteins by competitive interaction. Resin was separated from the 
released protein by a brief centrifugation (4000 x g for 5 min) and eluted proteins were 




2-4.1 Expression of recombinant 128 kDa fusion protein in E. coli
After transformation of E. coli MCI061 (pCI857) with the plasmid pSD9, the 
positive recombinant clone was induced at 42°C for 2 h, lysed and screened by 
Western immunoblotting for expression of the plasmid-encoded recombinant fusion 
protein using porcine hyperimmune serum raised against M. hyopneumoniae (prepared 
by Dr S.P. Djordjevic and G. J. Eamens).
The strain expressed a 128 kDa fusion protein which was recognised strongly by the 
hyperimmune serum. This protein consisted of p-galactosidase (117 kDa) and a 
recombinant M. hyopneumoniae protein (11 kDa) (Fig 2.5 A, lane 3). The E. coli 
MCI061 (pCI857, pEXl) strain expressed only the P-galactosidase component (Fig
2.5 A, lane 2) which was not recognised by the porcine serum (Fig 2.5 B, lane 2). The 
128 kDa fusion protein encoded by pSD9 was purified and used to generate rabbit 
polyclonal antiserum for immunological analysis. The antiserum reacted strongly 
against the 128 kDa protein (Fig 2.6 B, lanes 3 and 4). Immunoreactive bands 
identified below the recombinant 128 kDa fusion protein in lanes 3 and 4 (Fig 2.6 B) 
are most likely due to the presence of breakdown products of the recombinant fusion 
protein. The pre-absorbed antiserum was used to profile the ELISA reactivity of M. 
hyopneumoniae proteins separated by SDS-PAGE on a preparative 9% PrepCell 
column (Fig 2.7 A and B). This antiserum was also used to probe immunoblots 
containing M. hyopneumoniae whole cell extracts and fractions eluted from the 
PrepCell column. In both size fractionated (Fig 2.7 C and D) and whole cell
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Fig 2.5: Expression and identification of proteins recognised by porcine M. 
hyopneumoniae hyperimmune serum. A. Coomassie brilliant blue stained 11% 
polyacrylamide gel. Lane 1, MC1061 (pCI857); lane 2, MC1061 (pCI857, pEXl) 
(induced); lane 3, MCI061 (pCI857, pSD9) (induced); lane 4, whole cell extract of M 
hyopneumoniae strain J. Positions of molecular weight standards (in kDa) are indicated 
on the left of the gel. The 117 kDa (3-galactosidase and recombinant 128 kDa fusion 
protein are indicated by an arrow. B. Western immunoblot analysis of equivalent protein 
samples described in Fig 2.5A using porcine M. hyopneumoniae hyperimmune serum. 
The sizes of molecular weight markers (in kDa) are indicated on the left.
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Fig 2.6: Expression and identification of the M. hyopneumoniae 128 kda fusion protein 
encoded by the plasmid pSD9. A. Coomassie brilliant blue stained 11% polyacrylamide 
gel. Lane 1, MC1061 (pCI857); lane 2, MC1061 (pCI857, pEXl) (induced); lane 3, 
MC1061 (pCI857, pSD9) (induced); lane 4, purified 128 kDa fusion protein; lane 5, whole 
cell extract of M. hyopneumoniae strain J. Positions of molecular weight standards (in 
kDa) are indicated on the left of the gel. The recombinant 128 kDa fusion protein is 
indicated by an arrow. B. Western blot analysis of equivalent protein samples described in 
Fig 2.6A using rabbit 128 kDa fusion protein antiserum. The sizes of molecular weight 
markers (in kDa) are indicated on the left of the blot. The 42 kDa wild type protein present 
in M. hyopneumoniae whole cell extract is indicated by an arrow.
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Fig 2.7: Identification of the 42 kDa M. hyopneumoniae wild type protein using 
ELISA and Western immunoblotting to detect the protein in fractionated M 
hyopneumoniae strain J. A. Coomassie brilliant blue stained 15% polyacrylamide gel. 
Lanes 1-6 correspond to M. hyopneumoniae strain J protein fractions 6-11 eluted after 
separation using a 9% preparative SDS-PAGE polyacrylamide gel column. B. ELISA 
profile of fractionated M. hyopneumoniae strain J whole cell extracts showing ELISA 
positive peaks in fractions 8 and 9. C. Coomassie brilliant blue stained 11% 
polyacrylamide gel. Lane 1, purified recombinant 128 kDa fusion protein; lane 2, 
ELISA positive peak 8; lane 3, ELISA positive peak 9. The sizes of molecular weight 
markers (in kDa) are indicated on the left of the gel. D. Western blot analysis of 
equivalent protein samples described in Fig. 2.7A using rabbit 128 kDa fusion protein 
antiserum. The 42 kDa wild type protein present in M. hyopneumoniae purified 
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Fig 2.8: Expression and identification of proteins recognised by rabbit P-galactosidase 
antiserum. A . Coomassie brilliant blue stained 11% polyacrylamide gel. Lane 1, NCI061 
(pCI857); lane 2, MC1061 (pCI857, pEXl) (induced); lane 3, MC1061 (pCI857, pSD9) 
(induced); lane 4, whole cell extract ofM  hyopneumoniae strain J. Positions of molecular 
weight standards (in kDa) are indicated on the left of the gel. The recombinant 128 kDa 
fusion protein is indicated by an arrow. B. Western immunoblot analysis of equivalent 
protein samples described in Fig 2.8A using rabbit P-galactosidase antiserum. The sizes of 
molecular weight markers (in kDa) are indicated on the left of the blot The recombinant 
128 kDa fusion protein is indicated by an arrow.
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M hyopneumoniae protein preparations (Fig 2.6, lane 5) a single 42 kDa protein was 
identified using both Western blot analysis and ELISA (Fig 2.7 B). The specificity of 
the 42 kDa protein in the Western blot was shown to be due to the M. hyopneumoniae 
component of the fusion protein as no cross reactivity was found using rabbit P- 
galactosidase antiserum (prepared by Dr S.P. Djordjevic and G. J. Eamens) against 
any M. hyopneumoniae protein (Fig 2.8 lane 4). The predominant protein band 
recognised by the P-galactosidase antiserum is a 68 kDa protein found in all lanes 
which contain E. coli MCI061 (pCI857) extracts. Cross-reactivity against P- 
galactosidase was removed by extensive preabsorption with p-galactosidase 
impregnated nitrocellulose (compare Fig 2.6, lane 1 and Fig 2.8, lane 1). However, the 
pEXl encoded 117 kDa P-galactosidase protein (Fig 2.6 B, lane 2) was still 
recognised indicating that epitopes encoded by the polycloning site are being 
recognised.
2.4.2 Expression of recombinant 15 kDa protein encoded by the
plasmid pKFl
The plasmid pKFl(Fig 2.3) was constructed by excising the 0.8 kb M. hyopneumoniae 
DNA fragment from pSD9 (Fig 2.1) and ligating it into pHSG398 to produce pKFl 
(Fig 2.9). The recombinant DNA fragment is fused to the amino-terminal region of the 
lacZa gene and consequently encodes a much smaller recombinant protein than the 
128 kDa fusion protein expressed by the plasmid pSD9. After transformation of E. 
coli JM109 with pKFl, a 15 kDa recombinant protein was identified by Western 
immunoblotting using rabbit 128 kDa fusion protein antiserum (Fig 2.10). There are 
two reactive protein bands in the 15 kDa region, these proteins were N-terminally 
sequenced (results not shown) and were determined to be identical. This doublet could 
be due to folding of the protein, or cleavage of COOH terminal amino acids. The 
larger 15 kDa protein was purified using preparative SDS-PAGE columns and used as 
antigen to raise rabbit anti-15 kDa polyclonal antibodies. This protein consists of 4 
kDa
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Fig 2.9: Southern hybridisation analysis of plasmids pKFl and pSD9 using M  
hyopneumoniae 0.8 kb DNA fragment insert as a probe. A. Ethidium bromide stained 1% 
agarose gel. All plasmids were double digested using the restriction enzymes Pstl and 
Smal. Lane l, pKFl; lane 2, pSD9; lane 3, pEXl; lane 4, pHSG398. DNA markers (in 
kb) are indicated on the left of the gel. B. Southern blot hybridisation analysis of the 
equivalent plasmid digests. DNA markers (in kb) are indicated on the left of the blot. 
Arrow indicates 0.8 kb fragment.
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Fig 2.10: Expression and identification of M  hyopneumoniae 15 kDa recombinant 
antigen in E. coli JM109. A. Coomassie brilliant blue stained 15% PAGE gel. Lane 1, E. 
coli JM109; Lane 2, purified recombinant 15 kDaNrdF antigen. Lane 3, E. coli JM109 
(pKFl). Positions of molecular weight standards (in kDa) are indicated on the left of the 
gel. B. Western blot analysis of identical samples described above using rabbit 128 kDa 
fusion protein antiserum. The recombinant 15 kDa protein is indicated by an arrow on the 
right of the blot.
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encoded by the lacZa gene of pHSG398 and 11 kDa from the carboxyl terminal 
region of the 42 kDa M. hyopneumoniae NrdF protein.
2*4.3 Nucleotide sequence analysis of M. hyopneumoniae DNA
fragment
The complete nucleotide sequence was obtained for both strands of the M. 
hyopneumoniae 0.8 kb DNA fragment using the plasmid pKFl as a sequencing 
template (Fig 2.11 A). The sequence length was found to be 819 nucleotide base pairs 
with a G.C. content of 30.0% which is typical of mycoplasmal genomes (Herrmann, 
1992). Translation analysis of the 0.8 kb sequence revealed the presence of three open 
reading frames designated ORF1, ORF2 and ORF3 respectively (Fig 2.11 B).
The conserved 8 nucleotide sequence 5'-ATTGGGAG-3' is present 7 nucleotides 
upstream of the ATG methionine start codon of ORF2 and ORF3. In both cases the 
intervening sequence is composed exclusively of A and T residues indicative of 
mycoplasma ribosome binding sites (Taschke, 1987). The putative ribosome binding 
site of ORF2 overlaps the carboxyl-terminus of NrdF. The length of ORF2 is 150 
amino acids with a region of dyad symmetry 23 nucleotides downstream of the TAA 
stop codon. ORF3 is incomplete at the carboxyl-terminus, and is comprised of only 8 
amino acids, however, the presence of the conserved putative ribosome binding 
sequence and its relative position indicates that this is the beginning of a new open 
reading frame. A putative -10 promoter sequence (5'-TATAAT-3') was also observed 
33 nucleotide base pairs upstream of the ATG start codon ORF3 (Fig. 2.11 A). As for 
the rrn promotor of M. hyopneumoniae, a -35 consensus sequence was not found 
upstream of the ORF3 -10 sequence (Taschke, 1987). Amino acid comparisons were 
made between predicted translated products for all three open reading frames and 
proteins deposited in the GenBank, SwissProt, PDB, EMBL and DDBJ databases
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Fig 2.11: DNA sequence analysis of the cloned 0.8 kb M hyopneumoniae
chromosomal DNA fragment. A. Diagrammatic representation of the strategy used to 
obtain the nucleotide sequence of the 0.8 kb M. hyopneumoniae DNA fragment 
(shaded). Filled arrows indicate the position of open reading frames, the first of which 
contains sequence similarity to the nrdF gene of S. typhimurium. Thin arrows indicate 
the extent of the sequence reaction from synthesised oligonucleotide primers. Scale is 
given in kilobases. The open arrows indicate the position of putative M 
hyopneumoniae ribosome binding sites whilst the keyhole symbol indicates the 
presence of inverted repeats. B. Nucleotide sequence of the M. hyopneumoniae DNA 
fragment. Three open reading frames are given using three letter amino acid codes. 
Underlining denotes the conserved 8 nucleotide sequence which is 7 bases upstream 
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B
GAT CTA TTA TAT AAA CTA ATT GAA TTA GAA AAA GAT TAT CTC TAT GAT TTA TAT 
Asp Leu Leu Tyr Lys Leu Ile Glu Leu Glu Lys Asp Tyr Leu Tyr Asp Leu Tyr 
•  100 
TCT GAA GTT GGA CTT GCT GAA TCA GCA ATA AAA TTT AGC ATT TAT AAT GCC GGG 
Ser Glu Val Gly Leu Ala Glu Ser Ala lie Lys Phe Ser lie Tyr Asn Ala Gly
• 150
AAA TTC TTG CAA AAT CTA GGA TAT GAT TCA CCT TTT TCA AAA GAG GAA ACC GAA 
Lys Phe Leu Gin Asn Leu Gly Tyr Asp Ser Pro Phe Ser Lys Glu Glu Thr Glu
• 200
ATT GAA CCT GAA ATT TTT AGT CAA TTA TCG GCT CGA GCT GAT GAA AAT CAT GAC 
He Glu Pro Glu He Phe Ser Gin Leu Ser Ala Arg Ala Asp Glu Asn His Asp
• 250
TTT TTT TCA GGA AAT GGC TCT TCT TAT GTA ATG GCG CTT GCT GAA GAA ACC GAA 
Phe Phe Ser Gly Asn Gly Ser Ser Tyr Val Met Ala Leu Ala Glu Glu Thr Glu
'  300
GAT GAA GAT TGG GAG TTT TAA A ATG ACA AAT GAT GAA AAA TAT GAT ATA ATA 
Asp Glu Asp Trp Glu Phe Stop Met Thr Asn Asp Glu Lys Tyr Asp Ile He
• 350
AAC AAA TCT AAA TTA AGA GGA GAA ATT TTT GTT GTT TAT TTT TCC TCA ATT TCG 
Asn Lys Ser Lys Leu Arg Gly Glu He Phe Val Val Tyr Phe Ser Ser He Ser
• 400
AAT AAT ACC CAT CGG TTT GTC GAA AAA TTA AAC TTT GAA AAA GCA AGA ATT CCT 
Asn Asn Thr His Arg Phe Val Glu Lys Leu Asn Phe Glu Lys Ala Arg He Pro
. 450
GTT GAG ATT GAC CAA GAA TTA GTA GTT GAT AAA GAT TAT GTA CTT TTT TGT CCA 
Val Glu He Asp Gin Glu Leu Val Val Asp Lys Asp Tyr Val Leu Phe Cys Pro
. 500
ACT TAT AGT GGC GGG AAA GGT CTA AGA AGT GGG GCT GTC CCA AAA CAG GTA 
Thr Tyr Ser Gly Gly Lys Gly Leu Arg Ser Gly Ala Val Pro Lys Gin Val
550 ’ " '  ’  -  .
ATA AAA TTT TTA AAC AAT GAA CAA AAT CGT CGA TTT TGT AAA GCT GTA ATC GCT 
He Lys Phe Leu Asn Asn Glu Gin Asn Arg Arg Phe Cys Lys Ala Val He Ala 
600 ‘ ~  '
TCT GGA AAC ACT AAT TTT GGC GAT ACT TTT GCG CTT GCA GGC ACA ATT ATT TCC 
Ser Gly Asn Thr Asn Phe Gly Asp Thr Phe Ala Leu Ala Gly Thr He He Ser
. 650 '
CAA AAA TTA AAA GTT CCT TTT TTA TAT AGT TTT GAA TTA TTA GGA ACA AAT GAT 
Gin Lys Leu Lys Val Pro Phe Leu Tyr Ser Phe Glu Leu Leu Gly Thr Asn Asp
.  700
GAT GTA AAA AAG GTT CGG CAA ATT TTA GAA GAT TTT TGA GGA AAA TAA 
Asp Val Lys Lys Val Arg Gin He Leu Glu Asp Phe Trp Gly Lys Stop
750 ------------------------------->  < -------------------------------
GCTAA AAAAT AATGA ATATA AT AGT TAGTT CGCTA ACTAA ATTGG GAGAA 
800
AATAA ATG AAA AAA GTG GGT TTG GAT C 




MhyoO . 8 : DLLYKLIELEKDYLYDLYSEVGLAESAIKFSIYNAGKFLQNLGYDSPFSKEETEIEPEIFSQL 
Mpn RR2 :DL+Y+LIELEK.YL.+LY...G+.E .AIKFSIYNAGKFLQNLGYDSPF++EET.I+PEIF+QL 
MgenRR2 :+L+Y+LIELEKDYL.+LY...G+.+.AIKFS+YNAGKFLQNLGYDSPF+..ET.I+PEIF+QL 
MtubRR2 :+LL++L. + .E .+Y. .DLY.EVGL.E . . .KF. .YNA.K.L.NLGY++.F .++ET++.P .I. S . L 
EcoliRR2:DLL.+L.+.E ..Y..+LY+E...A+....F ..YNA.K .L .NLGY+..F..E..E+.P.I.+.L
StypRR2 :DLL.+L. + .E . .Y. . .LY+E.G ...... F. .YNA.K .L .NLGY++.F. .E..++.P.I. + .L
Bsub RR2:DLL.+L.E .E .+Y..DLY.+VGL+....KF..YNA.K .L .NLG+D..F .+E+..........
190 288
MhyoO.8 :SARADENHDFFSGNGSSYVMALAEETEDEDWEF 






Fig 2.12: Results of the predicted protein similarity search for ORF1 of the 0.8 kb M. 
hyopneumoniae DNA fragment. Amino acids are given as one letter codes. Identical 
amino acids are capitals, conserved amino acids are given as (+) symbols and variant 
amino acids are indicated as (.) symbols. DNA sequences were compared using the 
Blast 2 network service provided by the National Center for Biotechnology 
information searching the GenBank, SwissProt, PDB, EMBL and DDBJ databases. 
Amino acid sequence designations are as follows: MhyoO.& : M. hyopneumoniae 0.8 
kb ORF1 (underlined), overlying numbers indicate the predicted position (in bases) 
from the start of the 0.8 kb DNA fragment; Mpn RR2 : M. pneumoniae 
ribonucleotide reductase 2; MgenKR2 : M. genitalium ribonucleoside-diphosphate 
reductase (NrdF homolog); MtubKR2 : M. tuberculosis ribonucleotide reductase 
(NrdF homolog); EcoliRR2 : E. coli ribonucleoside-diphosphate reductase (NrdF 
homolog); ¿frypRITZ : S. typhimurium ribonucleoside-diphosphate reductase (NrdF 
homolog); Bsub RR2 : B. subtilis ribonucleoside-diphosphate reductase (NrdF 
homolog). Accession numbers and references for these amino acid sequences are 
given in Table 2.3.
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using a Blast2 network service provided by the NCBI. The predicted ORF1 
translational product shows similarity to a number of ribonucleoside-diphosphate 
reductase small subunit proteins (NrdF homolog) (Fig 2.12). A summary table of the 
percentage similarity for these comparisons is given in Table 2.3.
Table 2.3: Table summarising the results of a Blast2 similarity search of ORF1. 
Comparisons were made between predicted translated products of ORF1 and predicted 








M. pneumoniae AE000050 78% 90% Himmelreich et 
al, 1996




z83866 56% 71% Cole et al, 1996
E. coli X52693 54% 63% Gowrishankar,
1989
S. typhimurium X73226 51% 61% Jordan et al, 
1994
B. subtilis z68500 50% 65% Scotti et al, 
1996
The open reading frame ORF1 was subsequently designated nrdF due to the 
significant predicted amino acid similarity the sequence has to a number of nrdF 
homologs. The nrdF reading frame is incomplete at the 5' end, indicating that the gene 
encodes the carboxyl-terminus of the NrdF protein. This open reading frame is read in 
frame with the P-galactosidase protein encoded by pSD9 to produce the 128 kDa 
fusion protein, now designated the 128 kDa NrdF fusion protein. This open reading 
frame in the plasmid pKFl is read in frame with DNA encoding 4 kDa of the
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polycloning site to produce a recombinant 15 kDa NrdF protein. In both plasmids, 
pSD9 and pKFl, this M. hyopneumoniae open reading frame is 96 amino acids in 
length ending with a TAA stop codon. A region of dyad symmetry which may act as a 
transcriptional terminator was not found downstream of nrdF, suggesting that nrdF 
and ORF2 may be organised in an operon.
Predicted amino acid similarity comparisons (Blast2 network service. NCBI) for the 
ORF2 and proteins deposited in the GenBank, SwissProt, PDB, EMBL and DDBJ 
databases found similarity between predicted proteins of unknown function in a 
number of organisms (Fig 2.13). A summary table of the percentage similarity for 
these comparisons is given in Table 2.4.
Table 2.4. Table summarising the results of a Blast2 similarity search of ORF2. 
Comparisons were made between predicted translated products of ORF2 and predicted 








M. pneumoniae AE000050 64% 81% Himmelreich et 
al, 1996




z83866 58% 71% Cole et al, 1996
Escherichia
coli








z68500 51% 72% Scotti et al, 
1996
66
Fig 2.13: Results of the predicted protein similarity search for ORF2 of the 0.8 kb M 
hyopneumoniae DNA fragment. Amino acids are given as one letter codes. Identical 
amino acids are capitals, conserved amino acids are given as (+) symbols and variant 
amino acids are indicated as (.) symbols. DNA sequences were compared using the 
Blast 2 network service provided by the National Center for Biotechnology 
information searching the GenBank, SwissProt, PDB, EMBL and DDBJ databases. 
Amino acid sequence designations are as follows: MhyoO.S : M. hyopneumoniae 0.8 
kb ORF2 (underlined), overlying numbers indicate the predicted position (in bases) 
from the start of the 0.8 kb DNA fragment; Mpne MG : M. pneumoniae MG230 
homolog; Mgen MG : M. genitalium MG230; Mtub : Mycobacterium tuberculosis 
unknown; StyOKFB : Salmonella typhimurium NrdEF operon ORFB; Ecoli : E. coli 
ORF in the NrdEF operon; Bsubt:: Bacillus subtilis ORF in the NrdEF operon. 
Accession numbers and references for these amino acid sequences are given in Table 
2.4.
MhyoO . 8 : MTNDEKYDMMNKSKLSGEIFWYFSSISNNTHRFVEKLNFEKASIPVEIDQELWDKDYVLFCP
Mpne MG:............ K. .G. . +WYFSSISNNTHRF+EKL . FE . . RIPV. +D++ + . V+++YVLFCP




Bsubt :.....................+ . F . S . + . N . . RFV. K. . F++ . R . . . E+D..............
485 674
MhyoO . 8 : TYSGGKGLSSGAVPKOVMKFLNNEONRRFCKAVIASGNTNFGDTFALAGTIISOKLKVPFLYS
Mpne MG : TYSGG....SGAVPKQVI.FLNN+.NR. . C+.VI + SGNTNFG+TFA+AG.I+S+KL.VP.LY.
Mgen MG : TYSGG.... GAVPKQVI+FLNN+ . NR . . C+ . VIASGNTNFGDTF . LAGT+IS+KL . VP . LY.
Mtub : ......... G .VPKQVI.FLNN+.NR. . . + . VIA+GNTNFG . .F. .AG.++S+K. .VP+LY.
StyORFB: ..SGG....+GAVP+QVI+FLN+E.NR...+.VIASGN.NFGD.+..AG.+I+QK..VP+LY.
Ecoli : ..SGG....+GAVP+QVI+FLN+E.NR...+.VIASGN.NFG+.+..AG.+I++K..VP+LY.








Bsubt : FEL.GT+.DV+...Q .+E....
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The organisms which returned significant protein sequence similarity to the second 
open reading frame are the same organisms which returned similarity to the nrdF open 
reading frame. In all cases the proteins homologous to the predicted nrdF protein 
terminate with the same carboxy-terminal amino acid. Due to the small number of 
nucleotides in ORF3 there was no significant predicted amino acid sequence similarity 
between this reading frame and known sequences deposited in any of the databases 
searched.
2.4.4 Southern hybridisation analysis and molecular specificity of
the 0.8 kb M. hyopneumoniae DNA fragment
Southern blot hybridisation analysis against M. hyopneumoniae (strain J), M. 
flocculare (strain MS 42) and M. hyorhinis (strain GDL) chromosomal DNA was 
carried out using the 0.8 kb M. hyopneumoniae DNA fragment as a probe. This DNA 
probe hybridised strongly to a 2.45 kb HindlW restricted M. hyopneumoniae 
chromosomal fragment, and reacted weakly against a 5.7 kb Hindlll M. flocculare 
chromosomal fragment (Fig 2.14). Following overexposure of the autoradiograph, the 
0.8 kb fragment hybridised with a M. hyorhinis chromosomal DNA fragment of 2.6 
kb (result not shown). PCR amplification using primers specific for the 0.8 kb M. 
hyopneumoniae DNA fragment resulted in an amplified PCR product of 750 bp from 
M. hyopneumoniae chromosomal DNA (Fig 2.15).
At annealing temperatures below 50°C a number of low yield fragments less than 700 
bp in size were amplified from M. hyorhinis chromosomal DNA; these fragments 
were not amplified at annealing temperatures above 50°C. Under all conditions where 
amplification of the 750 bp fragment was achieved using M. hyopneumoniae DNA, an 
identically sized fragment was amplified using M. flocculare chromosomal DNA as a 
template (Fig 2.15).
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Fig 2.14: Southern hybridisation analysis of M  hyopneumoniae DNA, M  hyorhinis 
DNA, and M  flocculare DNA. Lane 1, M  hyopneumoniae chromosomal DNA digested 
with ///«dill; lane 2, M  hyorhinis chromosomal DNA digested with ///«dill; lane 3, M  
flocculare chromosomal DNA digested with ///«dill. DNA markers (in kb) are indicated 
on the left. A. Ethidium bromide stained 1% agarose gel. B. Southern blot analysis using 
the 0.8 kb DNA fragment as a probe. Arrows indicate the 2.45 kb ///«dill M. 
hyopneumoniae DNA fragment and 5.7 kb M. flocculare Hindill fragment.
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Fig 2.15: PCR amplification of porcine mycoplasma DNA using primers 1469 and 1470 
which target the M hyopneumoniae 0.8 kb DNA fragment. Genomic DNA from M 
hyopneumoniae, M. hyorhinis and M. flocculare (lanes 1-3 respectively) were used as 
templates for the PCR. Lane 4 is a control without template. The colours of the gel have 
been inverted to give the PCR product band a better contrast. The hybridisation temperature 
used was 55^. DNA markers (in kb) are indicated on the left and the 0.8 kb PCR product 
are indicated by an arrow.
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Fig 2.16: Detection of the 42 kDa NrdF protein in M. hyopneumoniae, M. hyorhinis and 
M. flocculare strains using Western immunoblotting. Proteins were initially separated 
using a 12% PAGE gel prior to transfer. Lane 1, M. hyopneumoniae J strain; lane 2, M 
hyopneumoniae strain 232; lane 3, M. hyopneumoniae strain YZ; lane 4, M 
hyopneumoniae Beaufort strain; lane 5, M hyopneumoniae Sue strain; lane 6, M 
hyopneumoniae OMZ strain; lane 7, M. hyopneumoniae C l735/2 strain; lane 8, M 
hyorhinis GDL strain; lane 9, M hyorhinis BTS7 strain; lane 10, M hyorhinis Field strain 
2; lane 11, M hyorhinis Field strain 1; lane 12, M flocculare Ms42. The 42 kDa protein 
is indicated by an arrow. A weakly cross-reactive antigen with a molecular mass of 49 
kDa is present in all lanes. Position of molecular weight markers (in kDa) are indicated 
on the right.
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2.4.5 Detection of NrdF antigen in different M. hyopneumoniae
strains
The presence of NrdF antigen in different strains was analysed by Western 
immunoblotting using rabbit anti-15 kDa NrdF serum. All seven geographically 
diverse strains of M. hyopneumoniae examined in this study demonstrated reactivity 
(Fig. 2.16 lanes 1-7) confirming the presence of the wild type 42 kDa NrdF protein in 
all seven strains tested. The 42 kDa protein is also detected in M. flocculare MS42 
(Fig. 2.16 lane 12) but not in any of the M. hyorhinis strains examined (Fig. 2.16 lanes 
8-11).
2.4.6 Surface accessibility of NrdF antigen
The surface accessibility of the 42 kDa NrdF protein was examined at EMAI by Dr. J. 
Chin and Mrs B. Turner using whole cell ELISA. Flow cytometric analysis of the 
primary antigen, methanol-fixed M. hyopneumoniae whole cells, suggested that the 
cells were intact. Rabbit antibodies raised against the recombinant 15 kDa NrdF 
antigen were shown to bind to the complementary epitopes of the 42 kDa M. 
hyopneumoniae protein on intact whole cells indicating that in-situ the protein is 
surface accessible. A proportional increase in competitive inhibition of antibody 
binding following the addition of increasing quantities of recombinant 15 kDa NrdF 
antigen was demonstrated. Furthermore, the addition of antigen failed to cause any 
detectable decrease in the ability of hyperimmune M. hyopneumoniae antiserum to 
bind these cells confirming the specificity of the rabbit anti-15 kDa NrdF serum to a 
surface accessible M. hyopneumoniae antigen (Fig. 2.17).
2.4.7 Growth inhibition of M. hyopneumoniae using NrdF anti­
serum and serum from experimentally infected swine
Sterile discs impregnated with rabbit anti-15 kDa NrdF serum (Fig.2.18 B) and swine 
hyperimmune anti-M. hyopneumoniae serum (Fig.2.18 A) inhibited the growth of 
freshly cultured M. hyopneumoniae. A distinct clearing zone around the perimeter of
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Fig 2.17: M. hyopneumoniae whole cell ELISA using rabbit anti-15 kDa NrdF serum 
demonstrating the surface accessibility of the 42 kDa NrdF protein in situ. The open 
circles and squares represent rabbit prebleeds prior to inoculation. Red filled squares 
represent rabbit serum raised against M. hyopneumoniae whole cells. Red filled circles 
show the effect of increasing the concentration of 15 kDa antigen on the ability of anti-15 
kDa serum to bind to M. hyopneumoniae whole cells.
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Fig 2.18: Growth inhibition assay using sterile paper discs (25 mm) impregnated with 
different serum samples overlayed onto a lawn of freshly cultured M. hyopneumoniae 
strain J. Inhibition of growth can be seen as a halo-like ring (indicated by an arrow) 
around the darker area where the paper disc was located. Inhibition can be seen around 
the discs impregnated with hyperimmune pig serum (A) and rabbit 15 kDa NrdF 
antiserum (B). No zone of clearing was detected around the rabbit prebleed serum (C).
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the disc (Fig.2.18 A and B), is in marked contrast to the absence of such zones around 
the rabbit prevaccination bleed impregnated disc (Fig.2.18 C) and swine 
prevaccination prebleed (result not shown). Zones of clearance around the 6 mm 
diameter disc were approximately 3 mm wide when observed by light microscopy. 
The zones of inhibition are a product of the inhibited growth of M. hyopneumoniae. 
Clearing increases closer to the disc presumably due to increased antibody 
concentrations. Zones of clearance are reduced when stained with Coomassie brilliant 
blue because the extreme regions of the zone contain small amounts of mycoplasmal 
growth; however this region stains because of the sensitive visualisation technique.
2.4.8 Histidine tagging of the 15 kDa NrdF antigen
The 0.8 kb insert in the plasmid pKFlO was confirmed to be identical to the M. 
hyopneumoniae DNA fragment in the plasmids pKFl and pSD9 by Southern 
hybridisation (Fig. 2.19). A number of potential positive constructs were detected by 
colony hybridisation after ligation of the electroeluted 0.8 kb PCR amplified DNA 
fragment from pKFlO into pQE9 (Fig.2.20 A). Positive constructs derived from the 
parental pQE9 vector were expected to express the recombinant 11 kDa NrdF 
histidine-tagged antigen after transformation of E. coli JM109 (Fig. 2.20 C lanes 1-5). 
A total of 5 clones which expressed the His-tagged 11 kDa antigen were identified and 
designated pETEl-5; of these constructs pETEl was used for the affinity purification 
of the NrdF antigen (Fig. 2.20 lane 6).
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Fig 2.19: Southern hybridisation analysis of plasmids pKFlO using M  hyopneumoniae 
0.8 kb DNA fragment insert as a probe. A. Ethidium bromide stained 1% agarose gel. AH 
plasmids were double digested using Pstl and SmdL. Lane 1, pKFlO; lane 2, pKFl; lane 3, 
pSD9. DNA markers (in kb) are indicated on the left. B. Southern blot hybridisation 
analysis of the equivalent plasmid digests using the 0.8 kb M  hyopneumoniae DNA 
fragment as a probe. Arrow indicates the 0.8 kb fragment.
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Fig 2.20: Detection of pQE9 constructs containing the 0.8 kb M. hyopneumoniae DNA 
insert. A. Colony hybridisation detection of E. coli JM109 transformants containing a 
plasmid construct with the 0.8 kb DNA insert This autoradiograph had 50 E. coli JM109 
colonies which contained pQE9 with or without the insert. Positive colonies which contain 
the insert appear as dark spots on the X-ray film. The arrow indicates a colony which was 
later determined to be a positive clone which expressed the 15 kDa NrdF antigen. The 
control was E. coli JM109 (pKFlO). B. Coomassie brilliant blue stained 15% 
polyacrylamide gel. Lanes 1-5, E. coli JM109 (pETEl-5) respectively; Lane 6, affinity 
purified histidine tagged 11 kDa NrdF protein; Lane 7, E. coli JM109. Positions of 
molecular weight standards (in kDa) are indicated on the right of the gel. C. Western 
immunoblot analysis of equivalent protein samples described in Fig 2.20 B using rabbit 15 
kDa NrdF antigen antiserum extensively preabsorbed against E. coli JM109. The 15 kDa 
histidine tagged NrdF antigen is indicated by an arrow.
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2.5 Discussion
This chapter described the characterisation of an antigen encoded by the 0.8 kb M. 
hyopneumoniae DNA fragment. This insert is contained in the plasmids pSD9 and 
pKFl and encodes approximately 11 kDa of the carboxy-terminal region of a 42 kDa 
wild type protein. The specific function of the wild type protein was not examined 
because the aim of this research is to develop a vaccine against PEP. Previous research 
carried out at EMAI has demonstrated that the encoded antigen is a potential 
candidate for use as a vaccine antigen. Only that part of the 42 kDa wild type protein 
which confers protection is desirable. Consequently, only the recombinant antigen 
which was identified as enhancing immunity against PEP was characterised and its 
essential role in protection against M. hyopneumoniae examined.
The plasmid pSD9 encoded a 128 kDa fusion protein whereas the plasmid pKFl 
encoded a 15 kDa protein. In both plasmids the 11 kDa M. hyopneumoniae antigen 
was fused to the COOH-terminus of a highly expressed gene; in pSD9 the insert was 
fused to the B-galactosidase transcriptional unit (cro’-lacT-lacZ’) which encodes a 117 
kDa protein and in pKF 1 it was fused to the lacZa gene which encodes approximately 
4 kDa of protein before the fusion point. Sequence analysis revealed that the cloned 
M hyopneumoniae DNA fragment shows high predicted amino acid similarity 
between the 11 kDa M. hyopneumoniae antigen and a carboxy-terminal region of the 
NrdF protein from a number of organisms. The NrdF protein is able to detoxify 
hydroxyurea in a reversible reaction where the radical is donated, thus conferring 
resistance against this potent DNA synthesis inhibitor (Reichard, 1993a). The protein 
also functions as a ribonucleoside-diphosphate reductase R2 subunit; this class of 
enzymes is responsible for the conversion of ribonucleotides to deoxyribonucleotides 
for use in DNA synthesis (Thelander and Reichhard, 1979). The 42 kDa protein 
identified in this study may play a similar role in M. hyopneumoniae.
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As there are no inverted repeat structures detected at the 3' terminal of M. 
hyopneumoniae nrdF and as the TAA stop codon of this gene is separated from the 
ATG start codon of ORF2 by only a single nucleotide, both genes are likely to be 
organised in an operon. This is consistent with the organisation of genetic information 
in other Mycoplasma spp. (Herrmann, 1992). The predicted amino acid sequence of 
ORF2 showed significant similarity with sequences from the same organisms which 
had significant similarity to nrdF. The predicted 150 amino acid protein encoded by 
ORF2 is homologous to MG230, YmaB and other predicted proteins which are found 
3’ to the NrdEF operon of those organisms. The organisation of these genes within the 
nrd locus appears to be conserved. In all cases the function of the predicted protein 
encoded by ORF2 as well as the homologous proteins remains to be elucidated. The 
conserved sequence 5'-ATTGGGAG-3' present 7 bases upstream of the start codons of 
both ORF2 and ORF3 may serve as a putative ribosome binding site (Gilson et al, 
1988; Taschke et al, 1987; Yogev et al, 1991). This sequence contains 4 nucleotides 
which can base pair with the conserved sequence 3'-CCUCCA-5' at the 3' end of the 
M. hyopneumoniae 16S rRNA. This degree of similarity is considered sufficient to 
initiate translation in E. coli (Taschke et al, 1987). The position of the putative 
ribosome binding site relative to the ATG start codon of ORF2 and ORF3 is identical 
to the putative consensus ribosome binding site of M. hyopneumoniae (Taschke et al, 
1987). A region of dyad symmetry is found 24 nucleotide base pairs downstream of 
the ORF2 TAA stop codon. This inverted repeat structure may act as a transcription 
termination signal. A putative -10 promoter sequence (5'-TATAAT-3') is found 33 
nucleotide base pairs upstream of the ATG start codon of ORF3. As for the rrn 
promoter of M. hyopneumoniae, a -35 consensus sequence was not found upstream of 
the putative ORF3 -10 sequence (Taschke et al, 1987).
Using Southern blot analysis, the 0.8 kb M. hyopneumoniae DNA fragment did not 
hybridise to Hind III restricted M. hyorhinis chromosomal DNA under stringent 
hybridisation conditions. This result is not surprising due to the differences previously
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described between these two species of mycoplasma at the DNA and protein levels 
(Bolske et al, 1987; Herrmann, 1992). However, the 0.8 kb DNA probe did detect a
5.7 kb M. flocculare Hin<\\\\ fragment of DNA. Similarly, PCR primers based on the 
DNA sequence of the 0.8 kb fragment were used to identify the presence of this DNA 
fragment in other porcine mycoplasmas which inhabit the respiratory tract of pigs. 
Although these primers clearly differentiated between M. hyopneumoniae and M. 
hyorhinis reference strains, the usefulness of such primers for routine diagnosis is 
limited by cross reaction with M. flocculare.
Western blot analysis revealed cross-reactivity between the NrdF antigen of M 
hyopneumoniae and a 42 kDa M. flocculare protein. These results for the encoded 
protein further support the Southern hybridisation and PCR results which indicate a 
conservation of the nrd locus between these two mycoplasmas. There is, however, no 
cross-reactivity between the M. hyopneumoniae antigen and a 42 kDa M. hyorhinis 
protein. Antibodies raised against the 11 kDa M. hyopneumoniae component react 
strongly with a 42 kDa wild type protein which is present in all of the geographically 
diverse M. hyopneumoniae strains tested. Generally, antigens recognised using 
hyperimmune anti-M. hyopneumoniae serum are conserved amongst geographically 
diverse strains (Scarman et al, 1997) and clearly the NrdF antigen is conserved 
amongst the diverse strains tested.
In the physiology of M. hyopneumoniae the absence of a cell wall and outer 
membrane make this pathogen particularly vulnerable to neutralising antibodies 
(Awumbila et al, 1991; Wannemueler and Galvin, 1994). Whole cell ELISA 
demonstrated that the NrdF antigen is surface accessible. This feature, coupled with 
the growth inhibition studies and the conservation of this antigen across the 
geographically diverse M. hyopneumoniae strains tested, makes the recombinant NrdF 
antigen a potential vaccine component.
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Chapter 3
Oral immunisation of mice with Salmonella typhimurium 
aroA expressing recombinant M. hyopneumoniae NrdF
antigen
M. hyopneumoniae is a mucosal pathogen which does not invade the lung epithelial 
cells of infected swine (Razin, 1992a), but colonises the external surfaces of these 
cells (Tajima and Yagahashi, 1982; Blanchard et al, 1992; Zeilinski et al, 1993; 
Zhang et al, 1995). In order to prevent microbial colonisation, an ideal vaccine 
candidate should be able to trigger an efficient mucosal response. A number of 
vaccine strategies can be used to achieve this desired mucosal immune response. 
Within this project a live attenuated bacterial vector was chosen to express and deliver 
the pSD9 128 kDa fusion protein and the pKFl encoded 15 kDa NrdF antigen. This 
chapter describes the construction and characterisation of S. typhimurium aroA 
SL3261 (pSD9) and S. typhimurium aroA SL3261 (pKFl) strains and the potential of 
these live recombinant vaccine strains to elicit an immune response in mice.
3.1 Ribonucleotide reductase
The 15 kDa recombinant antigen encoded by pKFl had very highly conserved amino 
acid similarity to a number of NrdF proteins. NrdF is the R2 subunit of a class I 
ribonucleotide reductase (RR). RR is a ubiquitous enzyme which catalyses the 
conversion of ribonucleotides into corresponding deoxyribonucleotides which are 
used in the synthesis of deoxyribonucleic acid (DNA) (Thelander and Reichard, 1979; 
Reichard, 1993a). The enzymatic reduction occurs through the replacement of the 
hydroxyl group at the C-2’ position with a hydrogen (Fig. 3.1)
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Ribonucleotide Deoxyribonucleotide
Fig. 3.1: Schematic representation of the production of deoxyribonucleotides from 
ribonucleotides catalysed by RR. Circled ‘P’ represents the phosphate group. The T  
hydroxyl group is replaced with a hydrogen (bold) (modified Reichard, 1993a).
There are three classes of RR which are characterised according to the type of radical 
which the enzyme uses to reduce the 2’ hydroxyl group. Class I RR are aerobic 
enzymes which utilise a tyrosyl radical maintained by an iron centre (Larsson and 
Sjoberg, 1986). This class has been detected in eukaryotes (Chaudhuri et al, 1992; 
Reichard, 1993a), prokaryotes (Jordan et al, 1994; Scotti et al, 1996) and some 
viruses (Slabaugh and Mathews, 1986; Lankinen et al, 1991; Cunha and Costa, 1992). 
Class II RR are found in a number of prokaryotic cells and use adenosyl cobalamin as 
the radical generator (Reichard, 1993a). Finally, class III RR use S- 
adenosylmethionine as the radical and are found in anaerobically grown prokaryotes 
(Reichard, 1993b).
Organisms are not restricted to a single class of RR enzyme and may contain genes for 
two or more of these enzymes. E. coll and S. typhimurium both have two class I 
enzyme opérons, nrdAB and nrdEF. E. coli also contain an anaerobic WY/Z)-encoded 
class III RR enzyme which allows it to be a facultative anaerobe (Jordan et al, 1996a).
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Lactococcus lactis also contains a class III RR encoded by a nrdDG operon and a 
class I nrdEF RR (Jordan et al, 1996b).
3.1.1 Class I (iron-tyrosyl radical) ribonucleotide reductase
Class I RR enzymes have been most extensively characterised in E. coli (Fontecave et 
al, 1992). However, essential features are conserved throughout all class I RR 
enzymes studied (Jordan et al, 1994). This enzyme comprises two non-identical 
dimeric protein subunits termed R1 and R2 (alternatively, B1 and B2 respectively) 
(Fig. 3.2). The subunits vary slightly in molecular weight depending on the organism. 
The R1 is the large subunit made up of two identical polypeptide chains ranging in 
molecular weight from 80 - 120 kDa. R2 is the smaller subunit and is also made up of 
two identical polypeptide chains which range in molecular weight from 40 - 50 kDa 
(Thelander and Reichard, 1979).
R1 subunit
R1 binding surface 
R2 subunit
Fig. 3.2: Schematic representation of RR showing the two subunits consisting of 
dimeric proteins (modified from Thelander and Reichard, 1979).
There are conserved essential sites in all class I enzymes. The R1 subunit contains 
redox-active sulfhydryl groups which may reduce the substrate in the absence of
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external hydrogen and are, therefore, considered a part of the active site of the enzyme 
(Reichard, 1993a). The R1 subunit also contains effector-binding sites for the 
allosteric regulation of the enzyme by dNTPs (Thelander and Reichard, 1979). The R2 
subunit contains the tyrosyl radical (Tyr*22) and conserved amino acids (Phe2^8, 
Phe212 and lie234) (Jordan et al, 1994). Also bound within each R2 subunit 
polypeptide is an iron (Fe(III)) centre (Asp84, Glu115, His118, Glu204, Glu238 and 
His241) (Jordan et al, 1994; Reichard, 1993a) which functions in the maintenance and 
generation of the tyrosyl radical. Radical scavengers such as hydroxyurea can 
irreversibly alter the iron centre. This prevents the formation of the tyrosyl radical 
(Thelander and Reichard, 1979; Slabaugh and Mathews, 1986) and so removes 
enzymatic activity. This interaction also detoxifies hydroxyurea and consequently the 
overexpression of the R2 subunit leads to hydroxyurea-resistant cell lines (Slabaugh 
and Mathews, 1986; Chaudhuri et al, 1992). The R2 subunit also contains the 
conserved R1 binding surface (Asp58’ Arg236 and Tyr356) (Jordan et al, 1994), a 
region necessary for assembly of the enzyme which is essential for activity.
3.1.2 NrdAB ribonucleotide reductase in bacteria and viruses
The predominant class I RR in E. coli and S. typhimurium is encoded by the nrdAB 
genes (Jordan et al, 1996). The transcription of E. coli nrdAB genes is temperature 
regulated and cell cycle dependent (Sun et al, 1992). These genes are also regulated 
by the trans-acting positive regulators Fis and DnaA proteins which operate 
independently from cell cycle control (Augustin et al, 1994). Allosteric regulation of 
this enzyme occurs through the binding of ATP, dATP, dGTP and dTTP at the 
effector-binding sites (Thelander and Reichard, 1979).
Viral protein homologs to the E. coli and S. typhimurium NrdAB proteins are found in 
the vaccinia virus, varicella-zoster virus, herpes simplex virus 1 (Jordan et al, 1994) 
and equine herpes virus type 1 (Telford et al, 1990). There are also a number of RR 
proteins in herpes simplex virus 2, Epstein-Barr virus (Jordan et al, 1994),
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pseudorabies virus (Lankinen et al, 1982) and African swine fever virus (Cunha and 
Costa, 1992). After target cells have been invaded, the viral RR enzyme is 
constitutively expressed enabling the virus to use the DNA replication machinery of 
the host cell to replicate itself.
3.1.3 NrdEF ribonucleotide reductase and protein homologs
In E. coli and S. typhimurium the nrdAB gene product is preferentially expressed in 
the bacteria over the nrdEF gene product under most environmental conditions 
(Jordan et al, 1996a). It is known that nrdEF is under the control of the cell cycle 
through the SOS regulator RecA (Scotti et al, 1996). However, the complexities of 
nrdEF regulation have yet to be fully elucidated and an understanding of this operon 
may provide the reasons why this second class I enzyme has evolved.
Amino acid comparisons between nrdAB gene products, viral homologs to the 
products of the nrdAB and nrdEF operons demonstrate low similarity (20% - 30%) 
between the nrdEF products and the other two class I enzyme R1 and R2 proteins 
(Scotti et al, 1996). However, essential functional regions are conserved between both 
enzymes (Jordan et al, 1994). Predicted amino acid similarity between the pKFl- 
encoded 15 kDa NrdF recombinant antigen did not return any significant similarity to 
the corresponding E. coli or S. typhimurium NrdB proteins, but did to the bacterial 
NrdF protein (Fig 2.15 and 2.16).
The organisation of the nrdEF operon is conserved in those species found to contain 
the NrdEF RR enzymes, S. typhimurium, E. coli (Jordan et al, 1996a), L. lactis 
(Jordan et al, 1996b) B. subtilis (Scotti et al, 1996) and M. genitalium (Peterson et al,
1993). In B. subtilis, a putative promotor and ribosome binding site is immediately 
upstream of an open reading frame (ymaA) which encodes a predicted 130 amino acid 
polypeptide of unknown function (Scotti et al, 1996). Downstream of the first open 
reading frame is a ribosome binding site which precedes the nrdE gene. No stem and
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loop structures are found between the nrdE and nrdF genes or the subsequent open 
reading frame. The fourth open reading frame (YmaB), like the first, encodes a 
hypothetical peptide of unknown function (Scotti et al, 1996). All open reading 
frames contain adjacent putative ribosome binding sites. There are no promotors 
found in the operon after the first open reading frame and the operon is terminated by 












ir ~ ~ i t
M. hyopneumoniae 
DNA fragment
Fig. 3.3: Diagrammatic representation of the nrdEF operon. Gene products and sizes 
in amino acids (aa) are given using B. subtilis designations. Keyhole symbol indicates 
the presence of inverted repeats. Arrow indicates the direction of transcription. Pr 
indicates the presence of a promotor sequence. The region of the nrdEF operon 
encoded by the 0.8 kb M. hyopneumoniae fragment inserted into the plasmids pKFl 
and pSD9 is given below the main map. The size of the gene product is given as 
amino acids (aa).
3.1.4 Blocking of subunit assembly to inhibit enzymatic activity
Association of the RR subunits can be prevented by a nonapeptide which blocks the 
conserved R1 protein binding with the carboxy terminal 9-11 residues of the R2 
subunit proteins (Telford et al, 1990; Climent et al, 1991). Inhibition studies of the 
herpes simplex virus type 1 (Telford et al, 1990) and E. coli RR (Climent et al, 1991)
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targeting this carboxy terminal region demonstrated that prevention of the assembly of 
the enzyme abolishes activity. It is this same carboxy-terminal region of the M. 
hyopneumoniae NrdF 42 kDa protein which is expressed as the 15 kDa NrdF antigen 
in the E. coli JM109 (pKFl) construct.
3.2 Mucosal immune system
3.2.1 Immune defences at mucosal surfaces
The lack of a cell wall in mycoplasmas makes these organisms vulnerable to 
neutralising antibodies against essential proteins (Awumbila and Rosenbusch, 1991; 
Wannamuehler and Galvin, 1994). If M. hyopneumoniae has only a single class I RR 
(NrdEF) then the 42 kDa wild type NrdF protein may be essential to metabolic 
function. Consequently, antibodies against the 15 kDa NrdF antigen may inhibit DNA 
synthesis and provide protection from the development of PEP. Because M 
hyopneumoniae is a mucosal pathogen, the immune response elicited by a vaccine 
against this organism must be localised to the respiratory mucosae. The immune 
defences at mucosal surfaces consist of mucin barriers, CMI and humoral responses. 
The importance of each mechanism differs depending on the organism and differences 
between responses in mammalian species can be large.
3.2.1.1 Mucins
Mucins are hydrophilic gels made up of glycoproteins that are secreted from epithelial 
goblet cells (McNabb and Tomasi, 1981). This gel forms a confluent barrier against 
colonisation by pathogens of the intestinal tract and regions of the respiratory tract. 
This layer is moved by the mechanical action of cilia which facilitate clearance from 
these surfaces. Mucins form a physical barrier preventing pathogens coming into 
contact with the underlying epithelial surfaces. Furthermore, secretory antibodies are 
able to cross-link with cysteine residues in the mucin layer. Bound antigen is thus
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trapped and may subsequently be removed by ciliary action (McNabb and Tomasi, 
1981).
3.2.1.2 Cell mediated immunity
The extent of the role played by CMI on mucosal surfaces is yet to be fully elucidated. 
CMI has been demonstrated at mucosal surfaces. Those responses identified include 
MHC restricted cellular cytotoxicity, natural killer cell activity and antibody 
dependent T-cell mediated cytotoxicity (Holmgren, 1991). The predominant response 
to oral ingestion of antigen is a type 2 Thelper mediated response, which regulates the 
humoral B-cell responses (McGhee et al, 1992; McGhee and Kiyono, 1993). 
However, significant type 1 Thelper responses, which mediate CMI, are elicited by 
intracellular pathogens such as S. typhimurium. The type 1 Thelper1secreted INF-y is a 
significant mediating cytokine in the immune defences (Holmgren, 1991) that 
enhances IgA production, inhibits viral replication, increases the activity of 
macrophages, inhibits the proliferation of type 2 Thelper cells and facilitates the 
secretion of IgA (Holmgren, 1991). However, down-regulation of pro-inflammatory 
cytokines, including INF-y, does not affect IgA production and secretion (Shalaby, 
1995) demonstrating the complexity of the secretory IgA response.
3.2.1.3 Humoral immunity
Secretory IgA is the predominant immunoglobulin of mucosal surfaces (Mestecky, 
1987; Brandtzaeg, 1989; Holmgren, 1991; Bernstein, 1992). The most common 
protective mechanism by which secretory IgA functions is via immune exclusion of 
antigens (Childers et al, 1989; Holmgren, 1991). This mechanism can prevent the 
adherence and uptake of bacteria, viruses, toxins, carcinogens and allergens (McNabb 
and Tomasi, 1981; Underdown and Schiff, 1986). Secretory IgA also increases 
antigen uptake by the M cells overlying the Peyer’s patch regions of the gut, which is 
critical for antigen presentation in the mucosal immune system (Holmgren, 1991). 
This isotype cannot act as a macrophage opsinin, nor can it fix complement
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efficiently. As a consequence secretory IgA does not initiate inflammatory reactions 
(Conley and Delacroix, 1987).
In mucosal secretions of the lower respiratory tract, IgG is the predominant isotype 
detected (Daniele, 1990). The mechanism by which this immunoglobulin transverses 
the epithelium is unclear; it is hypothesised that this isotype is secreted into the 
interstitial space and the immunoglobulin is carried by transudation into the mucosal 
secretions (Bernstein, 1992). In the broncheoalveolar mucosa, IgG fixes complement 
and opsinises antigen which, in cases of chronic infection, may lead to persistence of 
inflammation and an increase in epithelial permeability allowing colonisation by 
secondary invaders (Bernstein, 1992). However, under normal conditions IgG plays a 
major defensive role in the distal regions of the airways (Daniele, 1990).
Secretory IgM has been detected in mucosal secretions of humans which have an IgA 
deficiency (Brandtzaeg et al, 1968; Daniele, 1990). Helper T-cell clones in the 
mucosal inductive sites preferentially cause the class switching of IgM B-cells into 
IgA B-cells (James et al, 1986). Consequently, in healthy individuals secretory IgM is 
rarely detected.
3.2.2 Compartmentalisation of the common mucosal immune
system
The predominant defence of the common mucosal immune system is the eliciting of a 
secretory IgA response against antigen which is processed at sites which lie within the 
mucosal surfaces. This system is compartmentalised into inductive sites, where 
antigen is processed and remote effector sites, where primed immune cells actually 
function (for reviews see Brandtzaeg, 1984; Mestecky, 1987; Bergmann and 
Waldman, 1988; Brandtzaeg, 1989; Lintermans and Greve, 1995). The common 
mucosal immune system has been investigated primarily in humans, however, it has 
been identified as ubiquitous in mammals (Bergmann and Waldman, 1988). There are
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two separate inductive sites: the gut-associated lymphoid tissue and bronchus- 
associated lymphoid tissue (GALT and BALT respectively).
The GALT is represented almost exclusively by the Peyer’s patches, which are 
discrete regions enriched for macrophages, lymphocytes and some plasma cells found 
throughout the gastrointestinal tract (McGhee et al, 1992). Overlying the Peyer’s 
patches are specialised follicle-associated epithelial cells (also referred to as microfold 
(M) cells). These cells are specialised to uptake antigen without degradation and 
deliver the intact antigen to the underlying lymphoid tissue (McGhee et al, 1992). 
Distinct B-cell sites are present in this underlying region which serve as germinal 
centres where IgA class switching and affinity maturation occurs. Adjacent to these 
areas are T-cell sites, which contain all the major T-cell populations, and discrete 
accessory cell sites containing macrophages and dendritic cells. Following antigen 
stimulation and presentation in the Peyer’s patches the antigen-induced B- and T-cells 
migrate to distal effector sites via the lymphatic and circulatory system.
Similar structures analogous to the GALT Peyer’s patches have been identified in the 
proximal airways and less defined lymphoid aggregates have been identified in the 
more distal airways (Daniele, 1990; Bernstein, 1992). Morphological studies 
demonstrate that BALT regions are dynamic and undergo functional and structural 
changes depending upon antigenic stimulation (Daniele, 1990). In animals such as 
rabbits and mice, regions of BALT can be identified from birth in all individuals. In 
humans and pigs, however, the production of BALT is stimulated by antigen (Pabst 
andBinns, 1994).
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Fig 3.4: Schematic showing distribution of known IgA isotypes at different regions 
of the human body (modified from McGhee and Kiyono, 1993).
In higher mammals the predominant IgA subclass elicited by the GALT is IgA2 and 
the predominant subclass elicited by the BALT is IgAl. Although immune cells from 
both inductive sites can migrate to all effector sites, there are mucosal surfaces which 
have a predominant IgA subclass (Fig 3.4). This is taken as evidence that the GALT 
and BALT sites are compartmentalised and preferentially defend specific mucosal 
sites throughout an animal.
3.3 M u co sa l im m u n isa tion  as a route to protect aga in st
m ucosa l p a th ogen s
The mucosal immunisation route is advantageous in eliciting responses against 
mucosal pathogens because it provides a defence that can act at the point of entry,
91
effectively providing a “first line of defence”. Furthermore, a number of methods of 
mucosal antigen delivery have been developed which are capable of stimulating 
mucosal, cell-mediated and humoral immune responses (Staats et al, 1994). Oral 
tolerance, which immunosuppresses the systemic immune response, is a well 
documented phenomenon which develops after repeated exposure to low oral doses of 
protein antigen (Challacombe and Tomasi, 1980). Whilst oral tolerance is beneficial 
under certain circumstances, such as allergies and autoimmune diseases, it can limit 
the otherwise effective CMI and humoral immune responses against pathogens (Ruedl 
and Wolf, 1995) (Table 3.1).
Table 3.1: Table demonstrating the range of immune responses which provide
protection from various mucosal pathogens (modified from Staats et al, 1994).
Site of 
Challenge Infectious agent or product Protective mechanism
Lung Respiratory syncytial virus Anti-RSV IgG
Nasal mucosa Influenza Anti-influenza IgA 







Antigen specific polymeric secretory IgA 
and specific CMI responses
Subcutaneous Tetanus toxin IgG
3.3.1 Adjuvants
Antigens delivered parenterally with adjuvants such as cholera toxin and heat labile 
enterotoxin target the mucosal immune system and do not elicit oral tolerance (Staats 
et al, 1994). Although efficacious delivery of vaccine antigens can be achieved by this 
route, the required needle delivery is time consuming, labour intensive and requires 
trained personnel. Furthermore, some adjuvants such as cholera toxin produce
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detrimental side effects making the routine use of this adjuvant unacceptable 
(Husband, 1993).
3.3.2 Microspheres, liposomes and ISCOMS
Although the technology involved in the development of microspheres, liposomes and 
ISCOMS as mucosal delivery vehicles is different, all three rely upon encapsulation of 
the antigen to prevent degradation. Mucosal delivery of antigen using these methods 
delivers antigen to the Peyer’s patch regions and will elicit strong CMI, systemic IgG 
and secretory IgA responses (Staats et al, 1994). The use of this novel technology to 
deliver antigen is receiving considerable attention and may in the future provide 
efficacious vaccines against mucosal pathogens.
3.3.3 Attenuated viral and bacterial vectors
Live attenuated viral and bacterial vectors have been developed to be used as vaccines 
against the virulent parental strains (Attenuated viral vaccines are reviewed in 
Melnick, 1989 and Connell et al, 1992. Attenuated bacterial vaccines are reviewed in 
Dougan et al, 1989; Connell et al, 1992 and Lintermans and Greve, 1995). These 
attenuated organisms are capable of invading, causing limited infection in the host and 
stimulating a specific immune response analogous to that elicited by natural infection. 
These strains, however, are not capable of surviving without supplementation and 
consequently cannot cause disease, furthermore these strains will not result in 
potentially deleterious oral tolerance due to the invasive mode of antigen delivery. 
Attenuated Salmonella bacterial vectors are the most widely used vaccine delivery 
vehicles. These strains are well characterised and have been used to deliver 
heterologous antigen (reviewed in Curtiss et al, 1993). Consequently, attenuated 
Salmonella typhimurium aroA mutant (SL3261) was chosen within this study to 
deliver the candidate M. hyopneumoniae NrdF antigen.
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3.4 Salmonella typhimurium as a vaccine carrier
3.4.1 Salmonella typhimurium pathogenesis
Salmonella spp. are facultative intracellular pathogens which are capable of invading a 
variety of mammalian epithelial cells. Although rarely fatal, mortality is often 
associated with infection of young, aged or immunocompromised individuals. S. 
typhimurium causes acute enterocolitis, a disease with high morbidity but low 
mortality (Reed et al, 1986). This bacterium attaches to and invades intestinal 
enterocytes and the M cells overlying the Peyer’s patches of the GALT (Carter and 
Collins, 1974). It is able to avoid the host’s immune defence mechanisms (Galan,
1996) and can reach deep-lying cells. The pathogen may even transverse the intestinal 
barrier to reach the lymphoreticular organs (Curtiss et al, 1993). S. typhimurium can 
induce immune suppression which facilitates the establishment of the carrier state and 
may lead to complications associated with secondary infection (Curtiss et al, 1993). 
Primary infection with Salmonella stimulates both antibody and CMI responses 
(Flynn et al, 1990). Protection appears to be due to CMI, specifically a macrophage 
mediated inflammatory response (Al-Ramadi et al, 1991a) and a S. typhimurium 
specific cytotoxic T-lymphocyte response (Dougan et al, 1989; Flynn et al, 1990). 
The role of serum antibody responses is not clear. Infection elicits serum antibody 
responses, however, no correlation between immunoglobulin levels and protection has 
been demonstrated (Eisenstein et al, 1984).
3.4.2 Attenuated Salmonella mutants
Ideal live attenuated vaccine strains would need to contain well characterised stable 
mutations in more than one essential pathway (Roberts et al, 1994). The first 
attenuated vaccine was a S. typhi Ty21a, which contained a single mutation in the 
galE gene (Germanier and Fiirer, 1975). This strain was licensed as an oral typhoid 
vaccine and has been used successfully for a number of years (Roberts et al, 1994). 
Ty21a has proved to be stable, with no revertants being detected (Hone and Hackett,
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1989). This strain demonstrates that attenuated oral vaccines are achievable. 
Development of attenuated strains has lead to the construction of auxotrophic and 
regulatory mutants, which are used as vaccines against virulent parental strains as well 
as carriers for heterologous antigens (Table 3.2). The most widely characterised 
auxotrophic mutants are those with deletions in the aromatic amino acid biosynthesis 
pathway genes (aroA, aroC and aroD) (see next section) (Roberts et al, 1994) or the 
purine biosynthesis pathway genes (purA and purE) (McFarland and Stocker, 1987; 
O’Callaghan et al, 1988). The most common regulatory mutants contain deletions in 
the adenylate cyclase gene (cya), cAMP receptor protein gene (crp), or the genes 
involved in phosphate regulation (phoP and phoQ) (Roberts et al, 1994).
Table 3.2: Attenuated bacterial strains used as oral vaccines or delivery vectors.
Bacterial strain Mutation Reference
S. typhimurium aroA, aroD, aroC, galE, 
cya, crp, asd
Hoiseth and Stocker, 1981; 
Roberts et al, 1994
S. typhimurium aroA or pur A or pur A, 
aroA or purE, aroA
O’Callaghan et al, 1988
Bordetella pertussis aroA Roberts et al, 1990
P. multocida aroA Homchampa et al, 1992
Yersinia enterocolitica aroA Bowe et al, 1989
Salmonella choleraesuis cyal2( crp-cdt) Stabei et al, 1993
Salmonella typhi aroA Dougan et al, 1987a
Salmonella dublin aroA Roberts et al, 1994
Salmonella enteridis aroA Roberts et al, 1994
3 .4.3 Salmonella typhimurium aroA mutants
Aromatic-dependent S. typhimurium aroA gene mutants were developed, using 
transposon mutagenesis, as non-virulent live vaccine strains against typhoid (Hoiseth
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and Stocker, 1981). These strains are non-reverting mutants which carry a deletion in 
the aroA gene (Cardenas and Clements, 1992). The aroA encodes 3- 
enolpyruvylshikimate-5-phosphate synthetase which catalyses the conversion of 
shikimic acid into chorismic acid. The product of this reaction is an intermediate in 
the synthesis of the essential compounds PAB-folate and enterochelin, which are not 










Figure 3.5: Diagrammatic representation of the role of the AroA enzyme in S.
typhimurium (modified from Cardenas and Clements, 1992).
S. typhimurium aroA mutants have been demonstrated to be invasive yet non-virulent 
strains capable of eliciting immune responses which protect against subsequent 
virulent challenge (Hoiseth and Stocker, 1981; Cardenas and Clements, 1992; 
Lumsden and Wilkie, 1992; Mukkur, 1992; Curtiss et al, 1993; Dougan, 1994).
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3.4.4 Attenuated S. typhimurium mutants as delivery vectors for 
heterologous antigen
Attenuated Salmonella strains are capable of carrying and presenting heterologous 
antigen to the mucosal immune system and eliciting humoral, mucosal and cell 
mediated immune responses (Table 3.3) (Dougan et al, 1987b; Dougan et al, 1989). 
The DNA encoding the heterologous antigens may be present in the attenuated strain 
on a plasmid or alternatively the DNA may be inserted into the vector’s chromosomal 
DNA (Cardenas and Clements, 1992). Plasmids can be unstable and require genes 
which allow for selection, usually antibiotics, so that the plasmid is maintained within 
the attenuated strain (Cardenas and Clements, 1992). Multicopy recombinant plasmids 
allow for over-expression orheterologous antigen within attenuated carrier vectors. 
Delivery of a large antigen load is critical if a mucosal antibody response is to be 
elicited (Cardenas et al, 1994). Insertion of the heterologous antigen DNA into the 
chromosome of the host is more stable and does not require the use of selective 
antibiotics. Studies have demonstrated that if the antigen can be inserted under the 
control of a /«-vz'vo-activated promotor, such as nirB, large amounts of antigen can be 
produced and these recombinant strains can be effective in eliciting protective 
immune responses (Chatfield et al, 1992). The immune responses elicited by oral 
delivery of antigen using attenuated Salmonella spp. vectors is varied (Table 3.3). 
Even within a species, the immunogenicity of attenuated strains is variable (Roberts et 
al, 1994). The dose of delivered antigen and the vaccination regime appear to be the 
predominant factors affecting host immune responses (Killar and Eisenstein, 1986; 
Stabel et al, 1991; Cardenas and Clements, 1992; Stabel et al, 1993). Persistence of 
the attenuated organism in host cells and intracellular location of cloned antigens do
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not appear to be major contributing factors in the immunogenicity of a number of 
reported strains (Brown et al, 1987; Cardenas et al, 1994).
Table 3.3: Examples of types of heterologous antigens expressed in attenuated 
Salmonella spp. Elicited host immune responses and protective efficacy of vaccine 
strain are indicated (modified from Roberts et al, 1994).
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S. typhim urium  
aroA  aroC , a ro D
No Yes ND Yes Strugnell e t al, 
1992
0  antigen S h igella
fle x n e r i
S. typh i Ty21a Yes ND ND Yes Baron e t al, 
1987
8kDa OMP N esser ia
m en in g itid is
S. typhim urium  
aroA
Yes ND ND ND Tarkka e t al, 
1989
M protein S trep to co ccu s
p y o g e n e s
S. typhim urium  
aroA
Yes ND ND Yes Poirier e t al, 
1988
K1 capsule E sch erich ia
co li
S. typhim urium  
aroA




E sch erich ia
c o li
S. typhim urium  
aroA
Yes Yes ND N/A Brown e t al, 
1987
31 kDa B ru cella
abortu s
S. ch o lerasu is cya  
crp  c d t
No Yes ND ND Stabe 1 e t al, 
1993
31 kDa B ru cella
a bortu s
S. typhim urium  
aroA
Yes No ND ND Stabel e t al, 
1991
Nucleoprotein Influenza A S. typhim urium  
aroA




S. typhim urium  
aroA
ND ND ND Yes Bowen e t al, 
1990
gp63 P lasm odiu m
fa lc ip a ru m
»S', typhim urium  
WR4024




Dengue virus 4 S. typhim urium  
aroA
ND ND ND ND Roberts e t al, 
1994
IL-6 Murine S. typhim urium  
aroA
ND ND ND N/A Dunstan e t al, 
1996
IL-lß Human S. typhim urium  
aroA
Yes ND ND N/A Carrier e t al, 
1992
Flagellin-M S trep to co ccu s
p y o g e n e s
S. du blin  aroA Yes ND ND Yes Newton e t al, 
1991
LTB-HBsAg Hepatitis B S. du b lin  aroA Yes Yes ND ND Schodel et al, 
1990
Ab = antibody responses detected; CMI = cell mediated response detected; CTL = cytotoxic T-
lymphocytes detected; Protection = protection from virulent challenge; ND = not determined; N/A =
not applicable.
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3.5 Materials and methods
•̂5*1 Bacterial strains and plasmids
Plasmid DNA isolation and transformation were performed as described in Chapter 2. 
All plasmids used to transform S. typhimurium SL3261 aroA (Hoiseth and Stocker, 
1981) were modified to prevent host restriction by transforming initially into S. 
typhimurium SL5283 (Hoiseth and Stocker, 1981) prior to isolation and subsequent 
transformation into S. typhimurium SL3261.
Antibiotics were used at the following concentrations: chloramphenicol 50 pg/ml; 
ampicillin 100 pg/ml. All bacteria were grown overnight on Z agar with appropriate 
antibiotic selection then seeded into 250 ml LB with selection and grown at 37°C 
overnight in a shaking incubator. For vaccine studies, overnight LB cultures were 
used, seeded into 500 ml LB broth with selection and grown at 37°C to mid log phase 
(OD650 0.5 - 0.6) prior to harvesting by centrifugation (2000 x g for 15 min).
Growth curves were performed to determine if the recombinant antigens being 
produced by the strains containing the plasmids pKFl or pSD9 were deleterious to the 
viability of those strains. Two growth curve experiments were carried out using either 
S. typhimurium SL3261 (pKFl) or S. typhimurium SL3261 (pSD9). In both 
experiments, S. typhimurium SL3261 and S. typhimurium SL3261 containing the 
parental plasmid were grown as controls. All strains were grown overnight on Z agar 
with appropriate antibiotic selection then subsequently seeded into 300 ml LB with 
selection and grown at 37°C overnight in a shaking incubator. This overnight LB 
culture was subsequently used to seed a 300 ml LB culture with selection and grown 
at 37°C. Absorbance readings (OD 560 nm) were taken at time zero and at 30 minute 
intervals until the absorbance reached a plateau.
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Viable numbers of bacterial cells for all Salmonella strains were determined by taking 
duplicate samples in early, mid and late log phase. These samples were pelleted (2000 
x g for 15 min) and resuspended to an optical density of 1. The samples were serially 
diluted in sterile PBS and aliquots (100 pi) of each diluted sample were plated in 
duplicate onto Z agar with the appropriate selection and incubated overnight at 37°C 
prior to determining the number of viable bacterial cells grown.
3.5.2 Mice immunisation
Three independent mouse trials were carried out. Two trials were identical for 
treatments and controls, these were pooled and labelled Trial 1 (Table 3.4). The other 
trial had different treatment groups and is labelled Trial 2 (Table 3.5). Immunisation 
was performed essentially as described by Guzman et al (1991). Six to eight week old 
female BALB/c mice were caged separately according to treatment groups (Tables 3.4 
and 3.5). For live oral vector and vaccine groups, cultures were grown to mid­
logarithmic phase and subsequently pelleted by centrifugation (2000 x g for 15 min). 
Bacteria were resuspended in ice cold PBS to an optical density corresponding to 2 x 
109 viable bacteria per 100 pi. Immediately prior to immunisation an equal volume of 
3% sodium bicarbonate in PBS was added to give the final working dilution of 1 x 
109 viable bacteria per 100 pi. Mice in all oral groups were deprived of water 2 to 3 
hours before delivery of the vaccine (100 pi of the bacterial suspension) through an 
oesophageal cannula. For intraperitoneal (IP) immunisation a total of either 100 pg of 
128 kDa fusion protein or 50 pg of 15 kDa NrdF protein was diluted in 50 pi then 
subsequently emulsified in an equal volume of Freund’s complete adjuvant to give the 
final 100 pi volume for the primary immunisation. In subsequent immunisations 
Freund’s incomplete adjuvant was used, while the volume and antigen dose remained 
identical to the primary immunisation.
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Table 3.4: Mice immunisation protocol for trial 1
Trial 1 
Group Treatment Number of 
mice
Dose Route
a PBS 8 100 pi Oral
b SL3261 9 109 bacteria Live oral
c SL3261(pSD9) 7 109 bacteria Live oral
d 128 kDa fusion 
protein
8 100 pg in 
adjuvant
Intraperitoneal
Primary immunisation at day 0, boosters at day 30 and day 40 and sacrificed at day 50 
Table 3.5: Mice immunisation protocol for trial 2.
Trial 2
Group Treatment Number of 
mice
Dose Route
e PBS 5 100 pi Oral
f SL3261 5 109 bacteria Live oral
g SL3261(pKFl) 10 109 bacteria Live oral
h 15 kDa NrdF 
protein
5 50 pg in 
adjuvant
Intraperitoneal
Primary immunisation at day 0, boosters at day 30 and day 40 and sacrificed at day 50.
All mice received primary immunisation at day 0, boosters at days 30 and 40 and were 
sacrificed at day 50. Mice were killed by cervical dislocation prior to exsanguination 
by the severing of the brachial artery. Sera were collected and stored at -20°C. Lung 
lavages were collected by pertracheal cannulation by instilling 0.8 ml of PBS
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containing 2 mM phenylmethylsulfonylfloride. Lung lavages were centrifuged briefly 
at 3000 x g to remove debris then stored at -20°C.
3.5.3 Enzyme linked immunosorbant assay
An enzyme linked immunosorbant assay (ELISA) was used to determine mouse 
antibody responses for IgA, IgM and IgG isotypes in sera and lung lavage samples. 
Primary antigen was either 15 kDa NrdF protein diluted to a final concentration of 1 
pg/ml in carbonate buffer (30 mM sodium carbonate, 20 mM sodium hydrogen 
carbonate, pH 9.6), or S. typhimurium aroA SL3261 whole cell lysate, prepared by 
boiling 10 mg of cell pellet for 10 min in 0.5 M Tris-HCl (pH 6.8) containing 1% 
glycerol, 0.2% SDS and 0.5% (3-mercaptoethanol. Whole cell lysate was then pelleted 
(16000 x g 3 min RT) to remove debris and the protein concentration adjusted to 1 
pg/ml in carbonate buffer prior to use. Aliquots (100 pi) of the primary antigen were 
coated to 96 well microtitre plates (Nunc) by incubation for 1 h at 37°C. Plates were 
subsequently washed 5 times with 0.05% Tween 20 (Sigma) in PBS (pH 7.4). First 
antibody was mouse sera diluted 1 in 200, or lung lavage samples diluted 1 in 20; in 
both cases diluent was PBS containing 10% foetal bovine serum and 0.05% Tween 
20. Aliquots (100 pi) of the first antibody were added in triplicate and incubated for 1 
hr at 37°C. Following incubation, plates were washed as previously described and 100 
pi aliquots of horseradish peroxidase conjugated rabbit anti-mouse immunoglobulin 
antibodies (Bio Rad) diluted in PBS (pH 7.4) containing 10% foetal bovine serum and 
0.05% Tween 20 were added to each well. Rabbit anti-IgG (KPL) and anti-IgM (KPL) 
second antibodies were diluted 1 in 2000, whereas anti-IgA (KPL) was diluted 1 in 
400. Plates were incubated at 37°C for 1 h then washed as described above. ELISA 
plates were developed using 100 pi aliquots of tetramethylbenzidine dihydrochloride 
(Sigma). Development was stopped after 3 min by the addition of 50 pi 0.1 M 
phosphoric acid and the absorbance was read at 450 nm. Plates were blanked against a 
PBS control and variation between plates was standardised using positive control sera 
allowing isotype comparisons between groups.
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The surface accessibility of the NrdF antigen to the mouse immune response on intact 
M. hyopneumoniae cells was examined using whole cell ELISA. Coating of the plates 
with whole cells is described in section 2.3.6. Mouse primary antibodies were 
processed as described above.
ELISA was also used to determine the immunogenicity of the NrdF protein in infected 
swine sera (n = 6) from a previously described M. hyopneumoniae challenge trial 
(section 2.1). Primary antigen was 15 kDa NrdF protein prepared as described above. 
Primary antibody was swine serum diluted 1 in 100 in PBS (pH 7.4) with 2% skim 
milk powder (w/v) and 0.05% Tween 20. Secondary antibody (horseradish peroxidase 
conjugated goat anti-swine IgG (KPL) diluted 1 in 500 in PBS (pH 7.4) with 2% skim 
milk powder (w/v) and 0.05% Tween 20. All incubation conditions, plate washes 
between incubations and the development of ELISA plates were carried out as 
described above.
3.5.4 Statistical analysis
Treatment group antibody responses determined by ELISA results were compared 
against the oral PBS control treatment group using a Tukey multiple comparison test 
for unequal sample sizes as described by Zar (1984).
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3.6 Results
3.6.1 Expression of recombinant proteins in Salmonella
typhimurium aroA strains
In attenuated S. typhimurium aroA SL3261 (pSD9), a recombinant 128 kDa fusion 
protein, analogous to the E. coli (pSD9) protein, was expressed. This protein 
comprised 11 kDa of a 42 kDa M. hyopneumoniae NrdF protein fused to the carboxy- 
terminus of the 117 kDa fi-galactosidase protein (Fig 3.6, lane 1). The S. typhimurium 
aroA SL3261 (pKFl) strain expressed a 15 kDa non-fusion protein (Fig 3.7, lane 3), 
consisting of 11 kDa from the carboxyl-terminus of the 42 kDa M. hyopneumoniae 
NrdF protein and the remainder being the polycloning region of pHSG398 (Stanley 
andLuzio, 1984).
3.6.2 Viable counts and growth curves
There were no significant differences between strains in the number of viable bacteria 
after samples were standardised to an optical density of 1.0 (Table 3.6)
Table 3.6: Salmonella strain viable numbers after standardisation to an
optical density of 1.0.
Bacterial Strain Viable number per 100 pi Standard deviation
S. typhim urium  SL3261 1.83 x 1010 1.0 x 109
S. typhim urium  SL3261 (pEXl) 1.03 xlO 10 0.3 xlO9
S. typhim urium  SL3261 (pSD9) 1.30 x 1010 0.2 x 109
S. typhim urium  SL3261 (pHSG398) 1.43 xlO 10 0.6 x 109
S. typhim urium  SL3261 (pKFl) 1.20 x 1010 0.3 x 109
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Fig 3.6: Expression and identification of 128 kDa fusion protein in S. typhimurium
SL3261. A . Coomassie brilliant blue stained 11% PAGE gel. Lane l, S. typhimurium 
SL3261 (pSD9); Lane 2, S. typhimurium SL3261; Lane 3, S. typhimurium SL3261 
(pEXl); Lane 4, R  coli MC1061 (pSD9). Positions of molecular weight markers (in kDa) 
are indicated on the left of the gel. B. Western blot analysis of identical samples described 
above using rabbit 128 kDa fusion protein antiserum. The recombinant fusion protein is 
indicated with an arrow on the right of the blot
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Fig 3.7: Expression and identification of 15 kDa NrdF antigen in S. typhimurium
SL3261. A. Coomassie brilliant blue stained 15% PAGE gel. Lane 1, S. typhimurium 
SL3261; Lane 2, purified recombinant 15 kDa NrdF antigen; Lane 3, S. typhimurium 
SL3261 (pKFl); Lane 4, S. typhimurium SL3261 (pHSG398). Positions of molecular 
weight markers (in kDa) are indicated on the right of the gel. B. Western blot analysis of 
identical samples described above using rabbit 15 kDa NrdF antigen antiserum. The 
recombinant NrdF antigen is indicated with an arrow on the left of the gel.
106
Fig 3.8: Growth of S. typhimurium SL3261 (pSD9) overtime. Immunisation
groups are indicated as follows: S. typhimurium SL3261 (open box); S. typhimurium 
SL3261(pEXl) (half filled box); S. typhimurium SL3261 (pSD9) (filled box).
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Time (hours)
Fig 3.9: Growth of S. typhimurium SL3261 (pKFl) overtime. Immunisation
groups are indicated as follows: S. typhimurium SL3261 (open box); S. typhimurium 
SL3261(pHSG398) (half filled box); S. typhimurium SL3261 (pKFl) (filled box).
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S. typhimurium SL3261 containing either pSD9 or the parental pEXl plasmids do not 
grow as well as the same strain without the plasmid burden. Growth curves 
demonstrate that the overproduction of the pEXl-encoded 117 [3-galactosidase protein 
or the pSD9-encoded 128 kDa recombinant NrdF fusion protein causes the strain to 
grow at a slower rate (Fig 3.8). S. typhimurium SL3261 containing either pKFl or the 
parental pHSG398 plasmids are not burdened by the expression of the respective 
recombinant antigens (Fig 3.9).
3.6.3 Assessment of antibody responses in immunised mice
In both trials the absence of IgM antibody in lung lavage samples precludes the 
possibility of serum contamination of the mucosal washes. Consequently, the isotypes 
detected in the mouse lung lavage samples can be considered an accurate indication of 
immunoglobulin isotypes present.
Oral delivery of the live S. typhimurium SL3261(pSD9) and S. typhimurium 
SL3261(pKFl) vaccine strains elicited significant (P < 0.05) NrdF IgA antibody 
responses in the lungs of vaccinated mice (Fig 3.10 A and C, groups c and g 
respectively). This delivery route in Trial 1 elicited significant IgG in the lungs, 
however, in Trial 2 the observed increase in IgG was not significant (P < 0.05) 
(compare Fig 3.10 A, group g against group f). Similarly, oral immunisation with S. 
typhimurium SL3261(pSD9) elicited a significant 15 kDa NrdF serum IgG response 
(Fig 3.11 A group c), whereas in Trial 2 the increase in serum IgG for the 
corresponding treatment was detected but was not significant (Fig 3.11 C, group g). In 
both trials oral immunisation with the vaccine strains did not elicit significant IgM 
responses in the lungs or serum (Fig 3.10 A and C, groups c and g, and Fig 3.11 A and 
C, groups c and g).
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Fig 3.10: Levels of recombinant 15 kDa NrdF specific IgG, IgM and IgA
antibodies in mouse lung lavage samples after vaccination. A. Lung antibody levels 
from trial 1 specific for 15 kDa NrdF protein. B. Lung antibody levels from trial 1 
specific for S. typhimurium SL3261 whole cell proteins. C. Lung lavage antibody 
levels from trial 2 specific for 15 kDa NrdF protein. D. Lung lavage antibody levels 
from trial 2 specific for S. typhimurium aroA SL3261 whole cell proteins. 
Designations under the graphs correspond to treatment groups outlined in the 
immunisation protocol (Table 3.4 and 3.5). Standard error of the mean is indicated by 
vertical lines. Statistical significance (P < 0.05) comparing treatments against the PBS 
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Fig 3.11: Levels of recombinant 15 kDa NrdF specific IgG, IgM and IgA
antibodies in mouse serum samples after vaccination. A. Serum antibody levels from 
trial 1 specific for 15 kDa NrdF protein. B. Serum antibody levels from trial 1 specific 
for S. typhimurium SL3261 whole cell proteins. C. Serum antibody levels from trial 2 
specific for 15 kDa NrdF protein. D. Serum antibody levels from trial 2 specific for S. 
typhimurium aroA SL3261 whole cell proteins. Designations under the graphs 
correspond to treatment groups outlined in the immunisation protocol (Table 3.4 and 
3.5). Standard error of the mean is indicated by vertical lines. Statistical significance 
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Fig 3.12: Levels of recombinant 15 kDa NrdF specific IgG and IgA antibodies
detected in whole cell M. hyopneumoniae ELISA. A. mouse serum from trial 2. B. lung 
lavage samples from trial 2. Standard error of the mean is indicated by vertical lines. 
Designations under the graphs correspond to treatment groups outlined in the 
immunisation protocol (Table 3.5). Statistical significance (P < 0.05) comparing 
treatments against the PBS oral control group is indicated by an asterisk (*).
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All mice orally immunised with S. typhimurium aroA SL3261 and S. typhimurium 
aroA SL3261 vaccine strains had significant (P < 0.05) Salmonella IgG and IgM 
antibody responses in serum (Fig 3.11 B and D, groups b, c, f  and g) and IgA 
responses in lung lavage samples (Fig 3.10 B and D, groups b, c, f and g). These 
results indicate that the Salmonella vector is being recognised and processed by the 
hosts immune system and subsequently elicits a response. However, the 
intraperitoneal delivery of the M. hyopneumoniae NrdF protein also induced 
significant serum IgG, IgM (Fig 3.11 B and D, groups d and h) and lung IgG 
Salmonella antibody responses (Fig 3.10 B and D, groups d and h) indicating cross­
reactivity between the recombinant NrdF protein and epitopes found in the S. 
typhimurium SL3261.
Intraperitoneal delivery of the 15 kDa NrdF antigen in Trial 2 (Fig 3.11 C, group h) 
elicited significant (P < 0.05) serum IgG, IgM and lung IgG responses (Fig 3.10 C, 
group h). This delivery route in Trial 1, using the 128 kDa fusion protein, elicited a 
significant IgG response in the serum (Fig 3.11 A, group d), however, all other isotype 
responses in the lungs and serum within this treatment group were not significant.
In mice orally immunised with the 15 kDa antigen (Trial 2) there were significant 
secretory IgA levels (P < 0.05) which recognise the cell surface of M. hyopneumoniae 
in whole cell ELISA (Fig.3.12 B, group c). Significant serum IgG in the 




The burden of expressing the 128 kDa fusion protein in S. typhimurium SL3261 
(pSD9) appears to stress the vaccine strain, resulting in slower growth and decreased 
tolerance to higher bacterial numbers in culture. S. typhimurium SL3261 (pKFl) 
strain, which expresses the 15 kDa NrdF antigen, grew at the same rate as the control 
SL3261
The recombinant 15 kDa antigen encoded by the plasmid pKFl has no carrier 
molecule that would direct the protein to a particular cellular location. Interestingly 
there is no requirement to use strategies to express the NrdF antigen on the bacterial 
surface in order to promote a lung mucosal IgA response after oral vaccination. Due to 
a demonstrated 51% identical amino acid similarity, 61% similarity if conserved 
amino acids are considered (Table 2.3), some degree of cross reactivity is expected 
between the NrdF M. hyopneumoniae antigen and the NrdF protein of S. typhimurium. 
This does present a problem in the detection of NrdF specific antibody responses. 
Antibodies raised against the M. hyopneumoniae NrdF antigen recognise cross­
reactive epitopes in the S. typhimurium aroA SL3261 ELISA, resulting in high 
absorbance values in this ELISA due to the excess of S. typhimurium coating antigen 
in the assay wells. The lack of antibody response in the S. typhimurium aroA SL3261 
oral control groups against M. hyopneumoniae NrdF protein (Fig.3.12 A and C, 
groups b and f) indicates that the bacterial cross-reactive antigen is not immunogenic. 
This could be due to either the S. typhimurium protein not being expressed in 
sufficiently large quantities to induce a humoral immune response, or the bacterial 
antigen may not be processed and presented to the host immune system.
Results unique to Trial 2 were the presence of significant serum NrdF IgA in the oral 
vaccine (compare Fig 3.11 A, group c to Fig 3.11 C, group g), significant serum 
SL3261 IgA in the oral control groups (compare Fig 3.11 B, group b to Fig 3.11 D,
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group f), and significant serum NrdF IgM in the IP group (compare Fig 3.11 A, group 
d to Fig 3.11 C, group h). It is feasible that the 128 kDa fusion protein does not elicit 
the same serum immunoglobulin responses that are stimulated by the 15 kDa NrdF 
antigen.
The results described in this chapter demonstrate that, in mice, the recombinant 
vaccine strains are able to stimulate M. hyopneumoniae NrdF specific secretory IgA 
antibody in lungs and IgG in the serum after oral delivery. Furthermore, whole cell 
ELISA demonstrates the surface accessibility of the in-situ NrdF protein in M. 
hyopneumoniae to these mouse antibodies elicited against the pKFl-encoded 15 kDa 
NrdF antigen. Whole cell ELISA examination of the surface accessibility of the wild­
type NrdF subunit by mouse antibodies raised against the pSD9 encoded 128 kDa 
fusion protein was not undertaken. Due to the reduced growth rate demonstrated in 
growth curves and potential problems associated with the 117 kDa P-galactosidase 
fusion protein component, the S. typhimurium SL3261 (pSD9) vaccine strain was not 
chosen as the candidate vaccine strain for use in pig trials.
The successful oral immunisation against a heterologous mycoplasmal antigen in a 
Salmonella vector is unique not only because it demonstrates that there are no 
problems associated with the adenosine-tyrosine bias and different codon usage 
between the selected mycoplasma antigen and Salmonella vector, but also because an 
immune response specific for this antigen can reduce the severity of PEP in swine 
(Chapter 2). Although there are differences between the mucosal immune physiology 
of mice and swine, the induction of a secretory response, in mice, against a 
metabolically essential ribonucleotide reductase from a swine respiratory pathogen 
provides evidence that this vaccine strain may prove to be efficacious in protecting 
swine from M. hyopneumoniae infection.
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Chapter 4
Assessment of Immune Protection of Swine Orally Vaccinated with 
Attenuated Salmonella typhimurium SL3261 aroA Expressing the 
Recombinant 15 kDa M. hyopneumoniae NrdF Antigen.
Studies examining the complex interactions between the swine host and colonising M. 
hyopneumoniae have not as yet demonstrated a correlation between any single 
specific immune response and protection from PEP. In a recent study, pigs 
parenterally immunised with a pool of M. hyopneumoniae antigens were shown to 
have reduced lung pathology compared to unvaccinated controls. Serum and 
respiratory tract washing IgG and IgA concentrations in this study were demonstrated 
to be a poor prognostic indicator of protection against enzootic pneumonia (Djordjevic 
et al, 1997). However, resolution of the disease has been correlated with both the 
presence of serum antibodies (Messier et al, 1990) and an increase in cell-mediated 
immunity (CMI) during the later stages of infection (Adegboye, 1978a; Messier et al, 
1990). Current commercial vaccines comprise bacterin formulations which reduce the 
severity of PEP (Bilic et al, 1992; Christensen & Vraa-Andersen, 1993; Charlier et al, 
1993; Murphy et al, 1993; Dohoo and Montgomery, 1996). Whilst most of the studies 
have reported reductions in lung damage caused by PEP after bacterin immunisation, 
some studies failed to demonstrate economic improvement to pig production such as 
increases in average daily gains (Murphy et al, 1993; Morrow et al, 1994). 
Furthermore, the labour intensive mode of delivery and the cost of purchasing such 
vaccines may not justify their widespread commercial use. The purpose of the work 
described within this chapter was to evaluate whether oral immunisation of swine with 
the S. typhimurium SL3261 (pKFl) vaccine strain (described in Chapter 3) can elicit 
a mucosal immune response in the lungs and stimulate cellular and humoral immune
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responses in the serum. Furthermore, the effectiveness of this vaccine strain to protect 
swine from challenge with virulent M. hyopneumoniae was assessed.
4.1 Salmonellae in swine
4.1.1 Natural infections caused by Salmonellae
Swine are naturally infected with a number of Salmonellae serotypes. The resulting 
disease, porcine salmonellosis, manifests itself predominantly as septicemia or 
enterocolitis although pneumonia, encephalitis, meningitis, rectal stricture and 
lymphadenitis have also been reported as symptoms of this condition (Reed et al, 
1986). Salmonella choleraesuis is the predominant organism associated with porcine 
salmonellosis (Minev et al, 1984; Minev et al, 1987) and is usually associated with 
septicaemic disease (Wilcock et al, 1976). S. typhimurium is the second most 
frequently isolated pathogen in salmonellosis and is associated with the enteric form 
of the disease (Wilcock et al, 1976; Reed et al, 1986). A large number of other 
serotypes are associated to a lesser degree. A comprehensive study of porcine 
salmonellosis in Bulgaria between 1970 and 1985 reported S. choleraesuis and S. 
typhimurium as the predominant causal serotypes but also detected Salmonella agona, 
Salmonella jerusalem, Salmonella tennessee, Salmonella bovis-morbificans, 
Salmonella derby, Salmonella thompson and other undefined exotic serotypes (Minev 
et al, 1984; Minev et al, 1987).
4.1.2 Attenuated S. typhimurium strains in swine
Infection of swine with virulent Salmonella spp. occurs by the same route as described 
in section 3.5 (Salmonella typhimurium pathogenesis). The organism invades the 
Peyer’s patch regions of pigs and colonises the intestine and mesenteric lymph nodes 
(Stabel et al, 1991) stimulating secretory, humoral and CMI responses (Reed et al, 
1986). In swine, aroA mutants of S. typhimurium have been demonstrated to be both 
safe and efficacious in protecting immunised swine from infection with the virulent
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parental strain (Lumsden and Wilkie, 1992). Both attenuated S. typhimurium and S. 
choleraesuis have been used to deliver a 31 kDa Brucella abortis antigen to the 
mucosal immune system of swine (Stabel et al, 1991; Stabel et al, 1993). Delivery of 
the 31 kDa antigen using attenuated S. typhimurium stimulated mucosal (intestinal) 
and systemic antibody responses, however, no DTH or lymphoproliferative responses 
were detected (Stabel et al, 1991). Conversely, delivery of the 31 kDa antigen using 
attenuated S. choleraesuis stimulated DTH responses but no mucosal or systemic 
antibody responses (Stabel et al, 1993). These results indicate that the elicited immune 
response varies with the delivery vector strain and possibly with the amount of 
antigen delivered. To date there has been no study into the use of an attenuated 
Salmonella to deliver antigen for the stimulation of immunity against a mucosal lung 
pathogen of swine.
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4.2 Materials and methods
4.2.1 Bacterial strains, plasmids and media
Bacterial strains used in this work are described in Table 2.1. For vaccination, S. 
typhimurium SL3261 containing either the plasmid pKFl encoding the 15 kDa NrdF 
antigen or the parental plasmid pHSG398 (Takeshita et al, 1987) were grown to mid­
logarithmic phase in an orbital incubator at 37°C and subsequently pelleted by 
centrifugation (2000 x g for 10 min). Bacteria were then resuspended in ice cold PBS 
(pH 7.2) to an optical density corresponding to 2 x 109 viable bacteria per ml and 
stored on ice. Immediately prior to immunisation, an equal volume of 3% sodium 
bicarbonate in PBS (pH 7.2) was added to give the final working dilution of 1 x 109 
viable bacteria per ml in a final volume of 20 ml. For delayed type hypersensitivity 
(DTH) and lymphoprolifération assays, S. typhimurium SL3261 (pHSG398) cells 
were similarly grown and pelleted then placed in a boiling water bath for 10 min to 
heat kill the bacteria prior to use.
4.2.2 Viability of vaccine strain after storage on ice
The viability of the S. typhimurium SL3261 and S. typhimurium SL3261 (pKFl) 
strains after storage on ice was determined by preparing the strains for oral 
immunisation (section 3.5: Mice immunisation). At hourly intervals, samples were 
taken and a serial dilution series was made. Aliquots (100 pi) of each diluted sample 
was plated in duplicate onto Z agar with the appropriate selection and incubated 
overnight at 37°C prior to determining the number of viable bacterial colonies.
4.2.3 Experimental animal procedures
Pigs were anaesthetised for the collection of respiratory tract washings (RTW), 
challenge with virulent M. hyopneumoniae (Beaufort strain) and for DTH testing. Pigs 
between the ages of 6 to 10 weeks old were restrained in a bleeding cradle in dorsal 
recumbency and anaesthetised with a mixture of xylazine (100 mg/ml) and ketamine
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(100 mg/ml) formulated at 0.25 ml and 1 ml per 10 kg weight. Older pigs were 
restrained with a nose snare and anaesthetised with a similar mixture of xylazine and 
ketamine formulated at 0.28 and 1.12 ml per 10 kg weight. Blood samples were 
collected by venipuncture of the precava and RTW were collected by intubation. 
Following the introduction of an endotracheal tube a 10 ml aliquot of PBS was 
instilled and immediately removed by aspiration under vacuum using a fine (2 mm) 
silicon tube within the endotracheal tube. Pigs were challenged using infected lung 
filtrate. Consolidated infected lung tissue from pigs previously infected with the 
virulent M hyopneumoniae Beaufort strain and stored at -70°C was thawed, 
macerated in PBS (pH 7.2) and filtered through cheese cloth. Aliquots of 20 ml 
(equivalent to 9.2 g wet weight of infected lung) were administered to anaesthetised 
pigs through a silicon tube (4 mm) located within the endotracheal tube. For DTH and 
mitogenicity assays, inoculation of antigen or mitogen was given in triplicate in the 
ventral skin 2-3 cm lateral to the nipple line using 100 pi of 50 pg/ml antigen at each 
test site. Antigens used in the DTH tests during weeks 0 and 5 were purified 15 kDa 
NrdF antigen, heat killed whole cells of S. typhimurium SL3261 (pHSG398) and PBS. 
Phytohaemaggluttinin (PHA) was used as the mitogen. Only the mitogenicity assay, 
using PHA and PBS, was carried out at week 12. Tests were read as skin thickening 
(mm) at 48 h using a micrometer calliper.
Pig trials were carried out to assess the ability of the S. typhimurium SL3261 (pKFl) 
vaccine strain to elicit immune responses in immunised swine and to determine the 
protective efficacy against subsequent challenge. Five to six week-old pigs sourced 
from a M. hyopneumoniae-frQQ piggery were allocated to 4 treatment groups as 
indicated in Table 4.1. Pigs were double ear-tagged and individually weighed 5 days 
before the start of the trial, with groups and pens balanced by weight. Pigs allocated to 
the oral salmonella vector and oral salmonella vaccine groups were housed separately 
in one of two air-conditioned high security rooms each containing 5 pigs. Pigs in the 
control and NrdF intramuscular groups were housed in an experimental piggery with
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3-4 pigs per pen, as mixed treatment groups. The number of pigs per treatment was 
also balanced on both sides of the piggery, to reduce pen effects. The pigs were fed an 
antibiotic-free grower ration twice daily (at approximately 80% ad libita until 
slaughter at 19 weeks of age. All pig handling was performed with pigs in the lower 
security area before any movement of personnel to the high security area. Pigs in the 
oral salmonella vector group were always handled before those in the oral salmonella 
vaccine group. Personnel working in the high security facility used separate work 
clothes and waterproof overgarments which were disinfected on exit from each pen.
The time course of procedures used in the live oral vaccination and challenge trial are 
outlined in Table 4.2. At week 12, pigs were weighed and the average daily weight 
gain was calculated. Pigs were slaughtered at the end of week 12 and the lungs were 
collected to determine the extent of damage. Lung damage was determined both by 
Goodwin lung score (GLS) (Goodwin, 1969) and by the weighing of excised affected 
tissue and comparison with the average weight of all lungs in the trial. This value was 
then expressed as a percentage.
Table 4.1. Pig immunisation treatment groups.
Treatment Number of Pigs Dose Route
15 kDa NrdF 
intramuscular (IM)
6 1 ml containing 1.8 
mg/ml mixed 1:1 
with alhydrogel
Intramuscular
Control 6 - -
Oral Salmonella 
vector
S. typhim urium  SL3261 
(pHSG398)





S. typhim urium  SL3261 
(pKF 1 )




Table 4.2: M. hyopneumoniae live oral vaccine trial protocol.
Procedure WeekO Week 3 Week 5 Week 10 Week 12#
Immunisation* All groups Allgroups
Challenge All groups





RTW All groups All groups All groups












Weigh All groups All groups
control pigs did not receive any immunisation.
^Pigs were slaughtered and the lungs assessed for PEP damage after week 12.
4.2.4 Lymphocyte proliferation assays
Lymphoprolifération assays were carried out by B. Turner at EMAI. These assays 
were performed on separated lymphocytes derived from blood collected from control, 
oral salmonella vector and oral salmonella vaccine groups at pre-vaccination (week.O), 
post-vaccination (week.5), and post-challenge (week. 12). Blood was collected in 
heparinised vacuum tubes and processed within 4 hours from the time of collection. 
Blood (3 ml) was diluted with an equal volume of saline (0.85% w/v NaCl) and 
layered onto 3 ml of Nycoprep (density 1.077 g/cm3) then centrifuged at 2200 rpm 
(1200 x g) for 20 min at room temperature. Lymphocytes partitioning at the interface 
were aspirated into PBS containing 1% w/v glucose. The cells were pelleted by 
centrifugation at 1200 rpm (700 x g) for 10 min. Erythrocyte contaminants in the
preparation were lysed by brief resuspension of the cell pellet in 5 ml AMCO [0.85% 
(w/v) NH4CI, 0.1% (w/v) KHC03, 10 mM EDTA]. The erythrocyte-free cell pellet
was recovered by centrifugation and washed twice in 8 ml of PBS containing 1% w/v
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glucose. The washed cell pellet was then dispersed gently in Complete Medium (CM) 
(RPMI 1640 containing 5% foetal calf serum, 2 mM L-glutamine, 2 mM sodium 
pyruvate, 50 pM 2-mercapto-ethanol, 50 pg/ml penicillin and 50 I.U./ml 
streptomycin) at a cell density of 4 x 106/ml. Lymphoprolifération was carried out in 
triplicate by delivering 2 x 105 cells in 50 pi CM to each well of a flat-bottomed 96- 
well plate containing 200 pi of CM supplemented either with heat-killed M. 
hyopneumoniae (J strain) or S. typhimurium (pHSG398) (107 colony forming units
per well) or purified M. hyopneumoniae 15 kDa NrdF antigen (20 pg per well). 
Lymphocyte cultures were incubated at 37°C in 10% CO2 for 6 days and then pulsed
for 18 h with 0.5 pCi -^H-thymidine (925 Gbq/mmol, 25 Ci/mmol, Amersham). The 
cells in each well were then harvested onto glass fibre discs using a PHD cell 
harvester (Cambridge Technology), transferred into Pony vials (Packard) containing
2.5 ml of scintillant (Ultima Gold, Packard) and counted in a LKB scintillation 
counter. Stimulation indices were expressed as a ratio of counts per minute for each 
triplicate culture containing antigen to an equivalent replicate set without antigen.
4.2.4 Enzyme linked immunosorbant assay (ELISA) and Western
blot analysis
The Auspharm™ M. hyopneumoniae ELISA was used to determine the serological 
status of swine according to the method described by Sheldrake and Romalis (1992). 
Other ELISA methods based on 15 kDa NrdF antigen or whole cell S. typhimurium 
SL3261 antigens were performed as described in Chapter 2 with the following 
modifications. Primary antibody was pig serum or RTW diluted according to the 
immunoglobulin isotype being tested. ELISA detection of serum IgG used pig serum 
diluted 1 in 100 in PBS (pH 7.4) containing 2% skim milk powder and 0.05% Tween 
20 (Sigma) (PST). In the determination of all other isotypes a blocking step of 200 pL 
PST incubated for 1.5 h at room temperature was carried out prior to the addition of 
the primary antibody. Primary antibody was diluted 1 in 2 with PST in the RTW IgG 
ELISA. The primary antibody for all IgA ELISA was neat serum or RTW. Secondary
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antibodies were horseradish peroxidase conjugated goat anti-swine IgG (Bethyl 
Laboratories) diluted 1 in 500 using PBS (pH 7.4) or horseradish peroxidase 
conjugated goat anti-swine IgA (Bethyl Laboratories) diluted 1 in 400 using PBS (pH 
7.4). Plates were developed using 100 pi of 1 mM 2,2’- 
azinodiethylbenzthiazolinsulfonate (KPL) and read at 405 nm. Positive and negative 
control swine sera was used to allow comparisons of the same isotype between plates. 
A pooled swine prebleed serum was used as a negative control to determine 
background.
Western blot analysis was performed according to the modified method of Burnette 
(1981) in Chapter 2 (Section 2.2. SDS-PAGE and Western blot analysis). Rabbit anti- 
15 kDa NrdF serum was used as the primary antibody in Western immunoblots. Pig 
sera used to investigate the immunological recognition of the NrdF protein in swine 
were raised as described in Chapter 2 (Section 2.1: Preliminary research).
4.2.5 Statistical analysis
The effects of vaccination on lung scores, ELISA values and lymphocyte proliferation 
results were analysed within the same treatment group over time (if applicable) and 
between all treatment groups at the same time point. Values were initially assessed 
using analysis of variance (Zar, 1984) to indicate whether two or more of the samples 
displayed significant treatment effects. If a significant difference (P < 0.05) was 
obtained, a Tukey multiple comparison test for unequal sample sizes (Zar, 1984) was 
used to determine significance.
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4.3 Results
4.3.1 Strain viability after storage on ice
Both strains used for the oral immunisation of swine, S. typhimurium SL3261 and S. 
typhimurium SL3261 (pKFl), remained viable on ice until the end of monitoring at 6 
h (Fig 4.1). This indicates that variability between pig responses is due to differences 
in the swine and not due to the strain losing viability over time.
4.3.2 Antibody response against NrdF protein in swine after
experimental M. hyopneumoniae infection
The sera of the pigs experimentally infected with a virulent strain of M. 
hyopneumoniae (section 2.1: Preliminary research) produced an antibody response 
against the 15 kDa NrdF antigen. Whilst pre-challenge serological responses against 
NrdF were consistently low, experimentally infected pigs developed significant (P < 
0.05) levels of serum IgG against the NrdF antigen. These significant antibody levels 
remained elevated for at least 3 weeks post-challenge (Fig. 4.2).
4.3.3 Swine morbidity associated with vaccination and challenge
Swine given two oral doses of S. typhimurium SL3261 showed no signs of morbidity, 
diarrhoea or lethargy, associated with oral immunisation using live attenuated 
bacteria. Four weeks after challenge, one pig from the control group died from severe 
pneumonia, indicated by a Goodwin lung score of 55, complicated by secondary 
Actinomyces pyogenes infection which was confirmed by culture. One pig from the 
NrdF intramuscular group and one from the control group died during week 12 from 
mesenteric torsion possibly associated with handling during anaesthesia (Noyes et al, 













Fig 4.1 Viability o f immunisation strains, S. typhimurium SL3261(open squares) and
S. typhimurium SL3261 (pKFl) (red filled squares), after storage on ice.
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Fig. 4.2. ELISA detection o f antibodies specific for the 15 kDa NrdF antigen in 
experimentally challenged swine. Pigs from a M  hyopneumoniae-frQQ piggery were bled 
at weekly intervals and the animals were challenged with virulent Beaufort strain o f M  
hyopneumoniae at week 10 (indicated by an arrow). ELISA absorbance results are not 
blanked against a prebleed. Vertical bars represent standard deviation o f the mean. 
Statistical significance (P < 0.05) comparing bleeds against week 0 bleed is indicated by 
an asterisk (*).
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which were confirmed by culture and one of these pigs also had severe fibrinous 
pleuritis and concurrent infection with P. multocida and A. pyogenes. There were no 
other complicating factors or secondary infections identified in this vaccine trial.
4.3.4 Incidence and extent of PEP disease in challenged swine
Seven weeks following endotracheal challenge, M. hyopneumoniae specific antibodies 
were detected in all animals using the Auspharm ELISA (Fig. 4.3). All groups, except 
for the NrdF intramuscular group, when compared with a stock PEP negative control 
serum had a mean ELISA ratio greater than the positive cut off point of 3 indicating 
positive PEP status. The NrdF intramuscular group had an average ELISA ratio of 
2.92 (± 0.53) which is in the high inconclusive range (2 to 3). At necropsy, pigs from 
the oral salmonella vaccine group had visibly healthier lungs. This oral salmonella 
vaccine group had the lowest incidence of lung damage when measured by the 
percentage weight of affected lung with a mean of 6.4% ± 6.8, and the second lowest 
GLS with a mean of 16 ± 5.6 (Fig. 4.4). The NrdF intramuscular group also had a 
relatively low incidence of lung damage, when compared to the control groups, as 
measured by weight of tissue affected 7.5% ± 4.0 and the lowest incidence of damage 
when measured by GLS with a mean score of 15.3 ± 4.1. The control and oral 
salmonella vector groups had percentage lung affected values of 11.9% ± 5.65 and 
14.24% ± 9.27 respectively and GLS of 24.2 ± 6.4 and 26.2 ± 6.8 (Fig. 4.4).
4.3.5 Lymphoproliférative responses in pigs
The CMI response of pigs was determined by lymphoprolifération utilising 
lymphocytes purified from blood collected before vaccination (week 0), at post­
vaccination but before experimental challenge with M. hyopneumoniae (week 5), and 
also at post-challenge (week 12). Three different antigens were used in these 
lymphoprolifération assays. Fig. 4.5 shows that unvaccinated pigs and pigs in the oral 











Fig. 4.3. M. hyopneumoniae specific Auspharm™ antigen ELISA representing the 
average antibody ratio for each treatment group at different time points during the pig 
trial. An ELISA ratio below 2 is characteristic of a PEP negative sample group, 2-3 is 
inconclusive and above 3 is indicative of PEP infection. Treatment groups are indicated 
as follows: NrdF intramuscular (red filled box); control (open box); oral salmonella 
vector group (cross hatched box); oral salmonella vaccine group (black filled box). Error 












Fig. 4.4. Percentage lung affected by lesions in individual pigs at slaughter as 
determined by the weight of affected damaged tissue compared to an average weight of 
all pig lungs in the trial. Immunisation groups were: (A) NrdF intramuscular (average 
7.5%); (B) control (average 11.9%); (C) oral salmonella vector group (average 14.2%); 
(D) oral salmonella vaccine group (average 6.4%). Swine treatment group averages are 
represented by a horizontal bar.
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Fig. 4.5. Lymphocyte proliferation responses of pig treatment groups at week 0 
(Wk 0; prebleed), week 5 (Wk 5; postvaccination/prechallenge) and week 12 (Wk 12; 
post challenge). Antigens used as immunostimulants were (A) M. hyopneumoniae 
whole cell proteins; (B) S. typhimurium whole cell proteins; and (C) 15 kDa NrdF 
antigen. Immunisation groups are indicated as follows: control (red filled box); oral 
salmonella vector group (cross hatched box); oral salmonella vaccine group (black 
filled box). Error bars represent the standard error of the mean. Asterisk denotes 
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irrespective of the assay antigen. Following vaccination (week. 5) only animals in the 
oral salmonella vaccine group exhibited a significant lymphoproliférative response 
against S. typhimurium SL3261 whole cell proteins and also NrdF antigen. 
Lymphoprolifération response was subdued following experimental challenge (week. 
12) in all groups of pigs tested.
4.3.6 Delayed type hypersensitivity responses
The CMI response of pigs was also assessed by skin testing using S. typhimurium 
SL3261 cell proteins and also NrdF antigen (Table 4.3). A wheal and flare response at 
24 hours was not observed in any pig from each of the four groups post-vaccination or 
post-challenge. Intradermal inoculation with the mitogen PHA, however, elicited a 
significant immediate hypersensitivity response in all pigs at weeks 5 and 12 
compared to saline control inoculation sites on the same pig. There was no significant 
difference in the PHA response between treatment groups.
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Table 4.3: Average skin thickness of treatment groups following DTH and
mitogenic testing with indicated antigens at week 5 and 12














2.94 ±0.11 2.72 ± 0.09 2.64 ±0.12 2.61 ± 0.10
PHA* 3.57 ± 0.13 3.53 ±0.17 3.36 ±0.19 3.54 ±0.14
PBS 2.51 ±0.07 2.63 ± 0.09 2.47 ± 0.09 2.59 ±0.08
12 PHA* 5.33 ±0.14 5.33 ±0.11 5.47 ±0.32 5.14 ± 0.17
PBS 3.75 ± 0.09 3.92 ±0.09 3.46 ±0.18 3.84 ±0.07
PHA: phytohemmagglutinin; PBS: phosphate buffered saline (pH 7.4).
All treatment groups in week 5 and 12 had significant (P < 0.05) skin thickening indicative o f a 
positive mitogenic response to the PHA antigen.
4.3.7 Assessment of antibody responses
Intramuscular immunisation using the recombinant 15 kDa NrdF antigen elicited a 
NrdF specific IgG antibody response in the serum of swine detectable at week 5 and 
maintained at a level significantly greater (P < 0.05) than the swine prebleed (week 0) 
and all other treatment groups until slaughter (Fig. 4.6 C). After endotracheal 
challenge (week 5) a 15 kDa NrdF specific IgG response was also elicited in the oral 
Salmonella vaccine, control and oral salmonella vector groups (Fig. 4.6 C). There 
were no significant IgG NrdF antibodies detected in the respiratory tract washings of 
pigs from any of the treatment groups either after immunisation or after challenge 
with M. hyopneumoniae (Fig. 4.6 A). Similarly there were no NrdF specific IgA
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antibody responses elicited in the serum of swine during the course of the trial (Fig.
4.6 B). After immunisation (week 5) there was no significant NrdF specific secretory 
IgA detected in the lungs of any groups (Fig. 4.6 B). At seven weeks post challenge 
(week 12) there was a significant secretory NrdF IgA response detected in the lungs of 
pigs in the oral salmonella vaccine group (Fig. 4.6 B). The oral delivery of live S. 
typhimurium aroA SL3261 in either live oral treatment groups did not elicit 
Salmonella specific serum IgG or lung IgA antibody responses after vaccination 
(week 5) (Fig. 4.7). After challenge there was significant (P < 0.05) serum IgG 
Salmonella specific antibodies for all groups including the NrdF IP and control groups 
(Fig. 4.7). Challenge also elicited significant (P < 0.05) lung IgA Salmonella specific 
antibodies for the oral salmonella vaccine group (Fig. 4.7 B) and also significant (P < 
0.05) lung IgG in the oral salmonella vaccine group oral salmonella control 
groups(Fig 4.7 A).
4.3.8 Average daily weight gains
Due to the controlled rations fed daily to pigs, the average daily gain is a measure of 
feed conversion efficiency. The fastest growing swine group was the NrdF 
intramuscular group with an average daily increase of 747 g (Fig. 4.8). The control 
swine group had the lowest average daily gains at 671 g, the Salmonella vector 
treatment had an average gain of 707 g per day and the Salmonella vaccine group had 
an average gains of 716 g per day. Due to the small sample sizes and large variation 
within groups there were no statistical significance between groups.
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Fig.4.6. Levels of recombinant 15 kDa NrdF specific IgG and IgA antibodies in
swine lung lavage and serum samples at week 0 (Wk 0; prebleed), week 5 (Wk 5; 
postvaccination/ prechallenge) and week 12 (Wk 12; post challenge). (A) lung lavage 
IgG antibody levels (B) lung lavage IgA antibody levels (C) serum IgG antibody 
levels (D) serum IgA antibody levels. Immunisation groups are indicated as follows: 
NrdF intramuscular (red filled box); control (open box); oral salmonella vector group 
(cross hatched box); oral salmonella vaccine group (filled box). Error bars represent 
the standard error of the mean. Statistical significance (P < 0.05) comparing the same 
treatment group to the corresponding prebleed is indicated by a small asterisk (*). A 
large asterisk (*) denotes statistical significance (P < 0.05) to all other treatments at 
the same time period and to the corresponding prebleed. Vaccinations were carried out 
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Fig.4.7. Levels of S. typhimurium SL3261 specific IgG and IgA antibodies in 
swine lung lavage and serum samples at week 0 (Wk 0; prebleed), week 5 (Wk 5; 
postvaccination/ prechallenge) and week 12 (Wk 12; post challenge). (A) lung lavage 
IgG antibody levels (B) lung lavage IgA antibody levels (C) serum IgG antibody 
levels (D) serum IgA antibody levels. Immunisation groups are indicated as follows: 
NrdF intramuscular (red filled box); control (open box); oral salmonella vector group 
(cross hatched box); oral salmonella vaccine group (filled box). Error bars represent 
the standard error of the mean. Statistical significance (P < 0.05) comparing the same 
treatment group to the corresponding prebleed is indicated by a small asterisk (*). A 
large asterisk ( ) denotes statistical significance (P < 0.05) to all other treatments at 
the same time period and to the corresponding prebleed. Vaccinations were carried out 
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Fig. 4.8. Average daily weight gain (g) of individual pigs at slaughter. Treatment 
groups were: (A) NrdF intramuscular (average 747g); (B) control (average 671g); (C) oral 
salmonella vector group (average 707g); (D) oral salmonella vaccine group (average 716g). 
Swine treatment group averages are represented by a horizontal bar.
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4.4 Discussion
Cell mediated immune responses were examined in vaccinated pigs by 
lymphoprolifération and DTH using S. typhimurium and M. hyopneumoniae antigens 
including NrdF. The data in Fig. 4.5 demonstrate that oral immunisation with a live 
recombinant vector expressing heterologous antigen is able to elicit CMI responses. 
CMI was demonstrated by significant increases in the stimulation index of pigs orally 
dosed with S. typhimurium expressing the recombinant NrdF antigen. These animals 
responded not only against S. typhimurium proteins but also against M 
hyopneumoniae and the NrdF antigen. The surprising observation was a complete 
absence of lymphoprolifération in pigs in the oral salmonella vector group. It is 
conceivable that epitopes of NrdF antigen, which are conserved in the bacterial vector 
may be responsible for the lymphoproliférative responses against S. typhimurium 
proteins. As previously reported in orally immunised mice (Chapter 3), the analogous 
S. typhimurium NrdF antigen was not immunogenic. Antibodies elicited by oral 
immunisation using the Salmonella vector did not cross react with the recombinant M. 
hyopneumoniae NrdF antigen. However, antibodies raised against the 15 kDa NrdF 
antigen did cross react with Salmonella epitopes. Similarly, within this pig trial the 
lack of demonstrable lymphoproliférative responses in the oral salmonella vector 
group may also be due to the bacterial vector being poorly immunogenic. 
Alternatively, the bacterial vector unencumbered by recombinant NrdF expression 
may be better able to evade the swine immune response. Further studies are required 
to clarify these possibilities.
The inability to detect lymphoproliférative responses after M. hyopneumoniae 
challenge has been previously reported (Adegboye, 1978; Messier et al, 1990). Within 
this study, there is a strong humoral antibody response prevailing in all pigs post­
challenge. Recent reports indicate that diseased animals biased towards a T̂ eiper tyPe 
2 response produce high levels of IL-10 which suppress CMI responses (Li et al,
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1994). However, the presence of the cell-mediated PHA mitogenic response post­
challenge would discount complete immunosuppression of CMI (Adegboye, 1978). 
Furthermore, researchers have demonstrated that M. hyopneumoniae-specific 
lymphocyte populations are localised to the bronchial lymph close to the site of 
infection (Adegboye, 1978; Messier et al, 1990). Within this study only the 
circulating lymphocyte populations were sampled. As a consequence, the reported 
values may not indicate the extent of sensitisation of the lymphocyte populations in 
the lungs and peripheral lymph nodes.
Failure to observe DTH responses in pigs orally immunised with S. typhimurium 
SL3261(pKFl) could be due to a number of reasons. Widely variable DTH 
responses against heterologous antigen delivered across the mucosae by attenuated 
Salmonella have been reported for a number of animals including swine (Killar and 
Eisenstein, 1986; Stabel et al, 1991; Stabel et al, 1993; Roberts et al, 1994). 
Studies in pigs immunised with attenuated S. typhimurium or S. choleraesuis 
expressing heterologous Brucella abortus antigen demonstrate that DTH response 
is dependent upon strain immunogenicity, route, frequency and dosage of antigen 
delivery (Stabel et al, 1991; Stabel et al, 1993).
All pigs at slaughter exhibited lung damage characteristic of PEP indicating that 
protection was incomplete in all vaccine groups. There was no correlation between 
the extent of lung damage and the Auspharm™ ELISA ratio. This agrees with 
previous findings confirming that serology cannot be used to accurately predict 
disease severity when using this Auspharm™ ELISA (Djordjevic et al, 1994). The 
mean weighed lung tissue affected value (11.9%) for the control group, in this 
instance, does not accurately indicate the severity of damage within this group. The 
weight of tissue affected would have been higher except that two pigs were not 
included as both died before slaughter, one of which died from severe pneumonia.
The Goodwin lung score (24.2) includes the lungs from pigs which died. The two
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methods of measuring the extent of lung damage was carried out to allow for 
comparison of the methods. The GLS is an excellent method to examine large 
numbers of lungs rapidly, however, resolved lesions have the same weighting. 
Subsequently, the GLS method when compared to weighing affected tissue, may 
overestimate the severity of tissue damage.
The intramuscularly immunised pigs had significant serum anti-NrdF IgG levels after 
vaccination which were maintained after challenge when compared to pre-vaccination 
IgG levels. The post-challenge level of serum IgG in all pigs was significantly greater 
than pre-challenge IgG levels. However, serum IgG levels in the intramuscularly 
immunised pigs during this post-challenge period was significantly greater than all 
other treatment pigs. This indicates that the intramuscular route preferentially 
stimulates a serum antibody response. The production of significant secretory IgA 
post-challenge in the oral salmonella vaccine treatment pigs demonstrates that this 
route preferentially stimulates the mucosal immune system to respond against M. 
hyopneumoniae following challenge. Both of these routes when used to deliver the 15 







The results of this study confirm that S. typhimurium SL3261 (pKFl), when used as a 
live oral vaccine strain, is safe to use with pigs with no associated morbidity being 
detected. Pig trial results demonstrate that immunisation with M. hyopneumoniae 
NrdF antigen, either parenterally or using S. typhimurium as a delivery vector, resulted 
in reduced lung pathology and an increase in average daily gains indicating the 
recombinant NrdF antigen would be a beneficial component in a M. hyopneumoniae 
vaccine. Parenteral delivery of antigen, although reducing lung pathology and 
increasing daily gains, is a comparatively expensive mode of immunisation. Needle 
delivery is time consuming, labour intensive and expensive due to the costs involved 
in antigen preparation and in the purchase of adjuvants. Alternatively, live attenuated 
oral vaccines could be developed that are easy to administer and cheap to produce in 
large quantities. It is clear, however, that a number of modifications must be made to 
the S. typhimurium SL3261 (pKFl) live oral vaccine strain before the minimum 
requirements for use of genetically modified organisms in the field are met. Presently, 
the plasmid is maintained by antibiotic selection. This form of selection is easily 
controlled in vitro under laboratory conditions, however, once the strain is 
administered this selection is removed and the plasmid places a disadvantage on the 
recombinant strain due to the burden of expressing heterologous antigen. Antibiotic 
selection is also undesirable because it introduces the potential for transfer of bacterial 
antibiotic resistance into other bacterial gut flora. In the case of S. typhimurium 
SL3261 (pKFl) the plasmid is not mobile through conjugation. However, 
maintenance of the plasmids encoding the heterologous M. hyopneumoniae antigen 
must be ensured through other means to make this strain acceptable. The technology 
is available to stably incorporate the heterologous antigen DNA into the host 
chromosome. A potential promotor to direct chromosomal expression of the NrdF
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antigen would be the anaerobically inducible nirB promotor (Roberts et al, 1994). 
This genetic element has been used to stably express and deliver an antigen dose 
sufficient to elicit protective cellular and humoral immune responses against a 
mucosal pathogen after a single oral dose (Chatfield et al, 1992). Currently, host 
integration is a priority for future attenuated vaccine strains expressing NrdF antigen 
to overcome potential antibiotic resistance gene transfer, and plasmid stability 
problems.
The nrdF gene encodes the small subunit of a ribonucleotide reductase. This enzyme 
catalyses the conversion of ribonucleoside diphosphates to deoxyribonucleoside 
diphosphates, an essential step in DNA replication (Thelander and Reichard, 1979). 
In the physiology of M. hyopneumoniae, the absence of a cell wall and outer 
membrane makes this pathogen particularly vulnerable to neutralising antibodies 
(Awumbila and Rosenbusch, 1991; Wannemeuler and Galvin, 1994). Antibodies 
raised against the recombinant NrdF antigen reacted with a 42 kDa wild type NrdF 
protein in all 7 geographically diverse strains of M. hyopneumoniae tested. The 
presence of reactive epitopes in French, American and Australian strains indicates that 
this protein is conserved. Whole cell ELISA demonstrated the surface accessibility of 
the in-situ NrdF protein in M. hyopneumoniae. Furthermore growth inhibition studies 
demonstrate that serum antibodies specific for the NrdF antigen inhibit mycoplasmal 
growth. In inhibition studies of the herpes simplex virus type 1 (Telford et al, 1990) 
and E. coli (Climent et al, 1991) ribonucleotide reductase enzymes inhibition is the 
result of targeting of the carboxy-terminal region of the NrdF protein. This is the same 
carboxy-terminal region that is expressed in the S. typhimurium aroA SL3261 (pKFl) 
oral vaccine strain. No investigation was carried out to determine the mechanism by 
which these antibodies inhibited growth of the organism. It may be possible that the 
antibodies involved in inhibition within this study are preventing the assembly, and 
subsequent functioning of this enzyme.
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The colonisation of swine lung epithelium by M. hyopneumoniae elicits a damaging 
inflammatory response which results in lung lesion development. The immuno- 
modulating effect of this pathogen is clearly demonstrated in studies with 
thymectomised pigs (Tajima et al, 1984). Within this study, swine with compromised 
T cell and macrophage mediated immune responses after experimental M. 
hyopneumoniae infection had significantly reduced lung pathology. However, M. 
hyopneumoniae numbers in the lungs increased, highlighting the pathogen’s ability 
under natural conditions to elicit cellular, humoral and inflammatory responses which 
are both detrimental to the host yet also play a major role in pathogen clearance.
There are a number of diseases in which pathogenesis has been determined to be due 
to the eliciting of an immune response which subsequently results in more damage 
than if a response was not mounted against the colonising pathogen. The eliciting of a 
severe macrophage type-1 Thelper (Th I) mediated inflammatory response in sheep 
against Corynebacterium pseudotuberculosis results in chronic pneumonia and 
cachexia (Ellis et al, 1995). The eliciting of a dominant type-2 Thelper (Th2) mediated 
humoral response against cytomegalovirus in bone marrow transplant recipients 
frequently leads to severe and often fatal pneumonia (Sparrelid et al, 1997). The 
diseases seborrhoeic dermatitis (Nueber et al, 1996), Castlemans disease and systemic 
lupus erythematosus (Emilie et al, 1997) are all the result of a similar unregulated Th2 
mediated humoral response. Other diseases such as acute respiratory distress 
syndrome (ARDS) as well as AIDS-related wasting and pneumonia are both 
complicated by the a lack of immuno-modulation between effector arms of the 
immune system (Cohen et al, 1997; Headley et al, 1997).
As a M. hyopneumoniae vaccine, the use of attenuated Salmonella to deliver vaccine 
antigens can feasibly result in the immune regulation between the cellular and 
humoral immune responses. Studies have confirmed that orally administered 
Salmonella expressing recombinant antigen can elicit antigen specific Th I and Th2
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responses at distal mucosal sites (VanCott et al, 1996). Consequently, attenuated 
strains can ameliorate the immune bias towards macrophage-mediated inflammatory 
responses by priming both the cellular and humoral immune responses at the mucosal 
site of M. hyopneumoniae colonisation. This priming of immune responses is similar 
to the establishment of the natural BALT immune defences present in adult pigs, but 
not in newly weaned pigs (Pabst and Binns 1994). The predominant lymphocyte 
subset in the mucocilliary epithelium of weaned pigs are naive cytotoxic T cells 
(Pabst and Tschemig, 1995). In contrast, naive T helper cells are dominant in the 
respiratory lamina propria (Pabst and Tschemig, 1995) and in the same region only a 
small proportion of cells present are memory cells (Sheldrake, 1990; Pabst and 
Tschemig, 1995). In the bronchoalveolar space, macrophages represent almost all 
immune cells (Pabst and Binns, 1994). In natural infections, M. hyopneumoniae is 
dealt with initially by bronchoalveolar macrophages. The activation of macrophages 
leads to secretion of cytokines, which at a local level increase vascular permeability 
and upregulate the expression of epithelial adhesion molecules (Arai et al, 1990; 
Akira et al, 1993). These changes allow circulating monocytes, lymphocytes and 
neutrophils to bind to adhesion receptors and subsequently move from the vascular 
system into the tissue space causing margination of these cells and characteristic 
hyperplasia. In the lungs of infected pigs, macrophages are stimulated by M. 
hyopneumoniae colonisation and produce significantly higher levels of the cytokines 
IL-1, TNF-a, IL-6 (Asai et al, 1993; Asai et al 1994) and IFNy (Nishimoto, 1993). 
This cytokine profile is the same as the profile of mice infected with the human 
pathogen M. pneumoniae (Pietsch et al, 1994). However, in this mouse study the role 
of the inflammatory mediators was further demonstrated after re-infection which 
resulted in an exacerbation of pneumonic lung lesions corresponding to an increase in 
pro-inflammatory cytokines (Pietsch et al, 1994).
Examination of the cytokine responses during the progression of pneumonia raises the 
question of the role of TNF-a in PEP. This cytokine is identical at the protein level to
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cachectin which is a molecule named for its ability in mice and other experimental 
animals to induce drastic weight loss, fever and acute inflammatory reactions 
(cachexia) (Beutler et al, 1985; Arai et al, 1990; Tracey and Cerami, 1993, Ling et al,
1997). It is unlikely that the significant high levels of this molecule observed in pigs 
during PEP does not contribute to a large degree to the economic losses incurred by 
the disease.
The use of the S. typhimurium aroA SL3261 (pKFl) oral vaccine strain can be 
beneficial in the immuno-modulation of the macrophage mediated inflammatory 
response. Data from the pig trial described in Chapter 4 confirm that the predominant 
immune response observed is a mucosal IgA response. This secretory antibody 
response is mediated by the Th2 cytokine IL-10 (Yamamoto et al, 1996; Fayette et al, 
1997). This cytokine is multifunctional and serves to maintain IgA responses while 
also down-regulating macrophage mediated THl inflammatory responses, including 
TNF-a (Mulligan et al, 1993; Burdin et al, 1997).
Within the pig trial described in Chapter 4 of this thesis no actual CMI responses were 
experimentally demonstrated. However, this immune response was not specifically 
examined, and consequently, the role of CMI within this study cannot be commented 
upon. The significant lymphoproliférative responses in the orally immunised group 
may not have necessarily been from THl lymphocyte populations. Further 
investigation using cell sorting should be used to resolve the contribution of the 
various lymphocyte subsets. Similarly, a lack of DTH response is not indicative of 
CMI immunosuppression by the oral salmonella vaccine strain. As described in 
Chapter 4.3 (Discussion) the lack of a demonstrable DTH response can be due to a 
number of possibilities including antigen dose, Salmonella strain immunogenicity or 
immuno-modulation of the various lymphocyte populations. Alternately, 
immunosuppression of the DTH response may be due to the responsive lymphocytes
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congregating due to chemotactic attraction at the site of localised infection 
(Adegboye, 1978a; Messier e/ al, 1990).
Pigs in this study were vaccinated by intratracheal inoculation with a large dose of M. 
hyopneumoniae derived from the maceration of diseased lung. This dose does not 
represent the usual mode of pathogen transfer yet it results in PEP with the same 
severity as found in commercial piggery environments (Jericho, 1986). However, even 
though the severity is similar, the use of this inoculation may initially overwhelm a 
primed immune system and give higher lung scores than would be achieved under a 
typical low level frequent exposure scenario common in piggeries with M. 
hyopneumoniae (Jericho 1986). To overcome this problem, cohort studies using the 
vaccines described in this study must be organised so that the effect of natural, low 
level exposure can be elucidated. Furthermore, during these cohort trials, cytokines 
profiles could be monitored to give a clearer picture of which effector arms of the pigs 
immune system are being stimulated.
Currently, a cohort trial is being planned using the affinity purified His-tagged 11 
kDa recombinant antigen expressed by the plasmid pETEl. It would be very useful 
if during this pig trial cytokine profiles could be examined, especially for IL-10 and 
TNFa. Presently it is not possible to carry out large scale cohort trials using live 
attenuated recombinant vectors for the delivery of heterologous antigen. However, 
recent reports indicate a series of phase 2 clinical human trials using live attenuated 
S. typhi based vaccines are being planned in North America (Hone et al, 1992; 
Gonzalez et al, 1994; Levine et al, 1996; Tacket et al, 1997). If these attenuated 
vaccines are approved for use in humans it should not be long before this approval 
is extended for veterinary vaccine cohort trials.
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Appendix 1.
General solutions and buffers










Diluted with dH20  up to volume 
and pH checked to be 7.4
Splitting Buffer

















made up to volume with d ^ O  
and pH checked at 8.3





made up to 250 ml with d ^ O
Resolving Gel 10%
Acrylamide stock (35: 0.8) 2.85
12.5% 15% 20%
3.56 4.25 5.7 ml
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1.5 M Tris.HCl (pH 8.8) 2.5 2.5 2.5 2.5 ml
10% SDS 0.1 0.1 0.1 0.1 ml
dH20 4.5 3.80 3.4 1.65 ml
10% APS 50 50 50 50 pi
TEMED 50 25 10 10 pi
Stacking Gel 4%
Acrylamide stock (35: 0.8) 1.1 ml
0.5 M Tris.HCl (pH 6.8) 2.5 ml
10% SDS 0.1 ml
dH20 6.3 ml
10% APS 50 pi
TEMED 50 pi
Coomassie Stain Destain

















made up to volume with dK^O
Development buffer (4 chloro-l-napthol)
Solution A 20 pi H2O2 in 30 ml dt^O
Solution B 30 mg 4 chloro-l-napthol in 10 ml
methanol
Add solutions A and B immediately 
prior to use-
SDS PAGE preperative column gel
Resolving Gel 7.5% 9% 15%
Acrylamide stock (35: 0.8) 22.5 ml 27.0 ml 45.0 ml
1.5 M Tris.HCl (pH 8.8) 22.5 ml 22.5 ml 22.5 ml
10% SDS 0.9 ml 0.9 ml 0.9 ml
dH20 43.5 ml 39.0 ml 21.0 ml
10% APS 450 pi 450 pi 450 pi
TEMED 
Total volume: 90 ml
30 pi 30 pi 30 pi
Stacking Gel 4%
Acrylamide stock (35: 0.8) 1.33 ml
0.5 M Tris.HCl (pH 6.8) 1.3 ml
10% SDS 0.1 ml
dH20 6.1 ml
10% APS 50 pi
TEMED 5 pi










Denhardts lOOx salts 200 pg/ml
Salmon sperm DNA 20 pg/ml (boiled immediately prior to addition)
dH20 Make up to 50 ml
SDS 0.5% w/v add last
ELISA coating carbonate buffer
30 mM sodium carbonate
20 mM sodium hydrogen carbonate
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